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General introduction and outline of the thesis
GENERAL INTRODUCTION
Cardiac resynchronization therapy (CRT), the implantation of a dedicated device to resynchro-
nize the ventricles in heart failure, is an established treatment for patients who remain symp-
tomatic despite optimal medical therapy. It has a multitude of potentially beneficial effects, 
which include: improvement of symptoms, left ventricular reverse remodeling, improvement 
of left ventricular ejection fraction (LVEF), reduction of functional mitral regurgitation (FMR), 
decrease in the risk of ventricular arrhythmias and improvement in survival (Figure 1).1-4 The 
probability of these favorable outcomes occurring after CRT implantation, is dependent on the 
appropriate patient characterization by echocardiography.
Risk-stratification of cardiac disease entails the scientific estimation of the probability for 
serious, disease-related events, e.g. heart failure and sudden cardiac death (SCD), either to 
inform prognosis or guide management. Multimodality cardiac imaging (echocardiography, 
magnetic resonance and radionuclide techniques) has assumed a central role in the risk-
stratification of various cardiac diseases, encompassing multiple etiologies (Figure 2).5
Echocardiography for the prediction of outcome after CRT
Patients with a left bundle branch block (LBBB) morphology on the surface ECG, as well as a 
QRS duration of ≥150 ms, appear to derive most benefit from CRT in terms of symptom im-
provement and survival.6-8 It is less clear if these baseline characteristics also translate into a 
greater degree of left ventricular reverse remodeling and improvement in LVEF, both of which 
are quantified by means of echocardiography.9 Reverse remodeling is most commonly defined 
as a ≥15% reduction in the left ventricular end-systolic volume (LVESV) at 6 months after CRT 
implantation.10 Long-term outcome after CRT is strongly linked to reverse remodeling, but 
also to improvement in global longitudinal strain (GLS), which can be measured with speckle 
tracking strain echocardiography.11-13 These two measures, i.e. a reduction in LVESV and an 
improvement in GLS, reflect different mechanisms of CRT response – resynchronization and re-
cruitment of contractile reserve, respectively. It is unknown whether an improvement in both, 
an improvement in only one or no improvement in either, has different prognostic implications.
Echocardiography may be useful for predicting outcome after CRT not only when performed 
before implantation, but also thereafter. CRT exerts its beneficial effects by resynchronization 
of the left ventricle.1,2 Left ventricular dyssynchrony can be quantified with a novel, speckle 
tracking strain parameter, i.e. mechanical dispersion (MD).14,15 It is calculated as the standard 
deviation of the time from the onset of the QRS complex on the triggered ECG to the peak 
longitudinal myocardial strain in a 17-segment model.14,15 The degree to which left ventricular 
synchrony has been restored by CRT, quantified with MD, appears to predict outcome, i.e. a de-
crease in ventricular arrhythmias.16 What remains unknown, is if MD (as a measure of residual 
dyssynchrony after CRT implantation) also leads to improved survival. CRT restores mechanical 
efficiency to the failing left ventricle by resynchronization of contraction. The less efficiently 
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the left ventricle operates at baseline, the greater the potential is for recovery of efficient work 
after CRT. It is unknown whether a greater reserve of potentially recoverable left ventricular 
myocardial work efficiency before CRT occasions better outcome. Global, left ventricular work 
efficiency can now be quantified with a non-invasive technique, which involves speckle tracking 
strain echocardiography.17,18
FMR is common in heart failure patients, and a reduction in FMR is counted among the be-
neficial effects of CRT.19-27 This is achieved by a variety of mechanisms, i.e. resynchronization of 
the atrioventricular, inter- and intraventricular contraction, preload reduction and an increase 
in mitral valve closing forces.26,28-30 The impact of the evolution of FMR after CRT on mortality 
has not been adequately investigated in a large cohort. Furthermore, atrial fibrillation (AF) is 
a common occurrence in heart failure, and may contribute to the severity of FMR through left 
atrial and mitral annular dilatation.31-33 The impact of AF on the extent of FMR improvement in 
CRT has never specifically been investigated.
Echocardiography therefore plays a central role in the characterization of heart failure 
recipients of CRT, as well as in the delineation of the factors which will determine outcome. 
Results of research which have been included in this thesis, focus on the intersection of 
echocardiography and the following determinants of outcome after CRT: reverse remodeling, 
resynchronization and FMR improvement.
efficiently the left ventricle operates at baseline, the greater the potential is for recovery of 
efficient work after CRT. It is unknown whether a greater reserve of potentially recoverable 
left ventricular myocardial work efficiency before CRT occasions better outcome. Global, left 
ventricular work efficiency can now be quantified with a non-invasive technique, which 
i volves speckle tracking strain echocardiography.17,18 
 
FMR is common in heart failure patients, and a reduction in FMR is counted among the 
beneficial effects of CRT.19-27 This is achieved by a variety of mechanisms, i.e. 
esynchroniz tion of the atrioventricular, inter- nd intraventricular contraction, preload 
reduction and an increase in mitral valve closing forces.26,28-30 The impact of the evolution of 
FMR after CRT on mortality has not been adequately investigated in a large cohort. 
Furthermore, atrial fibrillation (AF) is a common occurrence in heart failure, and may 
contribute to the severity of FMR through left atrial and mitral annular dilatation.31-33 The 
impact of AF on the extent of FMR improv ment in CRT has never specifically been 
investigated. 
 
Echocardiography therefore plays a central role in the characterization of heart failure 
r cipients of CRT, as w ll as in the delineation of the factors wh ch will determine outcome. 
Results of research which have been included in this thesis, focus on the intersection of 
echocardiography and the following determinants of outcome after CRT: reverse remodeling, 















Figure 1: Summary of beneficial effects of cardiac resynchronization therapy (CRT), with highlighted (blue) 
determinants of outcome which are addressed in this thesis. FMR: functional mitral regurgitation, LV: left 
ventricular, LVEF: left ventricular ejection fraction, VT: ventricular tachycardia. 
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The role of multimodality imaging in the risk-stratification of cardiac disease
SCD is the cause of >4 million global deaths per year (one-fifth of all recorded deaths).34 Since it 
often occurs in individuals who were not previously known with cardiac disease, its prevention 
remains challenging.34 Insertion of an implantable, cardioverter-defibrillator (ICD) is the most 
effective approach to primary prevention (persons at high risk of SCD) and secondary prevention 
(patients with a previous, aborted episode of SCD).5 Currently, ICD candidates are selected on 
the basis of an LVEF <35%.34 This criterion, however, is neither sensitive, nor specific, and new 
approaches are required to improve upon this strategy.5 Various cardiac imaging techniques, 
e.g. speckle tracking strain echocardiography, late gadolinium contrast enhanced (LGE) cardiac 
magnetic resonance (CMR), as well as nuclear techniques, have shown promise for more ac-
curate SCD risk-stratification than LVEF in isolation.5
Genetic, dilated cardiomyopathy (DCM) is associated with more than 50 pathogenic genes 
(sarcomeric and lamin A/C mutations being the most common), as well as neuromuscular dis-
orders.35-37 Mutation carriers often remain asymptomatic until heart failure, arrhythmias or SCD 
supervenes.35,38 Preventive strategies have not been adequately defined, partly because early 
disease is challenging to detect.35 Advanced cardiac imaging techniques (e.g. echocardiographic 
tissue Doppler imaging, speckle tracking strain echocardiography, CMR and nuclear scans) can 
identify both structural and functional abnormalities early during the course of genetic DCM.35 
Furthermore, multimodality cardiac imaging can provide incremental benefit to LVEF for the 
risk-stratification of individuals with established, genetic DCM.35
Multimodality imaging is very promising as a risk-stratification tool for cardiac disease, and 
it has been reviewed, as well as further researched, in the context of genetic DCM, in this thesis.
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Figure 2: Examples of multimodality imaging in risk-stratification of cardiac disease. CMR: cardiac magnetic 
resonance.  




OUTLINE OF THE THESIS
The objective of this thesis was twofold: i) to investigate the role of echocardiography in 
predicting outcome after CRT, and ii) to review and investigate multimodality imaging in the 
risk-stratification of cardiac disease.
In Part I, the role of echocardiography in predicting outcome after CRT is discussed. Chapter 
2 investigates the relation between baseline QRS duration and the presence of an LBBB on the 
one hand, and the degree of left ventricular reverse remodeling and improvement of LVEF, 
on the other, in CRT recipients. In chapter 3, results are presented on the interaction of two 
important determinants of outcome in CRT, i.e. left ventricular GLS and left ventricular reverse 
remodeling, as well as their impact on survival. The benefits of restoration of mechanical 
dyssynchrony (measured by MD) in CRT patients (decrease in ventricular arrhythmias, as well 
as survival) are discussed in chapter 4. A novel, non-invasive technique for assessing cardiac 
mechanical efficiency is applied to CRT prognostication in chapter 5. Chapter 6 focuses on 
the prognostic influence of FMR in CRT recipients, with particular emphasis on the evolution 
thereof, i.e. what the impact on survival is when FMR is improved (or not improved) by CRT. In 
chapter 7, the impact of AF on the improvement in FMR in the CRT context is analyzed.
Part II provides a perspective on the use of multimodality imaging in the risk-stratification 
of various cardiac diseases. In chapter 8 a brief overview of multimodality imaging in the pre-
diction of SCD is given. Chapter 9 reviews the role of cardiac imaging in the risk-stratification 
of genetic DCM, especially when associated with neuromuscular disorders. The use of speckle 
tracking strain echocardiography in risk-stratification of genetic DCM, is explored in chapter 10.
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Impact of QRS complex duration 
and morphology on left ventricular 
reverse remodeling and left 
ventricular function improvement 
after cardiac resynchronization 
therapy
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Background: To evaluate the impact of the interaction of QRS duration and morphology on 
left ventricular (LV) reverse remodeling and LV functional improvement in heart failure (HF) 
patients treated with cardiac resynchronization therapy (CRT).
Methods: From an ongoing registry of HF patients treated with CRT according to contemporary 
guidelines, demographic, clinical, electrocardiographic (ECG) and echocardiographic characte-
ristics were analyzed. Patients were divided according to QRS duration and morphology: <150 
ms vs. ≥150 ms and left bundle branch block (LBBB) vs. non-LBBB, respectively. Echocardiogra-
phic measurements were performed at baseline and at 6 months of follow-up. The effect of the 
interaction between QRS duration and morphology on LV reverse remodeling and LV ejection 
fraction (LVEF) was analyzed using linear, mixed models.
Results: Of 1 467 patients (mean age 65±10 years, 77% male), 884 (60%) had a QRS ≥150 ms 
and 814 (55%) showed LBBB. The group with QRS ≥150 ms demonstrated larger LV reverse 
remodeling (mean reduction in LV end-systolic volume 34.3 ml vs. 14.8 ml; P<0.001) and im-
provement in LVEF (mean increase 6.8% vs. 5.2%; P<0.001) compared with their counterparts. 
Similarly, patients with an LBBB evidenced greater LV reverse remodeling (mean reduction in LV 
end-systolic volume 30.75 ml vs. 17.4 ml; P<0.001) and improvement in LVEF (mean increase 
6.9% vs. 3.7%; P<0.001) than those with non-LBBB QRS morphology.
Conclusions: LV reverse remodeling and LV functional improvement are greater among HF 
patients with LBBB morphology and increasing QRS duration who receive CRT.
2
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INTRODUCTION
Cardiac resynchronization therapy (CRT) is an established treatment for heart failure 
(HF) patients who remain symptomatic despite optimal medical therapy (New York Heart 
Association (NYHA) functional class II-III and ambulatory IV), with a wide QRS complex 
(≥120 ms) and reduced left ventricular ejection fraction (LVEF ≤35%).1 The benefits of 
CRT may differ, based on QRS complex duration and morphology. Recent registries, meta-
analyses and sub-studies of randomized controlled trials have shown that patients with left 
bundle branch block (LBBB) morphology and QRS duration ≥150 ms appear to benefit most 
from CRT in terms of improvement of clinical symptoms and survival,2-4 whereas in patients 
with non-LBBB morphology the benefit may be less, particularly when the QRS duration is 
<130 ms.5 However, little is known about the influence of QRS duration and morphology on the 
extent of LV reverse remodeling and improvement in LVEF. Accordingly, the present study eva-
luated the relation between baseline QRS duration and morphology, and LV reverse remodeling 




This retrospective, single-centre study included symptomatic HF patients who, despite re-
ceiving maximum-tolerated doses of optimal medical therapy, subsequently underwent CRT 
implantation according to contemporary guidelines.1 Demographic, clinical, electrocardiogra-
phic (ECG) and echocardiographic characteristics were analyzed. QRS duration and morphology 
were dichotomized into groups <150 ms vs. ≥150 ms and LBBB vs. non-LBBB, respectively. 
Echocardiographic measurements were performed at baseline (before CRT implantation) and 
at 6 months’ follow-up, according to current guidelines on LV chamber quantification.6 Left 
ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV) and LVEF 
were compared at baseline and 6 months’ follow-up between patients with and without LBBB, 
as well as between patients with QRS duration ≥150 ms and <150 ms. The Dutch Central Com-
mittee on Human-related Research (CCMO) allows the use of anonymous data without prior 
approval of an institutional review board provided that the data are acquired for routine patient 
care. All data used for this study were acquired for clinical purposes and handled anonymously.
Analysis of QRS morphology and duration
QRS duration was determined by automated, digital algorithms from a 12-lead, surface ECG. 
Calibration of the ECG was set at 0.1 mV/mm and the paper speed was 25 mm/s. Previously 
Chapter 2
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defined criteria were employed to define an LBBB, with the intrinsic complex being evaluated 
in the case of pre-existing pacing.7
Echocardiographic data acquisition and analysis
Prior to CRT implantation and at 6 months’ follow-up, transthoracic echocardiography was 
performed in all patients in the left lateral decubitus position using a commercially available 
echocardiographic system (E9 or VIVID 7, General Electric Vingmed Ultrasound, Milwaukee, 
USA). Images were obtained using 3.5 MHz or M5S transducers, while adjusting depth and 
gain settings. M-mode, 2-dimensional and Doppler data, triggered to the ECG, were acquired 
and digitally stored for off-line analysis (EchoPac 113, General Electric Vingmed Ultrasound, 
Milwaukee, USA). LVESV, LVEDV and LVEF were measured from the apical 2- and 4-chamber 
views, using the modified Simpson’s biplane method.
Implantation of CRT
The right atrial and ventricular leads were positioned conventionally through a subclavian or 
cephalic vein. For implantation of the LV lead, a coronary sinus venogram was obtained using a 
balloon catheter and the LV pacing lead was inserted in the coronary sinus with the help of an 
8 Fr guiding catheter and positioned, preferably, in a (postero-) lateral vein. All leads were con-
nected to a dual-chamber biventricular CRT device. The majority of the patients (94%) received 
a CRT device with defibrillator function (ICD) and 6% received a CRT device without defibrillator 
capability. Evaluation of the device function was combined with the regular controls at the 
HF outpatient clinic. The atrioventricular and inter-ventricular delays were set empirically at 
120-140 ms and 0 ms, respectively, and CRT optimization was performed at follow-up at the 
discretion of the treating physician.
Statistical analysis
Continuous variables are presented as mean and standard deviation when normally distributed. 
Dichotomous data are presented as numbers and percentages. Student t-tests were used to 
compare continuous variables, and χ2 tests were used to compare dichotomous data. Changes 
in LVESV, LVEDV and LVEF at 6 months’ follow-up were compared within and between groups 
using linear, mixed models corrected for gender and HF etiology. All analyses were performed 
with SPSS for Windows, version 23.0 (SPSS, Armonk, NY, USA). All statistical tests were two-
sided. A P-value <0.05 was considered statistically significant.
RESULTS
A total of 1 467 patients (mean age 65±10 years, 77% male) were included in the analysis 
(Table 1). Ischemic cardiomyopathy was diagnosed in 59% of patients. LBBB was present in 
2
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55% of patients and the mean QRS duration was 156±33 ms, with 60% of patients having a QRS 
duration ≥150 ms. Compared to patients with LBBB QRS morphology, patients with non-LBBB 
QRS morphology were more frequently male, had more frequently ischemic cardiomyopathy 
and atrial fibrillation and showed significantly better LVEF and smaller LV volumes. Compared 
to patients with QRS duration ≥150 ms, patients with QRS duration <150 ms were significantly 
younger, had more frequently ischemic cardiomyopathy, less frequently chronic kidney disease, 
showed significantly better LVEF and smaller LV volumes and were more frequently treated 
with beta-blockers.
Influence of QRS duration and morphology on LV reverse remodeling and 
LVEF improvement
The mean changes in LV volumes and LVEF, according to QRS morphology and duration, are 
summarized in Table 2. Patients with LBBB configuration exhibited greater LV reverse remode-
ling, greater decrease of LVEDV and improvement in LVEF than patients with non-LBBB QRS 
morphology. Similarly, patients with QRS duration ≥150 ms demonstrated greater LV reverse 
remodeling, greater reduction of LVEDV and improvement in LVEF compared to those with QRS 
duration <150 ms.
Figure 1 illustrates the influence of QRS duration on the reduction of LVEDV after CRT in pa-
tients with LBBB vs. patients with non-LBBB. Regardless of the QRS morphology, the reduction 
in LVEDV was more pronounced with increasing width of the QRS, particularly with QRS duration 
≥150 ms (inflection point). Beyond a QRS duration >190 ms, further decrease in LVEDV was not 
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was similar across the various QRS durations. 
 
 
Figure 1: Influence of QRS duration as a continuous variable on left ventricular end-diastolic volume (LVEDV) 
reduction after CRT. Red circles represent patients with left bundle branch block (LBBB) morphology and blue 
circles patients with non-LBBB morphology. The dotted lines represent the interpolation curve for each group 
(red = LBBB and blue = non-LBBB) and the solid line the overall population (black). 
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observed for patients with LBBB morphology, whereas patients with a non-LBBB QRS configu-
ration showed progressive LVEDV reduction. Figure 2 illustrates the influence of QRS duration 
as a continuous variable (dichotomized into patients with LBBB and non-LBBB configuration) 
on changes in LVESV: progressive reduction in LVESV was observed with increasing duration 
of the QRS, particularly ≥140 ms for both LBBB and non-LBBB patients. Figure 3 illustrates the 
influence of QRS duration as a continuous variable (dichotomized into patients with LBBB vs. 
non-LBBB) on changes in LVEF. LVEF increased particularly in patients with QRS duration ≥150 
ms and LBBB morphology and appeared to reach a plateau beyond 170 ms. LVEF improvement 
in patients with non-LBBB morphology was similar across the various QRS durations.





P-value QRS ≥150 
ms
(n=884)
QRS <150 ms 
(n=583)
P-value
Age (years) 65.7±10.2 65.1±11.1 0.3 66.5±10.4 63.9±10.8 <0.001
Male gender, n (%) 598 (73.5) 528 (80.9) 0.001 668 (75.6) 458 (78.6) 0.206
Ischemic etiology, n (%) 439 (53.9) 427 (65.4) <0.001 466 (52.7) 400 (68.6) <0.001



















































6 MWT (m) 326.2±122.5 319±121.5 0.305 321.0±124.0 326.0±119.1 0.504
QoL score 32.6±19.0 33.6±19.7 0.385 33.0±18.4 33.0±20.1 0.952
Diabetes, n (%) 170 (20.9) 146 (22.4) 0.54 176 (19.9) 140 (24.0) 0.071
eGFR <60 ml/min/1.73 m2, 
n (%)
326 (40.0) 262 (40.1) 0.956 381 (43.1) 207 (35.5) 0.006
LVEF (%) 25.7±7.9 28.3±8.3 <0.001 26.2±8.3 27.9±7.9 <0.001
LVEDV (ml) 219.0±80.3 192.9±71.4 <0.001 220.0±81.3 188.4±67.2 <0.001






































Values are mean ± standard deviation. ACE: angiotensin-converting enzyme, eGFR: estimated glomerular filtration rate, LVEF: 
left ventricular ejection fraction, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic volume, 6 
MWT: 6-minute walk test, NYHA: New York Heart Association, QoL: quality of life.
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LBBB: left bundle branch block, CI: confidence interval, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular 
end-systolic volume, LVEF: left ventricular ejection fraction. P-values based on linear, mixed model analysis.
 
Table 2: Changes in LV volumes and ejection fraction, according to QRS morphology and 
duration. 
 
 LBBB (n=814) Non-LBBB (n=653) P-value QRS ≥150 ms 
(n=884) 





95% CI Mean 
change 
95% CI Mean 
change 




































LBBB: left bundle branch block, CI: confidence interval, LVEDV: left ventricular end-diastolic volume, LVESV: left 





Figure 2: Influence of QRS duration as a continuous variable on left ventricular end-systolic volume (LVESV) 
reduction after CRT. Red circles represent patients with left bundle branch block (LBBB) morphology and blue 
circles patients with non-LBBB morphology. The dotted lines represent the interpolation curve for each group 
(red = LBBB and blue = non-LBBB) and the solid line the overall population (black). 
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DISCUSSION
The main findings of the present study are the greater benefit of CRT (in terms of LV reverse 
remodeling (defined as reduction in LVESV) and improvement in LVEF) in HF patients with LBBB 
and a QRS duration ≥150 ms, compared to patients with non-LBBB QRS morphology or shorter 
QRS duration.
Influence of QRS morphology and duration on CRT efficacy
Several studies have demonstrated the influence of QRS morphology and duration on the 
outcome of HF patients treated with CRT.8-11 In a large, retrospective cohort study, including 
Chapter 2
26
24 169 patients treated with CRT, Peterson et al. showed that patients with LBBB morphology 
and a QRS duration ≥150 ms presented lower rates of all-cause mortality (20.9% at 3 years) 
compared to patients with LBBB and QRS <150 ms (26.5% at 3 years) or with non-LBBB morpho-
logy (30.7% for QRS ≥150 ms and 32.3% for QRS <150 ms).4 These findings were also observed 
in a meta-analysis of 5 randomized trials including 5 813 CRT patients: QRS duration ≥150 ms 
was significantly associated with a reduction of the risk of the composite clinical endpoint (risk 
ratio 0.60; 95% confidence interval (CI) 0.53-0.67; P<0.001) whereas a QRS duration between 
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Figure 3: Influence of QRS duration as a continuous variable on left ventricular ejection fraction (LVEF) change 
after CRT. Red circles represent patients with left bundle branch block (LBBB) morphology and blue circles 
patients with non-LBBB morphology. The dotted lines represent the interpolation curve for each group (red = 
LBBB and blue = non-LBBB) and the solid line the overall population (black). 
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In the Resynchronization/defibrillation in Ambulatory Heart Failure Trial (RAFT), all-cause 
mortality and hospitalization for HF were reduced in patients with LBBB morphology, but not 
in those with non-LBBB morphology.2 In a meta-analysis of 4 randomized controlled trials re-
ported by Sipahi et al. (including 5 356 patients), composite clinical events (all-cause mortality 
and HF hospitalization) were reduced in patients with LBBB (relative risk (RR)=0.64, 95% CI 
0.52-0.77, P=0.00001), but not in patients with a non-LBBB morphology (RR=0.97, 95% CI 0.82-
1.15, P=0.75).13
Importantly, the prognosis of patients with CRT is also influenced by the response to CRT 
at mid-term follow-up, defined as LV reverse remodeling.14-16 In a study including 679 patients 
treated with CRT, LV reverse remodeling (reduction of ≥15% in LVESV) at 6 months of follow-up 
was associated with better prognosis independently of improvement in clinical status.14 How 
QRS duration and morphology affect the extent of LV reverse remodeling and the degree of 
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improvement in LV systolic function after CRT has not been extensively studied, especially in 
patients with more advanced stages of HF (NYHA class III and IV).
QRS morphology and duration vs. LV reverse remodeling and improvement 
in LVEF after CRT
The effects of CRT on LV volumes and LVEF according to the QRS duration and morphology 
have been studied in few randomized trials, including only patients with HF NYHA class I and II 
symptoms.10,17 In the Multicenter Automatic Defibrillator Implantation With Cardiac Resynchro-
nization Therapy (MADIT-CRT) trial, randomizing 1 820 patients (70% with LBBB morphology) 
with mild HF (NYHA class I and II) to CRT-D vs. ICD alone, patients with LBBB morphology had a 
greater decrease in LVEDV compared to those with non-LBBB (56.7±34.1 ml vs. 41.0±28.13 ml, 
respectively; P<0.001).10 Patients with LBBB also experienced a greater decrease in LVESV than 
patients with non-LBBB (62.1±31.5 ml vs. 45.7±28.13 ml, respectively; P<0.001).10 Lastly, LVEF 
improved by 11.9±5.1% in the LBBB group, vs. 8.8±4.9% in the non-LBBB group (P<0.001).10 
Similarly, in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction 
(REVERSE) trial, 610 patients with mild HF (NYHA class I and II; 60% with LBBB morphology) ran-
domized to CRT-ON vs. CRT-OFF, patients with LBBB experienced a 25.3 ml/m2 mean reduction 
in LVESV index (P<0.0001), whereas non-LBBB patients had smaller reductions in LVESV (6.7 
ml/m2; P=0.18).17 Moreover, baseline QRS duration was also a strong predictor of the change 
in LVESV index in the REVERSE trial. When patients were divided into quartiles according to 
baseline QRS duration, a progressively greater decrease in LVESV index was observed at 12 
months of follow-up for longer QRS durations.17
Our results are consistent with the MADIT-CRT and REVERSE trials,10,17 with LBBB and in-
creasing QRS duration (especially ≥150 ms) constituting the group of HF patients who benefit 
most from CRT in terms of LV reverse remodeling and LVEF improvement. In addition, similar 
to the REVERSE sub-study, the differences in LV reverse remodeling and improvement in LVEF 
remained significant after correcting for known confounders such as ischemic HF.17 More impor-
tantly, the present study expands the results of these randomized controlled trials by including 
a large number of patients with severe HF (NYHA class III and IV). This is highly relevant, since 
the majority of patients in previous randomized controlled trials and large registries had NYHA 
class III HF symptoms.4,18-20 However, the association between QRS morphology and duration 
and changes in LV volumes and LVEF after CRT in that group of patients has not been previously 
described. In addition, although the efficacy of CRT in NYHA functional class IV has been de-
bated, our results show that this group of patients may also show significant reduction in LV 
volumes and improvement in LVEF, thus supporting CRT implantation in this group of patients 
as indicated in current guidelines.1,21-23 Current guidelines for the diagnosis and management 
of HF patients recommend CRT for HF patients with LBBB morphology and QRS duration ≥150 
ms (class IA) or 130-149 ms (class IB).23 For HF patients with non-LBBB morphology the recom-
mendation level is II (IIa for patients with QRS duration ≥150 ms and IIb for patients with QRS 
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duration between 130-149 ms). The present results also support these recommendations since, 
for the first time, they demonstrate that the greatest benefit from CRT (in terms of LV reverse 
remodeling and LVEF improvement) was observed in a large population of NYHA class I-IV HF 
patients with LBBB morphology and QRS duration ≥150 ms.
Study limitations
This study was limited by its design: a retrospective, single-centre study, but an advantage 
is that it reflects experience from a large, real-world, referral centre. In this population, the 
number of patients receiving beta-blockers was still fairly low, although it was higher compared 
to many landmark trials which established the utility of CRT.18-20,24-27 This probably reflects that 
in daily practice, a significant percentage of severe HF patients do not tolerate beta-blockers. 
It is also known that other factors, such as the extent of scar tissue in the LV and the LV lead 
position may influence the response to CRT. These factors were not systematically available in 
the current population.
CONCLUSIONS
LV reverse remodeling and functional improvement are greater among HF patients with LBBB 
QRS morphology and increasing QRS duration (especially ≥150 ms) who received CRT. These 
findings are supportive of contemporary guidelines for CRT placement.
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Background: Cardiac resynchronization therapy (CRT) has the ability to reduce left ventricular, 
end-systolic volume (LVESV). A decrease of ≥15% is commonly defined as a CRT response. CRT 
can also improve LV global longitudinal strain (GLS). Changes in LVESV and LV GLS are individu-
ally associated with outcome post-CRT. The objective of the current study was to investigate 
how often improvement in both LVESV and LV GLS coincides and if this response has a different 
prognostic implication than an improvement in either LVESV or LV GLS alone, and when com-
pared to no improvement in either LVESV or LV GLS.
Methods: Baseline and 6-month echocardiograms were analyzed from CRT recipients with 
heart failure. LV reverse remodeling was defined as a ≥15% reduction in LVESV at 6 months 
post-CRT. A ≥5% absolute improvement in LV GLS was defined as a change in LV GLS.
Results: 1 185 patients were included (mean age 65±10 years, 73% male). Patients with an 
improvement in LVESV and LV GLS (n=131, 11.1%) had significantly lower all-cause mortality, 
compared to other groups. On multivariable analysis, an improvement in both LVESV and LV 
GLS (hazard ratio 0.47; 95% confidence interval 0.31-0.71; P<0.001) or an improvement in 
either LVESV or LV GLS (hazard ratio 0.57; 95% confidence interval 0.47-0.71; P<0.001) was 
independently associated with a better prognosis, compared to no improvement in either 
LVESV or LV GLS.
Conclusions: Changes in LVESV and LV GLS reflect different mechanisms of CRT response, 
which may not always be present in the same patient. Both improvement in LVESV and LV 
GLS occurred in 11.1% of patients. Either a reduction in LVESV and/or an improvement in LV 
GLS at 6 months post-CRT, is independently associated with improved long-term prognosis, 
compared to no change in both LVESV and LV GLS. These observations support the use of LV GLS 
as a meaningful parameter in defining CRT response, in addition to the more commonly used 
definition of a change in LVESV.
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INTRODUCTION
Cardiac resynchronization therapy (CRT) is indicated for heart failure (HF) patients who remain 
symptomatic despite receiving adequate medical therapy (New York Heart Association (NYHA) 
functional class II-III and ambulatory IV), together with a wide QRS complex (≥130 ms) and a left 
ventricular ejection fraction (LVEF) ≤35%.1,2 In appropriately selected candidates, CRT alleviates 
symptoms, induces LV reverse remodeling, improves LV function and decreases mortality.1
The ability of CRT to cause LV reverse remodeling, i.e. to reduce the LV end-systolic volume 
(LVESV), has been extensively documented.3-6 This is usually measured at 6 months post-implant. 
In addition, the degree of reduction in LVESV by CRT has been linked to long-term outcome.7 
Myocardial strain imaging quantifies active myocardial deformation, and global LV function is most 
commonly reported as global longitudinal strain (GLS). CRT can improve LV GLS, which also trans-
lates into an improved long-term outcome.8,9 From a prognostic perspective, it would be important 
to know to what extent these early changes (a reduction in LVESV and an improvement in LV GLS) 
are predictive of long-term survival. Accordingly, we have evaluated the outcome of CRT recipients 
with early (6 months post-implant) improvement in both these parameters (LVESV and LV GLS), 
compared to the outcome of patients without early (6 months) improvement, as well as of CRT re-
cipients with either improvement in LVESV or improvement in LV GLS, but not in both parameters.
METHODS
Study population
Clinical and echocardiographic data of HF patients who received CRT according to prevailing 
guideline recommendations were included from an ongoing, single-center registry.1,10 For this 
analysis, only patients who underwent transthoracic echocardiography at baseline and at 6 
months follow-up after CRT implantation were evaluated. Ischemic etiology of HF was defined 
by the presence of significant coronary artery disease. The NYHA functional class was assessed 
in all patients, and a clinical response to CRT was defined as a ≥1 NYHA class improvement at 6 
months after CRT. The quality of life was evaluated with the Minnesota Living with Heart Failure 
Questionnaire,11 and if feasible, a 6-minute walk test was performed.12
Echocardiographic data acquisition
Transthoracic echocardiograms were performed on all patients in the left lateral decubitus po-
sition with a commercially available echocardiographic system (VIVID 7 or E9, General Electric 
Healthcare, Horten, Norway). Data were acquired with 3.5 MHz or M5S transducers – adjusting 
the depth and gain settings when required. ECG-triggered, M-mode, 2-dimensional and Dop-
pler data were collected and stored in digital format for off-line analysis (EchoPac 113, General 
Electric Healthcare, Horten, Norway). LVESV and LV end-diastolic volume (LVEDV) were mea-
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sured on 2-dimensional 2- and 4-chamber apical views following Simpson’s method and LVEF 
was then calculated.13 LV GLS was measured from standard apical views (long-axis, 2-chamber 
and 4-chamber) using speckle tracking echocardiography.14 The inter- and intra-observer agree-
ment for LV GLS measurement in this population have previously been described.15 The inter- 
and intra-observer variability of LVESV and LV GLS measurement were assessed calculating the 
intra-class correlation coefficient (ICC) for both measures on 25 randomly selected patients. 
The ICC for inter- and intra-observer variability of LVESV were 0.91 (95% CI: 0.76-0.96, P<0.001) 
and 0.98 (95% CI: 0.96-0.99, P<0.001), respectively. The bias and 95% limits of agreement for 
inter-observer variability of LVESV were -15.2 ml and -71.5 to 41.1 ml, respectively, whereas 
the bias and 95% limits of agreement for intra-observer variability of LVESV were 0.8 ml and 
-27.7 to 29.4 ml, respectively. The ICC for inter- and intra-observer variability of LV GLS were 
0.92 (95% CI: 0.84-0.97, P<0.001) and 0.97 (95% CI: 0.89-0.99, P<0.001), respectively. The bias 
and 95% limits of agreement for inter-observer variability of LV GLS were 0.1% and -2.7 to 
2.9%, compared to the bias and 95% limits of agreement for intra-observer variability of LV GLS, 
which were -0.5% and -2.1 to 1.1%.
CRT implantation
Placement of the right atrial and ventricular leads was performed via a standard approach 
(subclavian or cephalic vein). A coronary sinus venogram was acquired prior to LV lead im-
plantation. An 8 Fr guiding catheter was subsequently used for insertion of the LV pacing lead 
into the coronary sinus, and for positioning in a (preferred) posterior/posterolateral vein. A 
connection was established between all leads and a dual-chamber, biventricular CRT device. In 
most patients (94%), a CRT device with defibrillator function was implanted, while 6% received 
a CRT device without defibrillator functionality. Patients were followed up with regular intervals 
at the HF outpatient clinic, at which time device function was checked. The atrioventricular and 
inter-ventricular delays were empirically set at 120-140 ms and 0 ms, respectively. Optimization 
of CRT devices was performed during follow-up, and at the discretion of the treating physician.
Definitions of early (6 months) CRT response
The definition of an echocardiographic response to CRT was based on the occurrence of LV 
reverse remodeling and improvement in LV GLS at 6 months of follow-up. LV reverse remode-
ling was defined as a reduction of ≥15% in the LVESV.16 The cut-off value of clinically meaningful 
LV GLS improvement after CRT has not been previously established. An absolute improvement 
of 5% in LV GLS was chosen as a threshold representing a substantial GLS response (Figure 1).
Statistical analysis
Means and standard deviations were used to present continuous data, while numbers and 
percentages were used to present categorical data. Continuous variables were compared with 
one-way analysis of variance (ANOVA), while χ2 and Fisher’s exact tests with post-hoc analysis of 
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subgroups were employed for comparison of categorical data (as appropriate). Survival analysis 
was conducted with the Kaplan-Meier method, and the eff ect of diff erent variables on event-free 
survival was examined with a Cox proporti onal hazards model. In order to evaluate the incremen-
tal value of LV GLS over a reducti on in LVESV for outcome, we performed likelihood rati o testi ng. 
All analyses were performed with SPSS for Windows, version 23.0 (SPSS, Armonk, NY, USA). All 
stati sti cal tests were two-sided, and a P-value <0.05 was considered stati sti cally signifi cant.
 
 
Figure 1: Parametric maps of left ventricular (LV) global longitudinal strain (GLS) for a cardiac resynchronization 
therapy (CRT) recipient with a substantial improvement in LV GLS. A) LV GLS parametric map before implantation 
of CRT, and B) the same patient after 6 months of CRT. LV segments coded in shades of blue denote elongation 
during systole, vs. LV segments coded in red, which indicate systolic shortening. LVEF: LV ejection fraction, 




Baseline patient characteristics 
 
A total of 1 185 patients (mean age 65±10 years, 73% male) with available echocardiographic 
data at baseline and 6 months’ follow-up were included (Table 1). Ischemic etiology was 
present in 56% of patients. The mean LVEF of the overall population was 27±8%.  
 
Changes in LVESV and LV GLS 
 
The mean reduction in LVESV after 6 months of CRT was 15.4±24.3 ml for the overall 
population (Figure 2), while LV reverse remodeling was observed in 674 patients (56.9%). The 
mean (absolute) change in LV GLS for the overall population after 6 months of CRT was 
1.0±3.5% (Figure 2). A ≥5% absolute improvement in LV GLS was observed in 148 (12.5%) 
patients. Improvement in both LVESV and LV GLS was noted in 131 (11.1%) of CRT recipients, 
compared to 469 (39.6%) who did not improve either their LVESV or GLS. In 585 (49.4%) 
patients, an improvement was seen in either LVESV or GLS, but not in both. 
 
Characteristics of patients according to CRT response pattern  
 
Table 1 compares the baseline characteristics of patients, divided according to the CRT 
response pattern. Those who improved both their LVESV and LV GLS, demonstrated a longer 
baseline QRS duration, compared to patients who either did not improve their LVESV or LV 
i r  1: Para etric maps of left  ventricular (LV) global longitudinal strain (GLS) for a cardiac resynchroniza-
ti on therapy (CRT) recipient with a substanti al improvement in LV GLS. A) LV GLS parametric map before im-
plantati on of CRT, and B) the same pati ent aft er 6 months of CRT. LV segments coded in shades of blue denote 
elongati on during systole, vs. LV segments coded in red, which indicate systolic shortening. LVEF: LV ejecti on 
fracti on, LVESV: LV end-systolic volume.
RESULTS
Baseline pati ent characteristi cs
A total of 1 185 pati ents (mean age 65±10 years, 73% male) with available echocardiographic 
data at baseline and 6 months’ follow-up were included (Table 1). Ischemic eti ology was present 
in 56% of pati ents. The mean LVEF of the overall populati on was 27±8%.
Changes in LVESV and LV GLS
The mean reducti on in LVESV aft er 6 months of CRT was 15.4±24.3 ml for the overall populati on 
(Figure 2), while LV reverse remodeling was observed in 674 pati ents (56.9%). The mean (ab-
solute) change in LV GLS for the overall populati on aft er 6 months of CRT was 1.0±3.5% (Figure 
2). A ≥5% absolute improvement in LV GLS was observed in 148 (12.5%) pati ents. Improvement 
in both LVESV and LV GLS was noted in 131 (11.1%) of CRT recipients, compared to 469 (39.6%) 
who did not improve either their LVESV or GLS. In 585 (49.4%) pati ents, an improvement was 
seen in ither LVESV or GLS, but not i  both.
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Characteristics of patients according to CRT response pattern
Table 1 compares the baseline characteristics of patients, divided according to the CRT response 
pattern. Those who improved both their LVESV and LV GLS, demonstrated a longer baseline 
QRS duration, compared to patients who either did not improve their LVESV or LV GLS, or who 
showed improvement in only LVESV or LV GLS. CRT recipients with neither an improvement in 
LVESV nor in LV GLS, were more frequently male and more commonly had an ischemic etiology 
of HF. In addition, patients not manifesting a decrease in LVESV or an improvement in LV GLS, 
had more renal dysfunction than those with an improvement in both LVESV and LV GLS.














(n = 1 185)
Age (years) 66.6±10.2 65.7±10.2 64.2±10.5 65.2±10.3
Male gender, n (%) 79 (60.3) 419 (71.6)† 363 (77.4)* 861 (72.7)
Ischemic etiology, n (%) 50 (38.2) 317 (54.2)* 298 (63.5)* 665 (56.1)
LBBB, n (%) 58 (44.3) 284 (48.5) 225 (48.0) 567 (47.8)
QRS duration at baseline (ms) 168.4±30.6 155.8±35.5*† 149.7±33.8* 154.6±34.8
































6 MWT (m) 354.7±110.6 332.8±120.2 327.5±122.1 332.8±120.2
QoL score 31.5±17.4 30.2±18.4† 34.6±20.2 32.1±19.1
Diabetes mellitus, n (%) 13 (10.0) 106 (18.1) 113 (24.1) 232 (19.6)
eGFR <60 ml/min/1.73 m2, n (%) 33 (25.2) 225 (38.5) 184 (39.2)* 442 (37.3)
LVEF (%) 26.6±7.7 27.3±7.9 27.7±8.2 27.4±8.0
LVEDV (ml) 201.3±67.7 205.1±75.6 203.0±78.3 204.0±76.0
LVESV (ml) 149.7±58.6 151.7±65.9 149.4±67.2 150.7±65.7



























Continuous variables are mean ± standard deviation. ACE: angiotensin-converting enzyme, eGFR: estimated glomerular fil-
tration rate, GLS: global longitudinal strain, LBBB: left bundle branch block, LV: left ventricular, LVEF: left ventricular ejection 
fraction, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic volume, 6 MWT: 6-minute walk test, 








Figure 2A: Absolute changes in mean, left ventricular global longitudinal strain (GLS) from baseline to 6 months 
after cardiac resynchronization therapy (CRT), according to different categories of CRT response. LV: left 




Figure 2B: Mean improvement in left ventricular end-systolic volume (LVESV) from baseline to 6 months after 
cardiac resynchronization therapy (CRT), according to different categories of CRT response. LV: left ventricular, 






Figure 2A: Absolute changes in mean, left  ventricular global longitudinal strain (GLS) from baseline to 6 
months aft er cardiac resynchronizati on therapy (CRT), according to diff erent categories of CRT response. LV: 




Figure 2A: Absolute changes in mean, left ventricular global longitudinal strain (GLS) from baselin  to 6 months 
after cardiac resynch onization therapy (CRT), according to different categories of CRT response. LV: left 




Figure 2B: Mean improvement in left ventricular end-systolic volume (LVESV) from baseline to 6 months after 
cardiac resynchronization therapy (CRT), according to different categories of CRT response. LV: left ventricular, 






Figure 2B: Mean improvement in left  ventricular end-systolic volume (LVESV) from baseline to 6 months aft er 
cardiac resynchronizati on therapy (CRT), according to diff erent categories of CRT response. LV: left  ventricular, 
GLS: global longitudinal strai .
Changes i  LV GLS and LVESV before and aft er CRT implantati on, according to diff eren groups 
of CRT response, are summarized in Figure 2. A greater improvement of LV GLS was observed in 
those pati ents who improved in both LVESV and LV GLS, than in pati ents who improved only in 
terms of LVESV or LV GLS, or neither (P<0.001). The LVESV decreased more signifi cantly in CRT 
recipients with LVESV and LV GLS improvement than in those recipients with an improvement 
in only LVESV or LV GLS, while LVESV increased in recipients without an improvement in either 
LVESV or LV GLS (P<0.001).
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CRT response pattern and survival
After a median follow-up of 53 months (interquartile range 25-80 months), 323 (27%) patients 
died. CRT recipients in whom a reduction in LVESV was seen together with an improvement in 
LV GLS, had significantly better survival compared to those who improved either in LVESV or LV 
GLS, or did not improve in LVESV and LV GLS (log-rank test, P<0.001; Figure 3). In patients with 
an improved LVESV and LV GLS, the cumulative survival rates at 24, 48, 72 and 96 months of 
follow-up were 92, 82, 75 and 62%, respectively. The group that demonstrated an improvement 
in either LVESV or LV GLS but not both, showed slightly worse cumulative survival (91, 79, 64 
and 53%, at 24, 48, 72 and 96 months of follow-up, respectively). In contrast, patients without 
improvement in LVESV or LV GLS had lower cumulative survival rates (81, 66, 49 and 37%, at 24, 
48, 72 and 96 months of follow-up, respectively).
 
Changes in LV GLS and LVESV before and after CRT implantation, according to different groups 
of CRT response, are summarized in Figure 2. A greater improvement of LV GLS was observed 
in those patients who improved in both LVESV and LV GLS, than in patients who improved 
only in terms of LVESV or LV GLS, or neither (P<0.001). The LVESV decreased more significantly 
in CRT recipients with LVESV and LV GLS improvement than in those recipients with an 
improvement in only LVESV or LV GLS, while LVESV increased in recipients without an 
improvement in either LVESV or LV GLS (P<0.001).  
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of follow-up were 92, 82, 75 and 62%, respectively. The group that demonstrated an 
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contrast, patients without improvement in LVESV or LV GLS had lower cumulative survival 
















Figure 3: Kaplan-Meier survival curves for time to cumulative survival, according to different categories of 
cardiac resynchronization therapy (CRT) response. LV: left ventricular, LVESV: left ventricular end-systolic 
volume, GLS: global, longitudinal strain. 
 
Figure 3: Kaplan-Meier survival curves for time to cumulative survival, according to different categories of car-
diac resynchronization therapy (CRT) response. LV: left ventricular, LVESV: left ventricular end-systolic volume, 
GLS: global, longitudinal strain.
A Cox proportional hazards model was used to investigate the association between response 
to CRT at 6 months’ follow-up and all-cause mortality, including as covariates, factors known 
to impact on mortality in HF (Table 2). On multivariable analysis, both a CRT response encom-
passing an improvement in LVESV and LV GLS (hazard ratio 0.47; 95% confidence interval (CI) 
0.31-0.71; P<0.001) and a response characterized by an improvement in either LVESV or LV 
GLS (hazard ratio 0.57; 95% CI 0.47-0.71; P<0.001) were independently associated with better 
survival compared to patients without improvement in LVESV or LV GLS.
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Table 2: Predictors of all-cause mortality risk, uni- and multivariate Cox proportional hazards models.
Univariable analysis Multivariable analysis
Variable HR 95% CI P-value HR 95% CI P-value
Age at implantation (years) 1.04 1.03-1.05 <0.001 1.03 1.02-1.04 <0.001
Male gender 1.48 1.16-1.89 0.001 1.39 1.07-1.82 0.015
Body mass index (kg/m2) 0.97 0.95-0.99 0.008 0.96 0.94-0.99 0.006
Diabetes mellitus 1.65 1.33-2.05 <0.001 1.37 1.08-1.74 0.010
Ischemic etiology of heart failure 1.55 1.27-1.89 <0.001 1.29 1.03-1.63 0.029
Diuretic use 1.75 1.33-2.31 <0.001 1.38 1.02-1.86 0.037
Hemoglobin (g/dL) 0.81 0.73-0.89 <0.001 0.92 0.82-1.02 0.114
Renal dysfunction (eGFR <60 ml/min/1.73 m2) 2.55 2.11-3.08 <0.001 1.91 1.55-2.37 <0.001
Clinical response 0.84 0.69-1.01 0.068 0.86 0.70-1.05 0.132
QRS duration pre-implantation (ms) 1.00 1.00-1.01 0.108 1.00 1.00-1.01 0.165
Atrial fibrillation 1.75 1.38-2.22 <0.001 1.43 1.10-1.85 0.007
CRT response category
<15% ↓LVESV and <5% ↓LV GLS













≥15% ↓LVESV and ≥5% ↓LV GLS 0.43 0.29-0.64 <0.001 0.47 0.31-0.71 <0.001
CI: confidence interval, CRT: cardiac resynchronization therapy, eGFR: estimated glomerular filtration rate, GLS: global longi-
tudinal strain, HR: hazard ratio, LV: left ventricular, LVESV: left ventricular end-systolic volume.
In order to further stratify those responders who showed an improvement in either LVESV 
or LV GLS but not both, and to investigate the association with outcome, this group of pa-
tients was divided into two subcategories, i.e. those with a decrease in LVESV, and another 
with an improvement in LV GLS. Patients with an improved LV GLS but without a decrease 
in LVESV, demonstrated similar event rates to those with a reduced LVESV but no change in 
LV GLS (log-rank test P<0.001; Figure 4). An identical, multivariable model was constructed, 
and analyzed according to four patterns of CRT response, i.e. i) improvement in LVESV and LV 
GLS, ii) improvement in LVESV, iii) improvement in LV GLS, iv) neither improvement in LVESV 
nor improvement in LV GLS. The hazard ratios of patients with improved LV GLS but without a 
decrease in LVESV (hazard ratio 0.58; 95% CI 0.33-0.99; P=0.05) and those with a reduced LVESV 
but no improvement in LV GLS (hazard ratio 0.57; 95% CI 0.46-0.71; P<0.001) were similar, while 
the first group demonstrated a trend towards better survival, and the second group retained an 
independent association with outcome.
Incremental value of LV GLS
In order to evaluate the incremental value of an improvement in GLS over a reduction in LVESV 
for mortality, likelihood ratio testing was performed. The baseline model (model 1) comprised 
all risk factors which were included in the multivariable regression model, i.e.: age at implan-
tation, male gender, body mass index, diabetes mellitus, ischemic etiology of heart failure, 
diuretic use, hemoglobin, renal dysfunction, clinical response, QRS duration pre-implantation 
and atrial fibrillation. Addition of a ≥15% decrease in LVESV to model 1, provided incremental 
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value (P<0.001; Figure 5). A third model, which included an improvement in GLS of ≥5%, was of 
further incremental value (P=0.039; Figure 5).
 
similar, while the first group demonstrated a trend towards better survival, and the second 
group retained an independent association with outcome. 
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Figure 4: Kaplan-Meier survival curves for time to cumulative survival. Survival is categorized according to four 
different cardiac resynchronization therapy (CRT) responses. LV: left ventricular, LVESV: left ventricular, end-
systolic volume, GLS: global, longitudinal strain. 
Figure 4: Kaplan-Meier survival curves for ti me to cumulati ve survival. Survival is categorized according to 
four diff erent cardiac resynchronizati on therapy (CRT) responses. LV: left  ventricular, LVESV: left  ventricular, 




Figure 5: Likelihood ratio test. Bars represent the incremental value of a ≥15% decrease in left ventricular end-
systolic volume (LVESV) and an improvement in LV global longitudinal strain (GLS) in addition to clinical risk 




Improvement in both LVESV and LV GLS was noted in 11.1% of CRT recipients. Furthermore, 
it was demonstrated that CRT responses defined by i) improvement in both LVESV (reduction 
of ≥15%) and LV GLS (≥5% absolute improvement), or ii) improvement in either LVESV or LV 
GLS at 6 months after implantation, are independently associated with a better prognosis, 
compared to the absence of both an improvement in LVESV and LV GLS. Additionally, we 
showed that the groups of CRT recipients with either a decrease in LVESV or an increase in LV 
GLS, had a similar prognosis. 
 
Decrease of LVESV after CRT 
 
The response to CRT has been defined by a spectrum of both clinical (change in NYHA, change 
in 6-minute walking distance, change in quality of life (QoL) score) and echocardiographic 
(change in LVESV, change in LVEDV, change in LVEF and change in LV GLS) parameters.7,8,17-19 
The most frequently used definition of CRT response is a ≥15% reduction in LVESV at 6 
months’ follow-up, due to evidence supporting its prognostic implications.7,17 The reduction 
which CRT causes in LVESV, has been documented in a number of landmark trials.3-5 In the 
Multicenter InSync ICD Randomized Clinical Evaluation II (MIRACLE-ICD II) trial, the LVESV 
decreased by 14±57 ml in the control group, compared to 42±77 ml in the CRT group 
(P=0.01).5 In the Resynchronization Reverses Remodeling in Systolic Left Ventricular 
Dysfunction (REVERSE) study, indexed LVESV declined by 25.3±28.5 ml/m2 in patients 
receiving CRT with a LBBB, compared to 1.7±25.8 ml/m2 in a control group (P<0.0001).3 
 
Figure 5: Likelihood rati o test. Bars represent the incremental value of a ≥15% decrease in left  ventricular 
end-systolic volume (LVESV) and an improvement in LV global longitudinal strain (GLS) in additi on to clinical 
risk factors (Model 1).
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DISCUSSION
Improvement in both LVESV and LV GLS was noted in 11.1% of CRT recipients. Furthermore, it 
was demonstrated that CRT responses defi ned by i) improvement in both LVESV (reducti on of 
≥15%) and LV GLS (≥5% absolute improvement), or ii) improvement in either LVESV or LV GLS at 
6 months aft er implantati on, are independently associated with a bett er prognosis, compared 
to the absence of both an improvement in LVESV and LV GLS. Additi onally, we showed that the 
groups of CRT recipients with either a decrease in LVESV or an increase in LV GLS, had a similar 
prognosis.
Decrease of LVESV aft er CRT
The response to CRT has been defi ned by a spectrum of both clinical (change in NYHA, change in 
6-minute walking distance, change in quality of life (QoL) score) and echocardiographic (change 
in LVESV, change in LVEDV, change in LVEF and change in LV GLS) parameters.7,8,17-19 The most 
frequently used defi niti on of CRT response is a ≥15% reducti on in LVESV at 6 months’ follow-up, 
due to evidence supporti ng its prognosti c implicati ons.7,17 The reducti on which CRT causes in 
LVESV, has been documented in a number of landmark trials.3-5 In the Multi center InSync ICD 
Randomized Clinical Evaluati on II (MIRACLE-ICD II) trial, the LVESV decreased by 14±57 ml in 
the control group, compared to 42±77 ml in the CRT group (P=0.01).5 In the Resynchronizati on 
Reverses Remodeling in Systolic Left  Ventricular Dysfuncti on (REVERSE) study, indexed LVESV 
declined by 25.3±28.5 ml/m2 in pati ents receiving CRT with a LBBB, compared to 1.7±25.8 ml/
m2 in a control group (P<0.0001).3
The degree of LV response at 6 months aft er CRT is also predicti ve of long-term outcome 
(log-rank test, P<0.001).7 Since survival is a very robust measure of outcome, a reducti on in the 
LVESV ≥15% has become the most accepted defi niti on of CRT response. This defi niti on, however, 
has certain limitati ons: change in LVESV refl ects only the change in LV volume following CRT, 
and does not take into account whether it has improved exclusively by increasing the eff ecti ve 
forward stroke volume. In additi on, a CRT response defi ned only by a reducti on in LVESV, does 
not refl ect acti ve deformati on of the myocardium. Speckle tracking strain echocardiography 
can overcome this limitati on by imaging acti ve myocardial deformati on. Global LV deformati on, 
measured by speckle tracking strain echocardiography, is most commonly reported as LV GLS.20
Improvement of LV GLS aft er CRT
In 141 CRT recipients signifi cant improvement in LV GLS (from -7.8±2.8% to -8.5±3.5%; P=0.01) 
was noted in responders (defi ned as a ≥15% reducti on in LVESV) but not in non-responders.9 
Pouleur et al.8 reported an improvement in LV GLS aft er CRT, which was associated with an 
improved outcome (24% reducti on in death or HF for every 1% recovery in LV GLS) over the fi rst 
12 months of CRT. The mean change in LV GLS was 1.4±3.1% in this populati on.8
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CRT response: LVESV and LV GLS
Inherent to the fact that a response to CRT is defined by means of different parameters, they 
may not all improve in the same patient, i.e. they may be discordant. Such discordant clinical 
and LV volumetric responses were witnessed in 440 CRT recipients.21 The combined clinical 
endpoint of ≥1 point improvement in NYHA class and/or ≥15% improvement in the 6-minute 
walking test distance was compared to an echocardiographic, volumetric response defined as 
≥15% reduction in the LVESV.21 While a clinical response was recorded in 84% of patients, an 
echocardiographic response was seen in only 63%.21 Discordance of CRT response parameters 
can be best investigated by the two measures which have been firmly linked to outcome after 
CRT, i.e. LVESV and LV GLS.
A discordant CRT response, defined as an improvement in LVESV or LV GLS, but not both, 
reflects different underlying mechanisms of CRT response. A reduction in LVESV without an 
improvement in LV GLS likely results from effective resynchronization of the LV by CRT, but with-
out recruitment of contractile reserve. Contractile reserve describes the potential of poorly 
contractile, though viable, areas of myocardium, to improve their systolic function in response 
to CRT. The presence of contractile reserve in CRT candidates has been demonstrated with 
dobutamine stress-echocardiography, and it is associated with better event-free survival.22-25 
On the other hand, an improved LV GLS without a substantial change in LVESV can be attributed 
to the recruitment of contractile reserve. These two echocardiographic parameters (LVESV and 
LV GLS) therefore represent two different mechanisms of the LV response to CRT, and they do 
not always occur in the same patient concurrently.
The results of the present study indicate that no improvement in either LVESV or LV GLS, is 
significantly associated with a worse outcome, while improvement in both of these parameters 
or either one of them is associated with a survival benefit. Even though an improvement in 
LV GLS has previously been linked to an improved outcome, ≥15% reduction in the LVESV is a 
more commonly used definition of CRT response. Our results therefore support the use of an 
improvement in LV GLS as a useful parameter for the evaluation of a CRT response. Further-
more, the fact that CRT recipients with either a reduction in LVESV or an improvement in LV GLS 
had similar associations with outcome, provides insight into the different mechanisms of CRT 
response. Patients with an improvement in LV GLS but without a reduction in LVESV would have 
been classified as non-responders by the conventional definition of a CRT response, i.e. ≥15% 
reduction in LVESV, although they experience similar survival rates at 6 months as compared 
with patients with reduction in LVESV ≥15%. This observation further strengthens the impor-
tance of a change in LV GLS in defining CRT response. Furthermore, the incremental value of an 
improvement in LV GLS over a reduction of LVESV (in addition to clinical risk factors) for survival, 
lends additional support to the independent contribution of LV GLS in CRT response.
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Study limitations
This was a retrospective, single-center study, which included patients who completed 6 months 
of follow-up. Patients who died during the first 6 months after CRT implantation could not be 
included, and could therefore have caused a selection bias. The measurement of LV GLS is not 
vendor-independent, and the threshold of LV GLS employed to define a response in the present 
study may not be generalizable to other patients in whom LV GLS was measured on a different 
vendor platform.14
CONCLUSIONS
Various clinical and echocardiographic parameters have been used to define a response to CRT, 
and due to different underlying mechanisms, they may not always be in agreement in the same 
patient. By observing the LV response to CRT in terms of two measures which have previously 
been associated with outcome, i.e. LVESV and LV GLS, we have demonstrated three different 
patterns of response, i.e. i) an improvement in both LVESV and LV GLS, ii) an improvement in 
either LVESV or LV GLS, but not both, iii) no improvement in either LVESV or LV GLS. An improve-
ment in both LVESV and LV GLS, or an improvement in either LVESV or LV GLS, at 6 months after 
CRT, are associated with better long-term outcome, compared to no improvement in LVESV or 
LV GLS. These findings support the use of LV GLS as a meaningful parameter in defining CRT 
response, since it reflects a different aspect of LV response to CRT than a change in LVESV, and 
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Background: In heart failure (HF) patients, left ventricular mechanical dispersion (LVMD) re-
flects heterogeneous mechanical activation of the left ventricle. In these patients, LVMD can be 
reduced after CRT. Whether lesser LVMD is associated with improved outcome is unknown. The 
purpose of the current study was to relate LVMD to long-term prognosis in a large cohort of HF 
patients after 6 months of cardiac resynchronization therapy (CRT).
Methods: Clinical, echocardiographic and ventricular arrhythmia (VA) data were analyzed from 
an ongoing registry of HF recipients of CRT. Baseline (prior to CRT) and 6-month echocardio-
grams were evaluated. LVMD was calculated as the standard deviation of the time from onset of 
the QRS complex to the peak longitudinal strain in a 17-segment model. Patients were divided 
into two groups, according to the median LVMD (84 ms) at 6 months post-CRT.
Results: Of 1 185 patients (mean age 65±10 years, 76% male), 343 (29%) died during a mean 
follow-up of 55±36 months. Baseline LVMD was not associated with all-cause mortality and 
VA at follow-up. In contrast, patients with less LVMD (≤84 ms) at 6 months post-CRT had lower 
event rates (VA and mortality) compared to those with LVMD >84 ms. On multivariable analysis, 
greater LVMD at 6 months after CRT was independently associated with an increased risk of 
mortality (hazard ratio 1.002; P=0.037) and VA (hazard ratio 1.003; P=0.026).
Conclusions: Larger LVMD at 6 months after CRT is independently associated with all-cause 
mortality and VA. LVMD may be valuable in identifying patients who remain at high mortality 
risk after CRT implantation.
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INTRODUCTION
Cardiac resynchronization therapy (CRT) is indicated in heart failure (HF) patients who remain 
symptomatic despite optimal medical therapy (New York Heart Association (NYHA) functional 
class II-III and ambulatory IV), with a wide QRS complex (≥120 ms) and a reduced left ventricular 
ejection fraction (LVEF ≤35%).1 CRT has been shown to improve symptoms, induce LV reverse 
remodeling, improve LVEF and reduce mitral regurgitation by resynchronizing the LV.1,2 These 
favorable effects have been associated with a decreased risk of ventricular arrhythmias and 
reduced mortality.3,4
LV mechanical dispersion (LVMD) is a novel, echocardiographic parameter based on speckle 
tracking echocardiography that measures the time dispersion to reach the peak systolic defor-
mation in the different LV segments.5,6 LVMD reflects mechanical heterogeneity, which has been 
related to ventricular arrhythmias in a number of cardiac diseases.5,7-11 A reduction in LVMD 
after CRT is related to a decrease in ventricular arrhythmias.9 Whether reduced LVMD after 
CRT translates into superior outcome is unclear. Accordingly, the present study evaluated the 
relation between LVMD at 6 months after CRT implantation, and the prognosis of HF patients.
METHODS
Patient population and data collection
HF patients who received CRT according to current guidelines and who completed clinical and 
echocardiographic follow-up at 6 months after CRT implantation were retrospectively evalu-
ated.1 Various clinical, laboratory and imaging data were collected at baseline and 6 months’ 
follow-up. Ischemic HF was defined by the presence of coronary artery disease, i.e. evidence 
in previous medical records or from non-invasive or invasive investigations. The Dutch Central 
Committee on Human-related Research (CCMO) allows the use of anonymous data without 
prior approval of an institutional review board, provided that the data are acquired for routine 
patient care. All data used for the present study were acquired for clinical purposes and han-
dled anonymously.
Among the clinical variables, the quality of life, according to the Minnesota Living with 
Heart Failure Questionnaire, the 6-minute walking distance and the NYHA functional class were 
considered to define the severity of HF.12,13 Renal function was defined by the estimated glo-
merular filtration rate (eGFR), calculated according to the Modification of Diet in Renal Disease 
Study (MDRD) equation.14 The efficacy of CRT was analyzed as the percentage of patients recei-
ving <98% and <90% of biventricular pacing, respectively.15 A significant burden of premature, 
ventricular contractions (PVCs) was defined as >10 000 per 24 hours.16,17
Transthoracic echocardiography was performed in the left lateral decubitus position prior 
to and at 6 months after CRT implantation in all patients, utilizing a commercially available 
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echocardiographic system (E9 or VIVID 7, General Electric Vingmed Ultrasound, Milwaukee, 
USA) equipped with 3.5 MHz or M5S transducers. As previously described,18 M-mode, 2-dimen-
sional and Doppler data were acquired and digitally stored for off-line analysis (EchoPac 113, 
General Electric Vingmed Ultrasound, Milwaukee, USA).
Speckle tracking echocardiography was used to measure LVMD at baseline and at 6 months 
after CRT implantation. LVMD was calculated as the standard deviation of the time from the 
onset of the QRS complex on the triggered ECG, to the peak longitudinal myocardial strain in 
a 17-segment LV model (Figure 1). The inter-observer and intra-observer variability of LVMD 
measurement were assessed by calculating the intra-class correlation coefficient (ICC) for both 
measures on 25 randomly selected patients. The ICC for inter-observer and intra-observer 
variability of LVMD were 0.84 (95% confidence interval (CI) 0.64-0.93; P<0.001) and 0.93 (95% 
CI 0.85-0.97; P<0.001), respectively.
Implantation of CRT
The subclavian or cephalic veins were utilized to place the right atrial and ventricular leads in a 
standard fashion. Coronary sinus venography was performed (with a balloon catheter) to guide 
LV lead implantation. The LV pacing lead was introduced into the coronary sinus through an 8 Fr 
guiding catheter, and preferably positioned in a (postero-) lateral vein. Thereafter all the leads 
were connected to a dual-chamber, biventricular CRT device. A CRT device with defibrillator 
function was implanted in most of the recipients. Patients were scheduled for regular follow-up 
at the HF outpatient clinic and to evaluate device function. The atrioventricular and inter-
ventricular delays were empirically set at 120-140 ms and 0 ms respectively, while optimization 
of the CRT device was left to the discretion of the treating physician.
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Figure 1: Assessment of left ventricular mechanical dispersion with 2-dimensional speckle tracking 
echocardiography. Left ventricular mechanical dispersion was calculated as the standard deviation of the time 
from the onset of the QRS complex on the ECG, to the peak longitudinal strain in 17 segments of the left ventricle. 
The segmental time to peak longitudinal strain data are presented in a color-coded, bull’s eye plot with the 





The clinical response to CRT was defined as improvement ≥1 NYHA functional class at 6 
months of follow-up.19 LV reverse remodeling was defined as ≥15% reduction in the LV end-
systolic volume (LVESV) at 6 months of follow-up. Patients were followed up for the 
occurrence of all-cause mortality, as well as the occurrence of ventricular arrhythmias 
(appropriate antitachycardia pacing and/or appropriate defibrillation by a CRT defibrillator). 
The follow-up started at 6 months when the clinical, electrocardiographic and 
echocardiographic responses were assessed. 
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Follow-up
The clinical response to CRT was defined as improvement ≥1 NYHA functional class at 6 months 
of follow-up.19 LV reverse remodeling was defined as ≥15% reduction in the LV end-systolic 
volume (LVESV) at 6 months of follow-up. Patients were followed up for the occurrence of 
all-cause mortality, as well as the occurrence of ventricular arrhythmias (appropriate antita-
chycardia pacing and/or appropriate defibrillation by a CRT defibrillator). The follow-up started 
at 6 months when the clinical, electrocardiographic and echocardiographic responses were 
assessed.
Statistical analysis
Continuous variables are expressed as means and standard deviations, and categorical data as 
numbers and percentages. Survival analysis was performed according to the Kaplan-Meier me-
thod for all-cause mortality as well as ventricular arrhythmias. Comparisons between groups 
were performed according to the log-rank test. A Cox proportional hazards model was used 
to investigate the association between LVMD at 6 months’ follow-up and all-cause mortality, 
as well as ventricular arrhythmias. To show hazard change across the range of LVMD, as a 
continuous variable, a spline curve was fit for LVMD vs. mortality as well as vs. ventricular 
arrhythmias, with overlaid confidence intervals (CI). Subsequently, multivariate spline models 
were constructed, after adjusting for the following covariates: gender, body mass index, diabe-
tes mellitus, etiology of HF, diuretics, hemoglobin, renal dysfunction, left ventricular reverse 
remodeling and clinical CRT response. All analyses were performed with SPSS for Windows, 
version 23.0 (SPSS, Armonk, NY, USA) and R, version 3.4.4 (R Foundation for Statistical Com-




A total of 1 185 patients (mean age 65±10 years, 76% male) with analysable echocardiographic 
data to calculate LVMD at baseline and 6 months after CRT were included. Strain analysis was 
not feasible in 90 (8%) patients. Baseline characteristics of the patient population are presented 
in Table 1. The etiology of HF was ischemic in 60% of patients and the mean LVEF at 6 months 
after CRT was 33.4±9.8%. The median baseline LVMD was 96.3 ms (interquartile range (IQR) 
74.5-126.4 ms), which decreased to 84.1 ms (IQR 65.4-112.4 ms) after 6 months of CRT. The 
percentage of patients with biventricular pacing <98% was 37%, and the percentage of patients 
with biventricular pacing <90% was 9%. The percentage of patients in our cohort with >10 000 
premature ventricular complexes per 24 hours, was 2.2%.
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Associati on between LVMD at baseline and 6 months of follow-up and 
survival
In total, 343 (29%) pati ents died during a mean follow-up of 55±36 months aft er the 6-month 
echocardiography. The pati ent populati on was dichotomized according to the median value of 
LVMD at baseline (96 ms). There were no diff erences in all-cause mortality rates between those 
pati ents with a greater (>96 ms) and a lesser (≤96 ms) LVMD at baseline (log-rank test, P=0.253). 
The pati ent populati on was subsequently dichotomized according to the median value of LVMD 
at 6 months (84 ms). Pati ents with lesser LVMD at 6 months (≤84 ms) had signifi cantly lower 
all-cause mortality compared with pati ents with more LVMD (>84 ms) (log-rank test, P<0.001; 
Figure 2). In pati ents with LVMD ≤84 ms at 6 months, the cumulati ve all-cause mortality rates 
were 13, 42 and 55% at 30, 90 and 120 months’ follow-up, respecti vely. In contrast, in the group 
of pati ents with LVMD >84 ms, the cumulati ve event rates were 18, 54 and 65% for the same 
follow-up ti me points.
Table 1: Pati ent characteristi cs at baseline.
N=1185
Age (years) 65±10
Male gender, n (%) 904 (76)
Ischemic eti ology, n (%) 712 (60)
Heart rhythm at baseline, n (%)
- Sinus rhythm
- Paced rhythm













6 MWT (m) 331±121
QoL score 32±19
Diabetes n (%) 253 (21)




LVMD (ms) 96.3 (74.5-126.4)
Values are mean ± standard deviati on. eGFR: esti mated glomerular fi ltrati on rate, LVEF: left  ventricular ejecti on fracti on, 
LVEDV: left  ventricular end-diastolic volume, LVESV: left  ventricular end-systolic volume, LVMD: left  ventricular mechanical 
dispersion, 6 MWT: 6-minute walk test, NYHA: New York Heart Associati on; QoL: quality of life.
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In contrast, in the group of patients with LVMD >84 ms, the cumulative event rates were 18, 
54 and 65% for the same follow-up time points. 
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6 MWT (m) 331±121 
QoL score 32±19 
Diabetes n (%) 253 (21) 
eGFR <60 ml/min/1.73 m2, n (%) 466 (39) 
LVEF (%) 27±8 
LVEDV (ml) 203±76 
LVESV (ml) 150±65 
LVMD (ms) 96.3 (74.5-126.4) 
Values are mean ± standard deviation. eGFR: estimated glomerular filtration rate, LVEF: left ventricular 
ejection fraction, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic volume, 
LVMD: left ventricular mechanical dispersion, 6 MWT: 6-minute walk test, NYHA: New York Heart Association; 















Figure 2: Kaplan-Meier curves for all-cause mortality. Time to all-cause mortality in patients with left ventricular 
mechanical dispersion ≤84 ms and >84 ms after 6 months of cardiac resynchronization therapy. LVMD: left 
ventricular mechanical dispersion. 
Figure 2: Kaplan-Meier curves for all-cause mortality. Time to all-cause mortality in pati ents with left  ven-
tricular mechanical dispersion ≤84 ms and >84 ms aft er 6 months of cardiac resynchronizati on therapy. LVMD: 
left  ventricular mechanical dispersion.
To investi gate the associati on between LVMD at 6 months and all-cause mortality, a Cox pro-
porti onal hazards model was constructed with variables known to infl uence mortality of HF 
pati ents (Table 2). On multi variable analysis, LVMD at 6 months was independently associated 
with increased mortality (hazard rati o 1.002; 95% CI 1.000-1.005; P=0.037). To show hazard 
Table 2: Uni- and multi variate Cox proporti onal hazards models for all-cause mortality.
Univariate analysis Multi variate analysis
Variable HR 95% CI P-value HR 95% CI P-value
LVMD at 6 months (ms) 1.004 1.002-1.006 <0.001 1.002 1.000-1.005 0.037
Age at implant (years) 1.040 1.029-1.050 <0.001 1.030 1.019-1.041 <0.001
Male gender 1.482 1.164-1.887 0.001 1.495 1.157-1.933 0.002
Body mass index (kg/m2) 0.969 0.947-0.992 0.008 0.960 0.936-0.985 0.002
Diabetes mellitus 1.649 1.329-2.046 <0.001 1.470 1.165-1.854 0.001
Ischemic eti ology of heart failure 1.547 1.265-1.893 <0.001 1.184 0.950-1.475 0.133
Diureti cs 1.751 1.325-2.313 <0.001 1.445 1.080-1.933 0.013
Hemoglobin (g/dl) 0.806 0.731-0.890 <0.001 0.935 0.842-1.039 0.212
Renal dysfuncti on
(eGFR <60 ml/min/1.73 m2)
2.546 2.105-3.080 <0.001 1.983 1.612-2.439 <0.001
LV reverse remodeling 0.537 0.380-0.759 <0.001 0.628 0.514-0.767 <0.001
Clinical response 0.839 0.694-1.013 0.068 0.921 0.756-1.121 0.412




change across the range of LVMD, as a continuous variable, a spline curve was fit for LVMD 
vs. mortality. For all-cause mortality, predicted from the 6-month LVMD, the assumption of 
linearity was not violated (χ2 4.4; P=0.12). There was an increase of hazards for LVMD between 
50 ms and 130 ms, after which a plateau appeared. At higher 6-month LVMD values, there is 
a decrease of the hazards, although there are too few observations in this range to support a 
meaningful, clinical interpretation (also reflected in the wider CIs at higher LVMD) (Figure 3A). 
When adjusted for multiple covariates, the assumption of linearity was also not violated (χ2 3.0; 
P=0.23), and the curve demonstrated a similar shape to the unadjusted model, with hazards 




Figure 3: Spline curves for left ventricular mechanical dispersion (LVMD) vs. all-cause mortality. Predicted 
mortality across a range of LVMD, plotted as a fitted spline model on a log-hazard scale, with overlaid confidence 
intervals. The unadjusted model is shown in panel A, and the adjusted model in panel B. Ln: logarithm, HR: 
hazard ratio. 
 
Association between LVMD at baseline and 6 months of follow-up and ventricular 
arrhythmias 
 
After a mean follow-up of 55±36 months, 403 (34%) of patients experienced a ventricular 
arrhythmia for which appropriate device therapy was delivered. No difference in freedom 
from ventricular arrhythmias was seen between those patients with a greater (>96 ms) and a 
lesser (≤96 ms) LVMD at baseline (log-rank test, P=0.781). Patients with lesser LVMD at 6 
months (≤84 ms) experienced greater freedom from ventricular arrhythmias, compared to 
those with more LVMD (>84 ms) (log-rank test, P<0.001; Figure 4). In patients with LVMD ≤84 
ms at 6 months, the cumulative rates for ventricular arrhythmia were 15, 55 and 77% at 30, 
90 and 120 months’ follow-up, respectively. In contrast, in those individuals with LVMD >84 
ms, the cumulative event rates were 21, 66 and 84% for the identical time points. 
 
Figure 3: Spline curves for left ventricular mechanical dispersion (LVMD) vs. all-cause mortality. Predicted 
mortality across a range of LVMD, plotted as a fitted spline model on a log-hazard scale, with overlaid confi-
dence intervals. The unadjusted model is shown in panel A, and the adjusted model in panel B. Ln: logarithm, 
HR: hazard ratio.
Association between LVMD at baseline and 6 months of follow-up and 
ventricular arrhythmias
After a mean follow-up of 55±36 months, 403 (34%) of patients experienced a ventricular ar-
rhythmia for which appropriate device therapy was delivered. No difference in freedom from 
ventricular arrhythmias was seen between those patients with a greater (>96 ms) and a lesser 
(≤96 ms) LVMD at baseline (log-rank test, P=0.781). Patients with lesser LVMD at 6 months (≤84 
ms) experienced greater freedom from ventricular arrhythmias, compared to those with more 
LVMD (>84 ms) (log-rank test, P<0.001; Figur  4). In patients with LVMD ≤84 ms at  onths, 
the cumulative rates for ventricular arrhythmia were 15, 55 and 77% at 30, 90 and 120 months’ 
follow-up, respectively. In contrast, in those individuals with LVMD >84 ms, the cumulative 
event rates were 21, 66 and 84% for the identical time points.
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Figure 4: Kaplan-Meier curves for freedom from ventricular arrhythmias. Ventricular arrhythmia-free survival 
in patients with left ventricular mechanical dispersion ≤84 ms and >84 ms after 6 months of cardiac 
resynchronization therapy. LVMD: left ventricular mechanical dispersion. 
 
To investigate the association between LVMD at 6 months and all-cause mortality, a Cox 
proportional hazards model was constructed with variables known to influence the mortality 
of HF patients (Table 3). On multivariable analysis, LVMD at 6 months was independently 
associated with ventricular arrhythmias (hazard ratio 1.003; 95% CI 1.000-1.005; P=0.026). To 
show hazard change for ventricular arrhythmias across the range of LVMD as a continuous 
variable, a spline curve was fit for LVMD vs. ventricular arrhythmias. For ventricular 
arrhythmias, predicted from the 6-month LVMD, the assumption of linearity was not violated 
(χ2 6.0; P=0.06). There was an increase of hazards for LVMD between 50 ms and 130 ms, after 
which a plateau appeared. At higher 6-month LVMD values, there was a decrease of the 
hazards, although there were too few observations in this range to support a meaningful, 
clinical interpretation (also reflected in the wider CIs at higher LVMD) (Figure 5A). When 
adjusted for multiple covariates, the assumption of linearity was also not violated (χ2 1.2; 
P=0.55), and the curve demonstrated a similar shape to the unadjusted model, with hazards 







Figure 4: Kaplan-Meier curves for freedom from ventricular arrhythmias. Ventricular arrhythmia-free sur-
vival in pati ents with left  ventricular mechanical dispersion ≤84 ms and >84 ms aft er 6 months of cardiac 
resynchronizati on therapy. LVMD: left  ventricular mechanical dispersion.
To investi gate the associati on between LVMD at 6 months and all-cause mortality, a Cox pro-
porti onal hazards model was constructed with variables known to infl uence the mortality of HF 
pati ents (Table 3). On multi variable analysis, LVMD at 6 months was independently associated 
with ventricular arrhythmias (hazard r ti o 1.003; 95% CI 1.000-1.005; P=0.026). To show hazard 
change for ventricular arrhythmias across the range of LVMD as a conti nuous variable, a spline 
curve was fi t for LVMD vs. ventricular arrhythmias. For ventricular arrhythmias, predicted from 
the 6-month LVMD, the assu pti on of linearity was not violated (χ2 6.0; P=0.06). There was an 
increase of hazards for LVMD between 50 ms and 130 ms, aft er which a plateau appeared. At 
higher 6-month LVMD values, there was a d crease of t e h zards, alth ugh th re were too 
few observati ons in this range to support a meaningful, clinical interpretati on (also refl ected 
in the wider CIs at higher LVMD) (Figure 5A). When adjusted for multi ple covariates, the as-
sumpti on of linearity was also not violated (χ2 1.2; P=0.55), and the curve demonstrated a 
similar shape to the unadjusted model, with hazards increasing for LVMD between 50 and 130 
ms, whereaft er a plateau was noted (Figure 5B).
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Table 3: Uni- and multivariate Cox proportional hazards models for ventricular arrhythmias.
Univariate analysis Multivariate analysis
Variable HR 95% CI P-value HR 95% CI P-value
LVMD at 6 months (ms) 1.003 1.001-1.006 0.006 1.003 1.000-1.005 0.026
Age at implant (years) 1.020 1.009-1.030 <0.001 1.018 1.008-1.030 0.001
Male gender 1.704 1.305-2.225 0.001 1.723 1.306-2.273 <0.001
Body mass index (kg/m2) 0.999 0.976-1.023 0.957 - - -
Diabetes mellitus 1.243 0.967-1.596 0.089 1.176 0.910-1.520 0.216
Ischemic etiology of heart failure 1.339 1.089-1.648 0.006 1.046 0.839-1.305 0.688
Diuretics 1.126 0.873-1.451 0.361 - - -
Hemoglobin (g/dl) 0.975 0.874-1.087 0.646 - - -
Renal dysfunction
(eGFR <60 ml/min/1.73 m2)
1.334 1.086-1.639 0.006 1.259 1.011-1.567 0.040
LV reverse remodeling 0.672 0.551-0.821 <0.001 0.704 0.569-0.872 0.001
Clinical response 0.759 0.621-0.928 0.007 0.832 0.675-1.026 0.086
CI: confidence interval, eGFR: estimated glomerular filtration rate, HR: hazard ratio, LVMD: left ventricular mechanical disper-
sion.
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Figure 5: Spline curves for LVMD vs. ventricular arrhythmias. Predicted occurrence of ventricular arrhythmias 
across a range of left ventricular mechanical dispersion (LVMD), plotted as a fitted spline model on a log-hazard 
scale with overlaid confidence intervals. The unadjusted model is shown in panel A, and the adjusted model in 




Patients with HF with greater LVMD at 6 months after receiving a CRT device, experienced a 
worse long-term outcome and more frequent ventricular arrhythmias, compared to patients 
with lesser LVMD. Additionally, the association between LVMD and mortality, as well as 
ventricular arrhythmias was independent of the occurrence of LV reverse remodeling at 6 
months. 
Figure 5: Spline curves for LVMD vs. ventricular arrhythmias. Predicted occurrence of ventricular arrhyth-
mias across a range of left ventricular mechanical dispersion (LVMD), plotted as a fitted spline model on a log-
hazard scale with overlaid confidence intervals. The unadjusted model is shown in panel A, and the adjusted 
model in panel B. Ln: logarithm, HR: hazard ratio.
DISCUSSION
Patients with HF with greater LVMD at 6 months after receiving a CRT device, experienced a 
worse long-term outcome and more frequent ventricular arrhythmias, compared to patients 
with l  LV D. Ad itionally, the association betw en LVMD and mortality, as well as ventri-
cular arrhythmias was independent of the occurrence of LV reverse remodeling at 6 months.
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Role of LVMD in diagnosis and risk-stratification
LVMD has been proposed as a marker of electromechanical heterogeneity of the left ventricle 
and is calculated as the standard deviation of the time from the onset of the QRS complex 
to the peak longitudinal myocardial strain (obtained with 2-dimensional speckle tracking 
echocardiography) in a 16- or17-segment LV model.5,6 LVMD has been utilized in the diagnosis 
and risk-stratification of various cardiac disorders.5,6,8-11,20-22 In post-infarct patients, LVMD has 
shown incremental value over LVEF to predict ventricular arrhythmias.22
Similarly, LVMD discriminated between post-infarct patients with and without ventricular 
arrhythmias in a prospective study.5 In addition, LVMD has been associated with ventricular ar-
rhythmias in HF patients with ischemic and non-ischemic etiologies.8 A greater LVMD, 6 months 
after CRT, has been demonstrated in recipients with ventricular arrhythmias at follow-up, com-
pared to those without arrhythmias.9 Our data support this observation, with more frequent 
ventricular arrhythmias documented in individuals with greater LVMD after CRT. However, the 
association between residual LVMD after CRT and all-cause mortality has not been evaluated.
LVMD and outcome after CRT
The main finding of this study is that LVMD after 6 months of CRT is independently associated 
with long-term outcome. Long-term outcome after CRT is influenced by a number of baseline 
characteristics, i.e. male gender, body mass index, diabetes mellitus, hemoglobin and impaired 
renal function.23-26 It is also well-established that LV reverse remodeling, as well as the extent 
thereof, impacts on long-term prognosis.27,28 In the Resynchronization Reverses Remodeling in 
Systolic Left Ventricular Dysfunction (REVERSE) trial, a ≥15% decrease in the indexed LVESV was 
an independent predictor of outcome.29 In contrast, although the clinical response to CRT was 
associated with better outcome, it was not independently associated with all-cause mortality 
in a study of 679 patients.30
LVMD and LV reverse remodeling after CRT are therefore more firmly linked to improved 
survival than a clinical response. A lesser LVMD likely reflects restoration of a more homogenous 
pattern of LV electromechanical activation by CRT, which accompanies LV reverse remodeling. 
Apical rocking, another surrogate of heterogenous LV activation, has demonstrated incremen-
tal value over LV reverse remodeling to predict mortality after CRT (hazard ratio 0.405; 95% CI 
0.283-0.579; P<0.0001).31 In addition, correction of apical rocking by CRT translated into lower 
all-cause mortality. Our results provide further support to the association of reestablishment of 
a more coordinated pattern of LV contraction and improved outcome after CRT.
In a recent meta-analysis, including 3 667 patients, the risk of ventricular arrhythmias was 
found to be significantly lower in CRT responders (i.e. in whom LV remodeling has taken place) 
than in non-responders (odds ratio 0.436; 95% CI 0.323-0.589; P<0.05).32 LV remodeling is 
therefore strongly related to both the risk of ventricular arrhythmias and outcome after CRT. In 
light of the connection between restoration of coordinated LV contraction (reflected by LVMD) 
and LV remodeling, the presence of more frequent ventricular arrhythmias in patients with a 
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greater LVMD after 6 months of CRT, is consistent with ventricular arrhythmia burden as the 
cause of increased mortality in this group.
The present study shows that LVMD after 6 months of CRT was significantly associated 
with long-term outcome independently of clinical response and LV reverse remodeling. Greater 
LVMD may thus identify a subgroup of patients who remain at high risk of mortality despite CRT. 
Such patients are candidates for close follow-up, as well as interventions which may modify 
their outcome, e.g. optimization of device programming, adjustment of pharmacotherapy and 
eventually mechanical LV support or cardiac transplantation.
Study limitations
This was a retrospective, single-center study and included patients who completed the 6 
months of follow-up echocardiographic evaluation. Therefore, there may be a selection bias, 
since LVMD could not be measured in patients who deceased during the first 6 months after 
CRT implantation. The mode of death was not systematically available. The measurements of 
LVMD are not vendor independent and the cut-off value of LVMD provided in this study may 
not be generalizable to other patients in whom LVMD was measured with different software.
CONCLUSIONS
LVMD after 6 months of CRT is independently associated with all-cause mortality and ventricu-
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Background: Cardiac resynchronization therapy (CRT) restores mechanical efficiency to the fai-
ling left ventricle (LV) by resynchronization of contraction. Global, LV myocardial work efficiency 
can be quantified non-invasively with echocardiography, although the prognostic implication 
of this parameter remains unexplored. The objective was to relate global, LV myocardial work 
efficiency before CRT to long-term prognosis.
Methods: Data were analyzed from an ongoing registry of heart failure patients with class I 
indications for CRT according to contemporary guidelines. Global, LV myocardial work efficiency 
was defined as the ratio of the constructive work in all LV segments, divided by the sum of con-
structive and wasted work in all LV segments, as a percentage ((constructive work/(constructive 
work + wasted work)) x 100%). It was derived from speckle tracking strain echocardiography 
and non-invasive blood pressure measurements, taken before CRT implantation. Patients were 
dichotomized according to the baseline, median global, LV myocardial work efficiency (75%; 
interquartile range 66-81%).
Results: A total of 153 patients (mean age 66±10 years, 72% male, 48% ischemic heart disease) 
were analyzed. After a median follow-up of 57 months (interquartile range 28-76 months), 31% 
of patients died. CRT recipients with less efficient energetics at baseline (global, LV myocar-
dial work efficiency <75%) demonstrated lower event rates than patients with more efficient 
baseline energetics (global, LV myocardial work efficiency ≥75%) (log-rank test, P=0.029). On 
multivariable analysis, global LV myocardial work efficiency <75% pre-CRT was independently 
associated with a decreased risk of all-cause mortality (hazard ratio 0.48, 95% confidence 
interval 0.25-0.92; P=0.027), suggesting that the potential for improvement in LV efficiency is 
an important mechanism in CRT benefit.
Conclusions: Global, LV myocardial work efficiency can be derived non-invasively from speckle 
tracking strain echocardiography data and non-invasive blood pressure recordings. A lower 




Prognostic implications of LV myocardial work before CRT
INTRODUCTION
Cardiac work refers to the amount of mechanical energy which is expended in the process 
of left ventricular (LV) contraction and relaxation.1 Electrical conduction disturbances strongly 
influence LV work. In the presence of a left bundle branch block (LBBB), the interventricular 
septum is activated early and contracts before aortic valve opening. The early contraction of 
the septum thereby stretches the LV lateral wall before it has contracted, and when the lateral 
wall is activated late, the interventricular septum is stretched, leading to inefficient cardiac 
work (without LV ejection of blood or stroke volume).2 Cardiac resynchronization therapy (CRT), 
an effective therapy in selected heart failure patients,3 restores mechanical efficiency to the fai-
ling LV by resynchronization of contraction. The less efficiently the LV operates at baseline, the 
greater the potential for recovery of efficient LV work with CRT. Whether a greater reserve of po-
tentially recoverable global, LV myocardial work efficiency before CRT translates into improved 
outcome, is unknown. Global, LV myocardial work efficiency can be quantified non-invasively 
with a novel, echocardiography-based technique.4 Speckle tracking strain echocardiography 
data are combined with non-invasive blood pressure recordings to calculate segmental cardiac 
work and subsequently, the global, LV myocardial work efficiency.2 Both preclinical and clinical 
studies have shown the validity of using this technique to quantify global, LV myocardial work 
efficiency non-invasively, including in a LBBB context.2,4,5 However, the prognostic implications 
of global, LV myocardial work efficiency in heart failure patients undergoing CRT have not been 
explored. We investigated the prognostic implication of the global, LV myocardial work effici-
ency measured before CRT implantation.
METHODS
Study population and definition of clinical measures
From an ongoing registry of heart failure patients treated with CRT,6 those with class I recom-
mendations for CRT (sinus rhythm and QRS duration ≥130 ms with LBBB morphology, LV 
ejection fraction (EF) ≤35% and New York Heart Association (NYHA) class II, III and ambulatory 
IV symptoms, despite adequate medical treatment),3 and simultaneous, non-invasive measure-
ment of blood pressure with brachial artery sphygmomanometry during echocardiography 
were selected. The institutional review board approved this retrospective analysis of clinically 
acquired data and waived the need for patient written informed consent.
Ischemic heart failure etiology was defined as the presence of significant coronary artery 
disease. The NYHA functional class was assessed in all patients, and a clinical response to CRT 
was subsequently defined as an improvement of ≥1 NYHA class at 6-month follow-up.7 Quality 
of life was evaluated with the Minnesota Living with Heart Failure Questionnaire, and if the 
patient’s condition allowed, a 6-minute walk test was also conducted.8,9 Renal function was 
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characterized by the estimated glomerular filtration rate (eGFR), according to the Modification 
of Diet in Renal Disease (MDRD) study equation.10
Conventional analysis of echocardiographic data
All patients underwent transthoracic echocardiography in the left lateral decubitus position with 
a commercially available echocardiography system (VIVID 7 or E9, General Electric Vingmed 
Ultrasound, Milwaukee, USA). Echocardiographic data were acquired with either 3.5 MHz or 
M5S transducers, while adjusting depth and gain settings as necessary. ECG-triggered, M-mode, 
2-dimensional and Doppler data were digitally archived for off-line analysis (EchoPac 202, Ge-
neral Electric Vingmed Ultrasound, Milwaukee, USA). The LV end-systolic volume (LVESV), LV 
end-diastolic volume (LVEDV) and the LVEF were calculated with the Simpson’s method from 
2-dimensional, apical, 2- and 4-chamber views.11
Calculation and definition of global, LV myocardial work efficiency
The global, LV myocardial work efficiency was calculated by proprietary software (EchoPac 202, 
General Electric Vingmed Ultrasound, Milwaukee, USA) from speckle tracking echocardiogra-
phic strain data, as well as non-invasive blood pressure recordings. Speckle tracking analysis 
was used to measure longitudinal LV strain from standard apical views (long-axis, 2-chamber 
and 4-chamber).12 The opening and closing time points of the aortic and mitral valves were 
identified from the parasternal, 2-dimensional images of the LV. Non-invasive blood pressure 
values were recorded with brachial artery sphygmomanometry at the time of transthoracic 
echocardiography. An LV pressure-strain curve was then constructed from the LV longitudinal 
strain data of the entire cardiac cycle, the mitral and aortic valve opening and closing times as 
well as non-invasive blood pressure values. Cardiac work was calculated automatically per myo-
cardial segment by the abovementioned software by differentiation of the strain values over 
time to yield the segmental shortening rate, which was then multiplied by the LV instantaneous 
pressure. The resultant, i.e. instantaneous power, was subsequently integrated over time, 
providing values for LV segmental and total LV work as a time function.2 Constructive work 
was defined as cardiac work performed during shortening of a myocardial segment in systole 
or during lengthening in isovolumic relaxation, whereas wasted work was defined as work 
performed by a segment during lengthening in systole, or during shortening against a closed 
aortic valve in isovolumic relaxation. The global, LV myocardial work efficiency was defined 
as the ratio of the constructive work in all LV segments, divided by the sum of constructive 
and wasted work in all LV segments, as a percentage ((constructive work/(constructive work + 
wasted work)) x 100%) (Figure 1).
5
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Figure 1: Change in global, left ventricular (LV) myocardial work efficiency due to effective cardiac 
resynchronization therapy (CRT). Parametric maps of global LV myocardial work efficiency in a patient A) before 
CRT and B) after 6 months of CRT. The global LV work efficiency increased from 62% to 84% after 6 months of 
CRT. Segmental values of LV work efficiency are expressed as percentages. CRT: cardiac resynchronization 
therapy, GWE: global, LV work efficiency. 
 
i r  : Change in global, left  ventricular (LV) myocardi l work effi  ci ncy due to ff ecti ve cardiac resyn-
chronizati on therapy (CRT). Parametric maps of global LV myocardial work effi  c ency in a pati ent  
CRT and B) aft er 6 months of CRT. The global LV work effi  ciency increased from 62% to 84% aft er 6 months 
of CRT. Segmental values of LV work effi  ciency are expressed as percentages. CRT: cardiac resynchronizati on 
therapy, GWE: global, LV work effi  ciency.
CRT implantati on and follow-up
Implantati on of CRT was performed according to a standard approach, i.e. inserti on of the right 
atrial and right ventricular leads via the subclavian or cephalic veins. Before inserti on of the LV 
lead, coronary sinus venography was performed. The LV pacing lead was then introduced into 
the coronary sinus through an 8 Fr guiding catheter, and positi oned in a posterior or postero-
lateral vein, if possible. All leads were connected to a dual-chamber, biventricular CRT device. 
Defi brillator functi onality was included in most (99%) of the implanted devices. CRT recipients 
were followed up at regular intervals at the heart failure outpati ent clinic, and the device was 
interrogated. Atrioventricular and interventricular delays were empirically set at 120-140 ms 
and 0 ms, respecti vely. CRT opti mizati on was performed during follow-up visits at the discreti on 
of the treati ng physician. A CRT response was defi ned by a ≥15% reducti on in the LVESV aft er 6 
months of CRT.7 The nati onal death registry and case records were reviewed for the occurrence 
of all-cause mortality during follow-up. Pati ents were followed up for the occurrence of the 
primary outcome, i.e. all-cause mortality.
Stati sti cal analysis
Means and standard deviati ons were used for presenti ng conti nuous data; numbers and 
percentages for categorical data. Conti nuous variables were compared by means of Student 
t-tests, while χ2 and Fisher’s exact tests (as appropriate) were used for the comparison of 
categorical data. Values of the baseline, global, LV myocardial work effi  ciency were compared 
with a log-rank test. A Cox proporti onal hazards model was used to investi gate the independent 
associati on between baseline, global, LV myocardial work effi  ciency and all-cause mortality. To 
show hazard change across the range of baseline global, LV myocardial work effi  ciency, as a con-
ti nuous variable, a spline curve was fi t for global, LV myocardial work effi  ciency vs. mortality, 
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with overlaid confidence intervals. Subsequently, a multivariate spline model was constructed, 
after adjusting for the following covariates: age at implantation, gender, body mass index, is-
chemic etiology of heart failure, beta-blockers, diuretics, hemoglobin, renal dysfunction, LVEDV 
at baseline, LVEF at baseline and CRT response. In order to evaluate the incremental value of 
baseline, global LV myocardial work efficiency over global longitudinal strain for outcome, we 
performed likelihood ratio testing. SPSS for Windows, version 23.0 (SPSS, Armonk, NY, USA) 
and R, version 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria) were used for 




In total, 153 heart failure patients treated with CRT (class I recommendation) and with echo-
cardiographic and blood pressure data were included for analysis (mean age 66±10 years, 72% 
male, 48% ischemic heart disease). Strain analysis and calculation of global, LV myocardial work 
efficiency were feasible in all 153 (100%) patients. Baseline characteristics for the overall popu-
lation are presented in Table 1. The median baseline, global, LV myocardial work efficiency was 
75% (interquartile range (IQR) 66-81%). Patients were subsequently dichotomized according 
to the median value of baseline, global, LV myocardial work efficiency, i.e. <75% and ≥75%. 
CRT recipients with baseline, global, LV myocardial work efficiency <75% were more frequently 
female, and had larger chamber dimensions (LVEDV, LVESV) and worse systolic function (LVEF) 
than those with baseline, global, LV myocardial work efficiency ≥75% (Table 1).
Baseline, global, LV myocardial work efficiency and survival
In total, 47 (31%) patients died during a median follow-up of 57 months (IQR 28-76 months). 
Patients with less efficient mechanics at baseline (global, LV myocardial work efficiency <75%), 
demonstrated lower event rates than those with more efficient baseline mechanics (global, LV 
myocardial work efficiency ≥75%) (log-rank test, P=0.029; Figure 2). In patients with baseline, 
global, LV myocardial work efficiency <75%, the cumulative, all-cause mortality rates were 5, 21 
and 30% at 25, 50 and 75 months follow-up, respectively. In contrast, in the group of patients 
with baseline, global, LV myocardial work efficiency ≥75%, the cumulative event rates were 19, 
37 and 49% at the same follow-up time points.
To investigate the association between baseline, global, LV myocardial work efficiency and 
all-cause mortality, a Cox proportional hazards model was constructed with variables known 
to influence mortality of heart failure patients (Table 2). On multivariable analysis, global, LV 
myocardial work efficiency <75% at baseline was independently associated with better survival 
(hazard ratio 0.48; 95% confidence interval 0.25-0.92; P=0.027). To show hazard change across 
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Figure 2: Kaplan-Meier curves depicting time to cumulative survival in cardiac resynchronization (CRT) 
recipients. Data are shown according to those with baseline, global, left ventricular (LV) myocardial work 
efficiency <75% and ≥75%. LV: left ventricular. 
 














Age (years) 65.5±10.2 64.0±9.9 66.9±10.3 0.081 
Male gender, n (%) 110 (71.9) 48 (62.3) 62 (81.6) 0.008 
Ischemic etiology, n (%) 74 (48.4) 33 (42.9) 41 (53.9) 0.170 
Heart rhythm at baseline, n (%) 
- Sinus rhythm  






































6 MWT (m) 344.7±114.7 371.3±111.3 316.7±112.4 0.011 
QoL score 30.2±19.4 27.8±17.8 33.0±20.9 0.135 
Diabetes, n (%) 24 (15.7) 8 (10.4) 16 (21.1) 0.070 
eGFR <60 ml/min/1.73 m2, n (%) 55 (35.9) 27 (38.0) 28 (40.0) 0.810 
LVEF (%) 24.9±6.9 22.4±6.9 27.5±5.8 <0.001 
LVEDV (ml) 216.1±78.5 232.3±81.8 199.8±71.8 0.010 
LVESV (ml) 164.2±67.2 182.2±71.8 146.0±57.1 <0.001 
Global, LV myocardial  








Values are mean ± standard deviation, unless otherwise specified. eGFR: estimated glomerular filtration rate, 
IQR: interquartile range, LV: left ventricular, LVEF: left ventricular ejection fraction, LVEDV: left ventricular end-
diastolic volume, LVESV: left ventricular end-systolic volume, 6 MWT: 6-minute walk test, NYHA: New York Heart 
Association, QoL: quality of life, *per definition. 
Figure 2: Kaplan-Meier curves depicting time to cumulative survival in cardiac resynchronization (CRT) re-
cipients. Data are shown according to those with baseline, global, left ventricular (LV) myocardial work ef-
ficiency <75% and ≥75%. LV: left ventricular.
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the range of baseline, global, LV myocardial work effi  ciency, as a conti nuous variable, a spline 
curve was fi t for baseline, global, LV myocardial work effi  ciency vs. mortality. For all-cause 
mortality, predicted from the baseline, global, LV myocardial work effi  ciency, the assumpti on 
of linearity was violated (χ2, 7.8; P=0.02). There was an increase of hazards for baseline, global, 
LV myocardial work effi  ciency between 70% and 85%. At very low, global, LV myocardial work 
effi  ciency values (<65%), there was also an increase of the hazards, giving a parabolic shape 
to the curve, although a lower frequency of observati ons in this range makes a meaningful, 
clinical interpretati on less robust (also refl ected in the wider confi dence intervals at low base-
line, global, LV myocardial work effi  ciency) (Figure 3A). When adjusted for multi ple covariates, 
the assumpti on of linearity was not violated (χ2, 3.7; P=0.16), and the curve demonstrated a 
similar shape to the unadjusted model for higher values, with hazards increasing for baseline, 
global, LV myocardial work effi  ciency between 70% and 85% (Figure 3B). At lower values (<65%) 
however, a plateau developed, although a low number of observati ons and wide confi dence 
intervals again made clinical interpretati on more challenging.
Incremental value of global, LV myocardial work effi  ciency
In order to evaluate the incremental value of global, LV myocardial work effi  ciency over global 
longitudinal strain for mortality, likelihood rati o testi ng was performed. The baseline model 
(model 1) comprised all risk factors which were included in the multi variable regression model, 
i.e.: age at implantati on, ischemic eti ology of heart failure, renal dysfuncti on and a response 
to cardiac resynchronizati on therapy (≥15% decrease in LV, end-systolic volume). Additi on of 
Table 2: Uni- and multi variable Cox proporti onal hazards models for all-cause mortality.
Univariable analysis Multi variable analysis
Variable HR 95% CI P-value HR 95% CI P-value
Baseline, global, LV myocardial work effi  ciency <75% 0.535 0.302-0.948 0.032 0.484 0.254-0.922 0.027
Age at implant (years) 1.040 1.006-1.075 0.019 1.009 0.974-1.045 0.620
Male gender 1.074 0.578-1.996 0.822 - - -
Body mass index (kg/m2) 0.996 0.933-1.063 0.901 - - -
Ischemic eti ology 1.816 1.031-3.201 0.039 1.229 0.646-2.341 0.530
Beta-blockers 0.740 0.403-1.359 0.332 - - -
Diureti cs 1.894 0.807-4.445 0.142 - - -
Hemoglobin (g/dl) 0.967 0.728-1.283 0.814 - - -
Renal dysfuncti on
(eGFR <60 ml/min/1.73 m2)
3.471 1.901-6.339 <0.001 3.463 1.761-6.809 <0.001
LVEDV at baseline 0.999 0.995-1.003 0.581 - - -
LVEF at baseline 0.995 0.955-1.036 0.804 - - -
Responder (≥15% reducti on LVESV aft er 6 months) 0.534 0.294-0.969 0.039 0.575 0.302-1.095 0.092
CI: confi dence interval, eGFR: esti mated glomerular fi ltrati on rate, HR: hazard rati o, LV: left  ventricular, LVEDV: left  ventricular, 
end-diastolic volume, LVEF: left  ventricular ejecti on fracti on, LVESV: left  ventricular, end-systolic volume.
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baseline, global longitudinal strain to model 1, provided incremental value (P=0.029; Figure 
4). A third model, which included baseline global, myocardial work effi  ciency, proved to be of 
further incremental value (P=0.002; Figure 4).
 
increasing for baseline, global, LV myocardial work efficiency between 70% and 85% (Figure 
3B). At lower values (<65%) however, a plateau developed, although a low number of 
observations and wide confidence intervals again made clinical interpretation more 
challenging.  
 
Incremental value of global, LV myocardial work efficiency  
 
In order to evaluate the incremental value of global, LV myocardial work efficiency over global 
longitudinal strain for mortality, likelihood ratio testing was performed. The baseline model 
(model 1) comprised all risk factors which were included in the multivariable regression 
model, i.e.: age at implantation, ischemic etiology of heart failure, renal dysfunction and a 
response to cardiac resynchronization therapy (≥15% decrease in LV, end-systolic volume). 
Addition of baseline, global longitudinal strain to model 1, provided incremental value 
(P=0.029; Figure 4). A third model, which included baseline global, myocardial work efficiency, 




Figure 4: Likelihood ratio test. Bars represent the incremental value of global longitudinal strain and global, 
left ventricular myocardial work efficiency in addition to clinical risk factors (Model 1). GLS: global longitudinal 




The primary finding of the present study, is that a lower global, LV myocardial work efficiency 
before institution of CRT is independently associated with better long-term outcome in 
patients with a class I indication for CRT, according to current guidelines. 
 
 
Figure 4: Likelihood rati o test. Bars represent the incremental value of global longitudinal strain and global, 
left  ventricular myocardial work effi  ciency in additi on to clinical risk factors (Model 1). GLS: global longitudinal 
strain, MWE: myocardial work effi  ciency.
 
Table 2: Uni- and multivariable Cox proportional hazards models for all-cause mortality. 
 Univariable analysis Multivariable analysis 
Variable HR  95% CI P-value HR  95% CI P-
value 












Male gender 1.074 0.578-
1.996 
0.822 - - - 
Body mass index (kg/m2) 0.996 0.933-
1.063 
0.901 - - - 







0.332 - - - 
Diuretics 1.894 0.807-
4.445 
0.142 - - - 
Hemoglobin (g/dl) 0.967 0.728-
1.283 
0.814 - - - 
Renal dysfunction 






LVEDV at baseline 0.999 0.995-
1.003 
0.581 - - - 
LVEF at baseline  0.995 0.955-
1.036 
0.804 - - - 
Responder (≥15% reduction LVESV 






CI: confidence interval, eGFR: estimated glomerular filtration rate, HR: hazard ratio, LV: left ventricular, LVEDV: 
left ventricular, end-diastolic volume, LVEF: left ventricular ejection fraction, LVESV: left ventricular, end-
systolic volume.  
Figure 3: Spline curves for baseline, global, LV myocardial work efficiency vs. all-cause mortality. Predicted 
mortality across a range of baseline, global, LV myocardial work efficiency, plotted as a fitted spline model on a 
log-hazard scale, with overlaid confidence intervals. The unadjusted model is shown in panel A, and the adjusted 
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The primary finding of the present study, is that a lower global, LV myocardial work efficiency 
before institution of CRT is independently associated with better long-term outcome in patients 
with a class I indication for CRT, according to current guidelines.
Non-invasive estimation of global, LV myocardial work efficiency
Cardiac work which is performed by an early-activated LV segment on an opposing, late-
activated LV segment (elongating the late-activated segment during contraction of the early-
activated segment), does not contribute to the LV stroke volume, and leads to inefficient LV 
function.2 This can be quantified by the global, LV myocardial work efficiency, i.e. the ratio of 
the constructive work in all LV segments, divided by the sum of constructive and wasted work 
in all LV segments, as a percentage ((constructive work/(constructive work + wasted work)) x 
100%). In order to estimate the global, LV myocardial work efficiency non-invasively, wasted 
LV work and constructive LV work have to be measured. Since the principles of non-invasive 
determination apply equally well to wasted and constructive LV work (the former representing 
work performed by a segment during lengthening in systole, or during shortening against a 
closed aortic valve in isovolumic relaxation, and the latter work performed during shortening of 
a myocardial segment in systole or during lengthening in isovolumic relaxation), experimental 
studies have focused on the validity of the non-invasive estimation of cardiac work.
Echocardiography-based, non-invasive estimation of cardiac work is a novel technique, 
with the objective to quantify the energy efficiency of the LV.4 In a canine validation study, 
a good correlation was demonstrated between invasive and non-invasive LV pressure-strain 
loops (r=0.96).4 In the same study, LV work was then calculated non-invasively in humans, 
and compared to regional, myocardial glucose metabolism (visualized with positron emission 
tomography (PET)).4 A very robust correlation was found between the non-invasive LV work 
and the regional, myocardial glucose metabolism (r=0.81).4 Further evidence for the validity of 
the non-invasive estimation of LV work has been provided in a murine model, which indicated 
a strong correlation between myocardial work (non-invasively estimated with magnetic reso-
nance imaging) and the influx rate constant of 18-fluoro-deoxyglucose (as a marker of the rate 
of myocardial glucose metabolism) on PET (r=0.75).5 Since LV work can be reliably estimated 
non-invasively, the global, LV myocardial work efficiency can be calculated from wasted and 
constructive LV work. This is achieved using echocardiography and sphygmomanometric blood 
pressure recordings. Since electrical conduction disturbances – specifically LV dyssynchrony – 
influence the global, LV myocardial work efficiency, this technique can be applied to investigate 
the effects of CRT on myocardial energetics.
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Global, LV myocardial work efficiency before CRT: implications for outcome
A lesser global, LV myocardial work efficiency before CRT was independently associated with 
better long-term outcome in our study. Abnormal LV activation due to a LBBB leads to dys-
synchronous LV contraction, which causes an early-activated LV segment to stretch an opposing 
late-activated segment and vice versa, but does not contribute to stroke volume and therefore 
leads to inefficient LV mechanics.2 Both the presence of an LBBB and other baseline LV dys-
synchrony measures are associated with long-term outcome in CRT.3,13-16
Inclusion criteria for our study comprised class I indications for CRT according to contem-
porary guidelines, i.e. including the presence of an LBBB.3 Despite selection of CRT recipients 
on the basis of a pre-existing LBBB and QRS ≥130 ms, the degree of baseline, global, LV myo-
cardial work efficiency was independently associated with long-term survival. This difference 
in outcome between CRT recipients with a greater or lesser baseline, global, LV myocardial 
work efficiency can therefore not be attributed to the presence of LBBB-induced dyssynchrony 
alone. Improvement of function in areas of poorly contractile but viable myocardium by CRT, 
will increase the amount of constructive work performed by the LV. This so-called recruitment 
of contractile reserve in CRT candidates has been demonstrated with dobutamine stress-
echocardiography, and it is associated with both the acute and long-term remodeling response 
to CRT, as well as better event-free survival.17-21 Since global, LV constructive work correlates 
with myocardial metabolic activity on PET, it can be considered an indication of contractile 
reserve in CRT recipients.4,20 Since the global, LV myocardial work efficiency is calculated from 
wasted and constructive LV work, it will improve with recruitment of contractile reserve. It 
therefore seems likely that, in our study patients, a difference in the contractile reserve is 
reflected in the baseline global, LV myocardial work efficiency, which is subsequently recruited, 
thereby increasing the global, LV myocardial work efficiency. Since the activation of contractile 
reserve in LV segments after CRT is associated with a better outcome, it is not surprising that 
the baseline, global, LV myocardial work efficiency is also associated with outcome. The trend 
towards a higher risk at very low values of global, LV myocardial work efficiency seen on both 
the unadjusted and adjusted spline curves (Figure 3), suggests that there may be a lower limit 
of contractile reserve, below which the myocardial contractile reserve is exhausted.
Furthermore, the incremental value of global, LV myocardial work efficiency over global 
longitudinal strain (in addition to clinical risk factors) for survival, lends additional support to 
the role of global, LV myocardial work efficiency as a useful imaging parameter in CRT.
Further studies, in larger populations, will be required to determine the value of measuring 
global, LV myocardial work efficiency before the implantation of CRT, especially with regard 
to selection of CRT candidates and in predicting long-term outcome. Global, LV myocardial 
work efficiency will be included as a parameter in the EuroCRT study, which is designed to 
prospectively evaluate multimodality imaging in the evaluation of various long-term outcome 




This study is subject to the limitations of a retrospective, single-center study. Since the 
calculation of global, LV myocardial work efficiency is dependent on speckle tracking strain 
echocardiography, the results are not vendor-independent.
CONCLUSIONS
Global, LV myocardial work efficiency can be derived non-invasively from speckle tracking strain 
echocardiography data and sphygmomanometric blood pressure recordings. A lower global, 
LV myocardial work efficiency before CRT, is independently associated with better long-term 
outcome in heart failure patients with a class I indication for CRT, according to current guide-
lines. Larger studies are required to confirm the usefulness of non-invasive measurement of 
global, LV myocardial work efficiency in predicting CRT response, as well as in the prediction of 
long-term outcome after CRT.
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Background: Functional mitral regurgitation (FMR) is common in heart failure (HF), and nega-
tively impacts prognosis. Cardiac resynchronization therapy (CRT) can improve FMR, but the 
long-term changes in and impact of FMR after CRT are still unclear. The present study investiga-
ted the prevalence, evolution and impact on mortality of FMR before and after CRT in patients 
with HF.
Methods: A total of 1 313 patients (66±11 years, 77% male, 59% ischemic heart disease) treated 
with CRT were evaluated. Patients were divided into 4 groups of FMR according to the evolution 
at 6 months after CRT: no or mild FMR at baseline which remained unchanged at 6 months 
(grade 0-1 FMR unchanged, n=609 (51%)), no or mild FMR which worsened to moderate to 
severe (grade 0-1 FMR worsened, n=66 (6%)), moderate to severe FMR which improved to 
no or mild (grade 2-4 improved, n=209 (18%)), and moderate to severe FMR which remained 
unchanged (grade 2-4 unchanged, n=309 (26%)).
Results: Over a mean follow-up of 51±38 months, 297 (25%) patients died. Those with baseline 
FMR grade 0-1 which remained unchanged at 6-month follow-up, as well as baseline FMR grade 
2-4 which improved, had lower mortality rates than patients with 6-month FMR grade 2-4 re-
gardless of baseline FMR grade (P<0.001). Baseline FMR grade 2-4 that remained unchanged at 
6-month follow-up was associated with increased mortality, independent of the clinical and left 
ventricular volumetric responses to CRT (hazard ratio 1.77; 95% confidence interval 1.41-2.22; 
P<0.001).
Conclusions: Moderate to severe FMR at baseline which remains unchanged at 6 months after 
CRT implantation is strongly associated with long-term mortality in patients with HF.
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INTRODUCTION
Functional mitral regurgitation (FMR) is common in heart failure (HF), with a prevalence of ap-
proximately 50% in ischemic cardiomyopathy and 56-65% in non-ischemic cardiomyopathy.1-3 
Moderate to severe FMR portends a poor prognosis, increasing HF hospitalizations and death.2,4 
Cardiac resynchronization therapy (CRT) is a well-established HF therapy.5 The prevalence of 
FMR after CRT treatment varies among studies.6-8 FMR may diminish, remain stable or worsen 
after CRT, which may impact prognosis after CRT. No randomized study has investigated the 
prevalence, evolution and impact on mortality of FMR before and after CRT in patients with HF. 
We analyzed the prevalence of FMR in a large cohort of HF patients undergoing CRT. Moreover, 
the relation between the change in FMR after 6 months of CRT, and the clinical and echocardio-
graphic response to CRT was evaluated. Finally, the changes in FMR after CRT were related to 
long-term outcome during extended follow-up.
METHODS
Patient population and data collection
HF patients who underwent quantitative assessment of MR severity at the echocardiographic 
core laboratory of Leiden University Medical Center and subsequent CRT implantation ac-
cording to contemporary guidelines were included in this retrospective evaluation.5 Patients 
who underwent mitral valve surgery (replacement or repair) prior to or after CRT implantation 
(n=110) and those with primary MR were excluded. Demographic, clinical, laboratory, electro-
cardiographic (ECG) and echocardiographic parameters were analyzed. Patients with previous 
infarction or revascularization, as well as significant coronary artery disease on invasive an-
giography, were considered to have ischemic cardiomyopathy, whereas the remainder were 
considered non-ischemic.
Clinical evaluation included assessment of New York Heart Association (NYHA) class, quality 
of life (QoL, using the Minnesota Living with Heart Failure Questionnaire)9 and a 6-minute walk 
test (6 MWT) if able.10 Clinical and echocardiographic assessments were routinely repeated at 
6 months after CRT implantation. Thereafter, patients were scheduled for regular outpatient 
visits.
Echocardiographic data acquisition and analysis
Two-dimensional transthoracic echocardiography was performed in all patients using a com-
mercially available echocardiographic system (VIVID 7 or E9, General Electric Vingmed Ultra-
sound, Milwaukee, USA) prior to CRT implantation and after 6 months. Images were acquired 
with 3.5 MHz or M5S transducers, adjusting depth and gain settings as appropriate. M-mode, 
2-dimensional and Doppler data, triggered to the ECG, were obtained and stored digitally for 
Chapter 6
84
off-line analysis (EchoPac 113, General Electric Vingmed Ultrasound, Milwaukee, USA). Left ven-
tricular end-systolic volume (LVESV), LV end-diastolic volume (LVEDV) and LV ejection fraction 
(LVEF) were measured from the apical 2- and 4-chamber views, using the modified Simpson’s 
biplane method.11 The severity of FMR was evaluated according to current recommendations, 
using a multiparametric approach, including qualitative and semi-quantitative indices, and was 
graded on a 4-point scale: no or mild=1, moderate=2, moderate to severe=3, and severe=4.12
Implantation of CRT
Right atrial and ventricular leads were positioned in a conventional manner, as previously de-
scribed, and CRT optimization was performed during follow-up at the discretion of the treating 
physician.13
Changes in FMR grade after CRT and definitions of response to CRT
Changes in FMR were evaluated at 6-month follow-up. Patients were divided in 4 groups: 
patients with no or mild FMR (grade 0-1) at baseline which remained unchanged at 6 months; 
patients with no or mild FMR (grade 0-1) at baseline which worsened to moderate to severe MR 
at 6 months (grade 2-4); patients with moderate to severe FMR (grade 2-4) at baseline which 
improved to no or mild (grade 0-1) at 6 months; and patients with moderate to severe FMR 
(grade 2-4) at baseline which remained unchanged at 6 months.
These FMR changes were related to 6-month response to CRT. A positive clinical response 
to CRT was defined as ≥1 class improvement in NYHA class at 6-month follow-up, whereas 
a positive echocardiographic response was defined as ≥15% reduction in LVESV at 6-month 
follow-up.13
Long-term outcome
Patient data were prospectively collected in the departmental Cardiology Information System 
(EPD-Vision®, Leiden University Medical Center, Leiden, The Netherlands) and subsequently 
analyzed. The institutional review board approved the research and waived the need for writ-
ten patient informed consent provided that the data were acquired for routine patient care. In 
the present evaluation, all data were acquired for clinical purposes and handled anonymously. 
Data on survival were retrieved from medical records and the municipal civil registries.
Statistical analysis
Continuous variables are presented as means and standard deviations, and categorical data 
as numbers and percentages. Continuous variables were compared with one-way, between-
group analysis of variance (ANOVA), using Bonferroni correction for multiple comparisons, and 
general linear mixed models. Categorical data were compared with the χ2 and Fisher’s exact 
tests, as appropriate. The event-free survival rates for each FMR group were evaluated with the 
Kaplan-Meier method and compared with the log-rank test. The follow-up period started at 6 
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months aft er CRT implantati on, when change in FMR grade was assessed and FMR groups were 
defi ned. Independent associates of all-cause mortality were evaluated with the Cox proporti o-
nal hazards model, with the following variables entered into the model: baseline grade 0-1 FMR 
unchanged, baseline grade 2-4 FMR improved, baseline grade 0-1 FMR worsened, baseline 
grade 2-4 FMR unchanged, age, male sex, body mass index, diabetes mellitus, ischemic eti ology 
of HF, diureti c use, hemoglobin, renal dysfuncti on, LVEF at 6 months, positi ve echo response, 
positi ve clinical response and atrial fi brillati on. All analyses were performed with SPSS for Win-
dows, version 23.0 (SPSS, Armonk, NY, USA). All stati sti cal tests were two-sided and a P-value 
<0.05 was considered stati sti cally signifi cant.
RESULTS
Evoluti on of FMR aft er 6 months of CRT
A total of 1 313 pati ents (mean age 66±11 years, 77% male) with HF and baseline echocar-
diography who were treated with CRT were included in the analysis. The eti ology of HF was 
ischemic in 59% of pati ents, the mean LVEF was 27±8% and the mean QRS durati on 156±33 ms. 
No or mild FMR was noted in 735 (56%) pati ents, whereas 578 (44%) had moderate to severe 
MR. During 6-month follow-up 120 pati ents did not return for echocardiography. Thus, the 
study populati on consisted of 1 193 pati ents.
The severity of FMR before and aft er CRT implantati on is displayed in Figure 1. Overall, 
675 (57%) pati ents had no or mild FMR at baseline, while 518 (43%) pati ents had moderate 




Evolution of FMR after 6 months of CRT 
 
A total of 1 313 patients (mean age 66±11 years, 77% male) with HF and baseline 
echocardiography who were treated with CRT were included in the analysis. The etiology of 
HF was ischemic in 59% of patients, the mean LVEF was 27±8% and the mean QRS duration 
156±33 ms. No or mild FMR was noted in 735 (56%) patients, whereas 578 (44%) had 
moderate to severe MR. During 6-month follow-up 120 patients did n t return for 
echocardiography. Thus, the study population consisted of 1 193 patients. 
 
The severity of FMR before and after CRT implantation is displayed in Figure 1. Overall, 675 
(57%) patients had no or mild FMR at baseline, while 518 (43%) patients had moderate to 
severe FMR. Of the 675 patients with grade 0-1 FMR at baseline, the MR grade remained 
unchang d at 6-month foll w-up in 609 (90%), whereas the MR grade progressed to grade 2-
4 FMR in 66 (10%). Of the 518 patients with grade 2-4 FMR at baseline, the MR grade 




Figure 1: Distribution of no or mild functional mitral regurgitation (FMR), as well as moderate to severe FMR. 




Figure 1: Distributi on of no or mild functi onal mitral regurgitati on (FMR), as well as moderate to severe 
FMR. Data are shown at baseline (before cardiac resynchronizati on therapy (CRT)) and aft er 6 months of CRT.
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unchanged at 6-month follow-up in 609 (90%), whereas the MR grade progressed to grade 2-4 
FMR in 66 (10%). Of the 518 patients with grade 2-4 FMR at baseline, the MR grade improved 
to grade 0-1 in 209 (40%) and remained unchanged in 309 (60%) at 6-month follow-up.
Baseline characteristics of the 1 193 patients according to the change in FMR are sum-
marized in Table 1, while changes in clinical and echocardiographic parameters are shown in 
Table 2. Patients with grade 2-4 FMR at baseline which improved or remained unchanged at 6 
months after CRT, had larger LV volumes and lower LVEF at baseline. Patients with grade 2-4 
FMR at baseline which remained unchanged had more severe symptoms and more frequently 
had renal failure at baseline.
Table 1: Baseline characteristics according to FMR changes from baseline to 6 months after CRT.
Baseline 
















Age (years) 64.4±10.5 65.7±9.7 67.1±9.0* 66.5±10.8*
Male gender, n (%) 494 (81.1) 56 (84.8) 150 (71.8) 225 (72.8)
Ischemic etiology, n (%) 371 (60.9) 36 (54.5) 113 (54.1) 174 (56.3)





































6 MWT (m) 346.5±1 17.0 336.35±159.1 337.8±105.5 295.1±115.4*‡
QoL score 30.8±19.1  31.8±20.3 28.9±17.7 37.2±19.0*‡
Diabetes mellitus, n (%) 142 (23.3) 15 (22.7) 36 (17.2) 57 (18.4)
eGFR <60 ml/min/1.73 m2, n (%) 209 (34.3) 21 (31.8) 71 (34.0) 173 (56.0)
LVEF (%) 28.2±7.8 28.5±7.5 25.4±7.6*† 25.3±8.3*†
LVEDV (ml) 194.6±70.9 203.3±87.5 217.4±75.7* 231.8±86.0*†



























Continuous variables are mean ± standard deviation. ACE: angiotensin-converting enzyme, eGFR: estimated glomerular filtra-
tion rate, FMR: functional mitral regurgitation, LVEF: left ventricular ejection fraction, LVEDV: left ventricular end-diastolic 
volume, LVESV: left ventricular end-systolic volume, 6 MWT: 6-minute walk test, NYHA: New York Heart Association, QoL: 
quality of life. *P<0.05 vs. baseline no or mild FMR unchanged at 6 months; †P<0.05 vs. baseline no or mild FMR worsened at 
6 months; ‡P<0.05 vs. baseline moderate to severe FMR improved at 6 months.
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Clinical and echocardiographic responses to CRT
Changes in NYHA functional class HF symptoms at 6-month follow-up for each FMR group are 
presented in Figure 2. Overall there was an improvement in NYHA functional class HF symptoms 
across all the FMR groups. However, the clinical response rate (≥1 class improvement in NYHA 
class from baseline to 6 months) was significantly lower among patients with grade 0-1 FMR 
at baseline which worsened at follow-up (45%) compared to the other groups (63% for those 
with grade 0-1 FMR at baseline which remained unchanged, 70% in patients with grade 2-4 
FMR which improved and 66% in patients with grade 2-4 FMR which remained unchanged 
(P=0.013)). Changes in LVESV at 6-month follow-up for each FMR group are presented in Figure 
3. LVESV decrease was significantly greater in patients with grade 2-4 FMR at baseline which 
improved and in those with grade 0-1 FMR at baseline which remained unchanged at 6-month 
follow-up compared to patients with grade 2-4 FMR at baseline which remained unchanged and 
patients with grade 0-1 FMR at baseline which worsened (P<0.001). LV reverse remodeling was 
significantly more frequent among patients with grade 0-1 FMR at baseline which remained 
unchanged and grade 2-4 FMR at baseline which improved at 6-month follow-up (62% and 
77%, respectively) compared to those with grade 0-1 FMR at baseline which worsened and 
grade 2-4 FMR at baseline which remained unchanged (29% and 58%, respectively; P<0.001).
Evolution of FMR vs. long-term outcome
During a mean follow-up of 51±38 months, 297 (25%) patients died. When stratified according 
to FMR responses over 6 months, a cumulative 44 (7%), 109 (18%), 162 (27%) and 187 (31%) 
of the 609 patients with grade 0-1 FMR at baseline which remained unchanged at 6 months 
after CRT, died at 24, 48, 72 and 96 months of follow-up, respectively. Similar survival rates 
were observed in the group of 209 patients with grade 2-4 FMR which improved at 6 months of 
follow-up. In contrast, the group of 66 patients with grade 0-1 FMR at baseline which worsened 
showed significantly higher cumulative all-cause mortality events. Finally, the group of 309 
patients with baseline grade 2-4 FMR which did not improve after CRT showed the highest 
mortality rates (log-rank test, P<0.001; Figure 4). By multivariable analysis (Table 2), baseline 
grade 2-4 FMR which remained unchanged at 6 months after CRT was independently associated 
with increased risk of mortality (hazard ratio (HR) 1.77; 95% confidence interval (CI) 1.41-2.22, 




In this study, a fairly high prevalence of moderate to severe FMR (43%) was present at baseline 
among HF recipients of CRT. The FMR grade improved to no or mild FMR aft er 6 months of CRT 
in a substanti al proporti on (40%) of pati ents. In additi on, among those with no or mild FMR 
at baseline, a minority (10%) developed moderate to severe FMR aft er CRT. Pati ents in whom 
baseline no or mild FMR progressed to moderate to severe FMR and those with moderate to 
severe baseline FMR in whom CRT did not improve FMR, had a worse long-term prognosis 
compared with pati ents who exhibited no or mild FMR aft er 6 months of CRT (Figure 5). This 





Figure 2: Changes in New York Heart Association (NYHA) class, according to different patterns of evolution of 
functional mitral regurgitation (FMR). Changes in NYHA class are shown from baseline to 6 months after cardiac 
resynchronization therapy (CRT), according to the different patterns of evolution of FMR. *P<0.05 vs. other 
groups. Vertical bars represent standard error of the mean. 
 
Prevalence of FMR in HF 
 
The reported prevalence of FMR among patients with HF has varied in prior studies.4,8,14 In 
the present study of a large, unselected group of patients, the 43% prevalence of moderate 
to severe FMR at baseline was similar to the series of Rossi et al.4 (moderate 49%, severe 24%) 
and Cipriani et al.8 (55% moderate to severe).  
 
Figure 2: Changes in New York Heart Associati on (NYHA) class, according to diff erent patt erns of evoluti on 
of functi onal mitral regur itati on (FMR). Changes in NYHA class are shown from baseline to 6 months aft er 
cardiac resynchronizati on therapy (CRT), according to the diff erent patt erns of evoluti on of FMR. *P<0.05 vs. 
other groups. Verti cal bars repr s nt st dard error of the mean.
 
 
Figure 3: Changes in left ventricular end-systolic volume (LVESV), according to different patterns of evolution 
of functional mitral regurgitation (FMR). Changes in LVESV from baseline to 6 months after cardiac 
resynchronization therapy (CRT) are shown, according to different patterns of evolution of FMR. *P<0.01 vs. 
other groups. Vertical bars represent standard error of the mean. 
 
Effects of CRT on FMR 
 
Numerous studies have documented the ability of CRT to reduce FMR both acutely, long-
term, during rest and exercise.15-20 CRT addresses various aspects of FMR pathophysiology; 
by resynchronizing the atrioventricular and inter- and intraventricular contraction, LV preload 
is optimized and mitral valve closing forces are increased, leading to FMR reduction. By 
inducing LV reverse remodeling, papillary muscle tethering on mitral leaflets is reduced and 
mitral annulus dimensions shrink, resulting in improved leaflet coaptation.19,21-23 In the 
present study, patients with no or mild FMR at baseline which remained unchanged at 6-
month follow-up and patients with moderate to severe FMR at baseline which improved at 6 
months after CRT showed the most pronounced LV reverse remodeling, suggesting that CRT 
ameliorates the underlying pathophysiology of FMR. Interestingly, we found less NYHA 
functional class improvement and less LVESV reduction in CRT recipients with no or mild FMR 
at baseline which worsened at 6 months compared to other groups, whereas the worst 
survival was seen in those with moderate to severe FMR at baseline which remained 
unchanged. These data demonstrate that mechanisms underlying symptomatic improvement 
and LVESV changes after CRT are multifactorial in origin, reflecting more than only changes in 
FMR. 
 
Figure 3: Changes in left  ventricular end-systolic volume (LVESV), according to diff erent patt erns of evolu-
ti on of functi onal mitral regurgitati on (FMR). Changes in LVESV from baseline to 6 months aft er cardiac 
resynchronizati on therapy (CRT) are shown, accordin  to diff erent patt erns of evoluti on of FMR. *P<0.01 vs. 
other groups. Verti cal bars represent standard error of the mean.
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Prevalence of FMR in HF
The reported prevalence of FMR among patients with HF has varied in prior studies.4,8,14 In 
the present study of a large, unselected group of patients, the 43% prevalence of moderate to 
severe FMR at baseline was similar to the series of Rossi et al.4 (moderate 49%, severe 24%) and 
Cipriani et al.8 (55% moderate to severe).
 
 
Figure 4: Kaplan-Meier survival curves for time to cumulative survival in different patterns of functional mitral 
regurgitation (FMR) evolution. Data are shown for patients with baseline grade 0-1 FMR which remained 
unchanged at 6 months, baseline grade 2-4 FMR which improved at 6 months, baseline grade 0-1 FMR which 
worsened at 6 months and baseline grade 2-4 FMR which remained unchanged at 6 months. 
 
Table 2: Predictors of all-cause mortality risk, univariable and multivariable Cox proportional 
hazards models. 
 Univariable analysis Multivariable analysis 
Variable HR  95% CI P-value HR  95% CI P-value 
Baseline grade 0-1 FMR 
unchanged 
- - - - - - 
Baseline grade 2-4 FMR 
improved  
1.03 0.79-1.34 0.821 1.19 0.89-1.59 0.239 
Baseline grade 0-1 FMR 
worsened  
1.58 1.01-2.48 0.046 1.30 0.76-2.23 0.337 
Baseline grade 2-4 FMR 
unchanged  
2.16 1.77-2.65 <0.001 1.77 1.41-2.22 <0.001 
Age (years) 1.04 1.03-1.05 <0.001 1.03 1.02-1.04 <0.001 
Male gender 1.37 1.10-1.71 0.005 1.42 1.09-1.85 0.009 
Body mass index (kg/m2) 0.97 0.95-0.99 0.009 0.98 0.96-1.01 0.131 
Diabetes mellitus 1.72 1.42-2.09 <0.001 1.56 1.23-1.99 <0.001 
Ischemic etiology of heart 
failure 
1.58 1.32-1.90 <0.001 1.18 0.95-1.47 0.138 
Diuretic use 1.77 1.38-2.28 <0.001 1.23 0.91-1.66 0.176 
Hemoglobin (g/dl) 0.80 0.73-0.87 <0.001 0.92 0.83-1.03 0.147 
Renal dysfunction (eGFR  
<60 ml/min/1.73 m2) 
2.71 2.28-3.23 <0.001 1.94 1.57-2.40 <0.001 
LVEF at 6 months (%) 0.96 0.95-0.97 <0.001 0.98 0.96-0.99 <0.001 
Positive echo response* 0.61 0.52-0.73 <0.001 0.82 0.66-1.02 0.080 
Positive clinical response  0.82 0.68-0.99 0.040 0.82 0.67-1.01 0.059 
Atrial fibrillation 1.76 1.43-2.18 <0.001 1.39 1.08-1.79 0.010 
CI: confidence interval, eGFR: estimated glomerular filtration rate, FMR: functional mitral regurgitation, HR: 
hazard ratio, LVEF: left ventricular ejection fraction. *LVESV reduction of ≥15% at 6 months after cardiac 
resynchronization therapy. 
Figure 4: Kaplan-Meier survival curves for time to cumulative survival in different patterns of functional mi-
tral regurgitation (FMR) evolution. Data are shown for patients with baseline grade 0-1 FMR which remained 
unchanged at 6 months, baseline grade 2-4 FMR which improved at 6 months, baseline grade 0-1 FMR which 
worsened at 6 months and baseline grade 2-4 FMR which remained unchanged at 6 months.
Effects of CRT on FMR
Numerous studies have documented the ability of CRT to reduce FMR both acutely, long-term, 
during rest and exercise.15-20 CRT addresses various aspects of FMR pathophysiology; by resyn-
chronizing the atrioventricular and inter- and intraventricular contraction, LV preload is opti-
mized and mitral valve closing forces are increased, leading to FMR reduction. By inducing LV 
reverse remodeling, papillary muscle tethering on mitral leaflets is reduced and mitral annulus 
dimensions shrink, resulting in improved leaflet coaptation.19,21-23 In the present study, patients 
with no or mild FMR at baseline which remained unchanged at -month follow-up and patients 
with moderate to severe FMR at baseline which improved at 6 months after CRT showed the 
most pronounced LV reverse remodeling, suggesting that CRT ameliorates the underlying pa-
thophysiology of FMR. Interestingly, we found less NYHA functional class improvement and less 
LVESV reduction in CRT recipients with no or mild FMR at baseline which worsened at 6 months 
compared to other groups, whereas the worst survival was seen in those with moderate to 
severe FMR at baseline which remained unchanged  These data demonstrate that mechanisms 
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underlying symptomatic improvement and LVESV changes after CRT are multifactorial in origin, 
reflecting more than only changes in FMR.
Table 2: Predictors of all-cause mortality risk, univariable and multivariable Cox proportional hazards models.
Univariable analysis Multivariable analysis
Variable HR 95% CI P-value HR 95% CI P-value
Baseline grade 0-1 FMR unchanged - - - - - -
Baseline grade 2-4 FMR improved 1.03 0.79-1.34 0.821 1.19 0.89-1.59 0.239
Baseline grade 0-1 FMR worsened 1.58 1.01-2.48 0.046 1.30 0.76-2.23 0.337
Baseline grade 2-4 FMR unchanged 2.16 1.77-2.65 <0.001 1.77 1.41-2.22 <0.001
Age (years) 1.04 1.03-1.05 <0.001 1.03 1.02-1.04 <0.001
Male gender 1.37 1.10-1.71 0.005 1.42 1.09-1.85 0.009
Body mass index (kg/m2) 0.97 0.95-0.99 0.009 0.98 0.96-1.01 0.131
Diabetes mellitus 1.72 1.42-2.09 <0.001 1.56 1.23-1.99 <0.001
Ischemic etiology of heart failure 1.58 1.32-1.90 <0.001 1.18 0.95-1.47 0.138
Diuretic use 1.77 1.38-2.28 <0.001 1.23 0.91-1.66 0.176
Hemoglobin (g/dl) 0.80 0.73-0.87 <0.001 0.92 0.83-1.03 0.147
Renal dysfunction (eGFR 
<60 ml/min/1.73 m2)
2.71 2.28-3.23 <0.001 1.94 1.57-2.40 <0.001
LVEF at 6 months (%) 0.96 0.95-0.97 <0.001 0.98 0.96-0.99 <0.001
Positive echo response* 0.61 0.52-0.73 <0.001 0.82 0.66-1.02 0.080
Positive clinical response 0.82 0.68-0.99 0.040 0.82 0.67-1.01 0.059
Atrial fibrillation 1.76 1.43-2.18 <0.001 1.39 1.08-1.79 0.010
CI: confidence interval, eGFR: estimated glomerular filtration rate, FMR: functional mitral regurgitation, HR: hazard ratio, 
LVEF: left ventricular ejection fraction. *LVESV reduction of ≥15% at 6 months after cardiac resynchronization therapy.
Association of changes in FMR and outcome
Most important is whether the changes in FMR grade after CRT impact the long-term prognosis 
of HF patients. In the Cardiac Resynchronization Therapy in Heart Failure (CARE-HF) trial, FMR 
grade at 3 months’ follow-up was an independent predictor of survival.24 In a study by Verhaert 
et al.,25 at 6 months post-CRT both the extent of decrease and the degree of residual FMR were 
independently associated with survival.25 More recently, data from the Italian Clinical Service 
Project (Clinical-Trials.gov Identifier: NCT01007474) reported that at 1 year after CRT implanta-
tion, FMR worsened by 1 grade in 42% of patients and remained significant but unchanged from 
baseline in 58%.8 The absence of improvement in FMR at 1 year follow-up after CRT was inde-
pendently associated with increased all-cause mortality. Findings from our large-scale study 
support the fact that FMR response to CRT during the first 6 months is an important predictor 
of long-term survival, and provide new insights to this relationship. Moderate to severe FMR at 
baseline, which remained unchanged at 6 months after CRT implantation, was independently 
associated with all-cause mortality in HF patients. This association remained significant after 
adjusting for multiple variables known to impact on HF mortality, including the LV remode-
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ling response to CRT. Although FMR and LV volumetric response to CRT are intertwined, the 
fact that a reduction in FMR was an independent predictor of survival after accounting for 
LV reverse remodeling demonstrates that the FMR reduction is not merely a reflection of the 
volumetric response of the LV, but contributes uniquely to long-term survival.
Therapeutic options for residual FMR after CRT
The results of the present study are clinically relevant as they emphasize the unmet treatment 
need for HF patients in whom FMR persists or worsens after CRT. Therapeutic options for pa-
tients with residual moderate to severe FMR after CRT are limited, and they may be considered 
for percutaneous mitral valve repair. The use of the MitraClip device (Abbott Vascular, Menlo 
Park, CA) impacted favorably on symptoms, LV remodeling and LV function in the Percutaneous 
Mitral Valve Repair in Cardiac Resynchronization Therapy (PERMIT-CARE) study of 51 patients 
with residual moderate to severe FMR after CRT.26 More recently, the results of the Percuta-
neous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation 
(MITRA-FR) trial, randomizing 152 HF patients to optimal medical therapy (including CRT) and 
152 patients to optimal medical therapy and MitraClip implantation, showed similar outcomes 
in terms of all-cause mortality and unplanned hospitalization for HF.27 The ongoing Cardiovascu-
lar Outcomes for Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients 
with Functional MR (COAPT) trial (Clinical-Trials.gov Identifier: NCT01626079) will provide 
further evidence on the efficacy of transcatheter mitral valve repair in this high-risk group.
Study limitations
Some limitations should be acknowledged. This was a retrospective, single-center study. FMR 
severity may be influenced by LV loading conditions, i.e. preload (e.g. diuretics) or afterload (e.g. 
general anesthesia), which may vary over time. Patients who died before 6 months, underwent 
mitral valve repair or replacement and those without follow-up echocardiography at 6 months 
were excluded, potentially introducing selection bias. Nonetheless, medical therapy (with CRT 
when appropriate) is the accepted standard of care for most HF patients with FMR,28 and thus 
the outcomes of the present study are likely representative of what may be expected post-CRT. 
Finally, although this is currently the largest study to date examining the outcomes of FMR 
after CRT in HF patients, it was likely under-powered to determine whether FMR worsening 
from grade 0-1 at baseline to 2-4 at 6 months is an independent predictor of mortality, as this 




In the present, large-scale study of HF patients treated with CRT, moderate to severe FMR 
at baseline, which remained unchanged at 6 months, was strongly associated with increased 
all-cause mortality independent of LV remodeling and the clinical response to CRT.
Figure 5: Clinical outcome of different patterns of evolution of functional mitral regurgitation (FMR) after 
cardiac resynchronization therapy (CRT). Mechanisms of the effect of CRT on FMR are shown for four differ-
ent patterns of evolution of FMR and their impact on clinical outcomes.
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Background: Functional mitral regurgitation (FMR) and atrial fibrillation (AF) are frequent heart 
failure (HF) complications. Cardiac resynchronization therapy (CRT) can improve FMR; however, 
little is known about the influence of AF on FMR improvement. The purpose of the current 
study was to investigate the mechanisms and impact of baseline AF on FMR improvement after 
CRT.
Methods: CRT recipients with HF, AF or sinus rhythm (SR) at baseline with moderate to severe 
FMR, were included from an ongoing registry. Left atrial (LA), mitral annular (MA) and left ven-
tricular (LV) dimensions were evaluated echocardiographically. FMR improvement was defined 
as ≥1 grade decrease from baseline to 6 months’ follow-up. Clinical and echocardiographic 
measurements were performed at baseline and 6 months’ follow-up.
Results: 419 patients (mean age 66±8 years, 73% male) were analyzed. At 6 months’ follow-up, 
FMR improved in 145 (45.6%) patients with SR vs. 31 (30.7%) in patients with AF (P=0.011). 
Despite similar LV reverse remodeling at 6 months after CRT (LV end-systolic volume decreased 
by 32.1±43.2 ml in the SR group, and by 27.7± 6.3 ml in those with AF; P=0.353), patients with 
SR exhibited smaller LA volumes (63.0±26.5 ml vs. 103.1±41.0 ml; P<0.001) and MA diameters 
(42.3±5.6 mm vs. 46.1±5.8 mm; P<0.001), compared to AF patients.
Conclusions: FMR improvement is more common in CRT recipients in SR vs. AF, despite a similar 
degree of LV remodeling. LA volume and MA diameter are greater in the AF group, causing the 
negative impact of AF on FMR improvement in CRT, as well as indicating a potential therapeutic 
target, i.e. AF rhythm control.
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INTRODUCTION
Functional mitral regurgitation (FMR) is a frequent complication of heart failure, with a preva-
lence of 50-65%.1,2 Global or regional left ventricular (LV) dysfunction or remodeling can cause 
FMR by tethering of the mitral valve leaflets and impaired closing forces.3 Atrial fibrillation (AF) 
is another common manifestation of heart failure (increasing in prevalence from 5% in New 
York Heart Association (NYHA) class I to 50% in class IV), and it may contribute to the severity 
of FMR through left atrial (LA) and mitral annular dilatation.4-6 Both AF and FMR worsen the 
prognosis of patients with heart failure, although the impact of AF is more controversial.2,7,8
Heart failure patients with AF who remain symptomatic despite optimal medical therapy 
(NYHA class III and ambulatory IV), with wide QRS complex (≥130 ms) and reduced LV ejection 
fraction (LVEF ≤35%), are candidates for cardiac resynchronization therapy (CRT).4,9 CRT not 
only improves LV systolic function, but can also decrease FMR by a variety of mechanisms.3,9 
In addition, CRT has been associated with a reduction of LA dimensions and a decrease in the 
burden of AF.10 Since AF may influence the severity of FMR in heart failure patients through LA 
enlargement and mitral annular dilatation, the purpose of the present study was to investigate 
if the presence of baseline AF has an impact on the extent of FMR improvement which occurs 
after CRT.
METHODS
Study population and design
Heart failure patients with moderate to severe FMR at baseline who subsequently received 
CRT, were selected from an ongoing clinical registry.11 Patients with heart failure, who remain 
symptomatic despite receiving maximum tolerated doses of optimal medical therapy, are 
included in the registry on implantation of a CRT device. The institutional review board ap-
proved the study and waived the need for written informed consent for retrospective analysis 
of clinically acquired data anonymously handled. All data used for the present study were 
acquired for clinical purposes and handled anonymously. Demographic, clinical, electrocardio-
graphic and echocardiographic data were collected. Patients were divided according to the 
baseline rhythm: AF vs. sinus rhythm (SR). AF at baseline was classified according to current 
guidelines: i) paroxysmal ii) persistent iii) long-standing persistent and iv) permanent.12 Clinical, 
electrocardiographic and echocardiographic assessment was performed at baseline (before 
CRT implantation), and repeated at 6 months’ follow-up. Ischemic heart failure was defined by 
the presence of coronary artery disease. The following functional parameters were evaluated: 
NYHA functional class, quality of life (Minnesota Living with Heart Failure Questionnaire) and 
(when patients’ functional status permits) 6-minute walk test. Patients were excluded if they 
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underwent mitral valve repair, replacement or percutaneous mitral valve repair at any time, or 
if the cause of mitral regurgitation was organic.
CRT implantation technique
The right atrial and ventricular leads were placed via a standard subclavian or cephalic vein 
approach. Coronary sinus venography was used to guide the LV lead implantation. All leads 
were subsequently connected to a dual-chamber, biventricular CRT device. CRT devices with 
defibrillator function were implanted in the majority of patients (96%), while 4% received a 
CRT device without a defibrillator function. Patients were followed up at regular intervals in the 
heart failure clinic, with concurrent interrogation of device function. Atrioventricular delays 
were empirically set at 120-140 ms, while interventricular delays were similarly set at 0 ms. CRT 
device optimization was performed at the discretion of the treating physician during follow-up 
visits.
Echocardiographic acquisition and data analysis
Transthoracic echocardiograms were performed in the left lateral decubitus position with a 
commercially available echocardiographic system (E9 or VIVID 7, General Electric Vingmed 
Ultrasound, Milwaukee, USA). ECG-triggered M-mode, 2-dimensional and Doppler data were 
collected and digitally stored in order to facilitate off-line analysis (EchoPac 113, General Elec-
tric Vingmed Ultrasound, Milwaukee, USA). LV end-systolic (LVESV) and end-diastolic (LVEDV) 
volumes were measured on 2-dimensional apical 2- and 4-chamber views according to the 
Simpson’s method, whereafter LVEF was calculated.13 The LA volume was measured during 
mid-systole in optimized apical 2- and 4-chamber views, while the mitral valve annulus diame-
ter was similarly measured during mid-systole in an apical 4-chamber view and a parasternal 
long-axis view (Figure 1). Both qualitative and quantitative parameters were employed to grade 
FMR severity according to contemporary recommendations on an ordinal scale, with none=0, 
mild=1, moderate=2, moderate to severe=3 and severe=4.14 Improvement in FMR was defined 
as ≥1 grade decrease from baseline to 6-month follow-up.
Statistical analysis
Continuous data are presented with means and standard deviations, while categorical data are 
expressed in numbers and percentages. Independent samples t-tests were used to compare 
continuous variables and χ2 tests, as well as Fisher’s exact tests (as appropriate) for comparison 
of categorical variables. A binary logistic regression analysis was performed to investigate the 
association of rhythm at baseline with improvement of FMR, correcting for left bundle branch 
block (LBBB), angiotensin-converting enzyme (ACE)-inhibitor use, rhythm at baseline and bi-
ventricular pacing >90%. Analyses were performed with SPSS for Windows, version 23.0 (SPSS, 
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RESULTS
Baseline patient characteristics
Of 1 570 heart failure patients treated with CRT, 419 patients (mean age was 66±8 years, 73% 
male) presented with moderate to severe FMR. Baseline characteristics of patients in AF (n=101) 
and patients in SR (n=318) are presented in Table 1. Among patients with baseline AF, 52 (51%) 
had paroxysmal, 44 (44%) permanent, 4 (4%) persistent and 1 (1%) long-standing persistent 
AF. Thirty-three (33%) patients with baseline AF underwent direct current cardioversion before 
CRT implantation, 10 (10%) His bundle ablation and 1 (1%) AF catheter ablation.
Improvement in FMR severity after CRT
CRT induced comparable reductions in LVESV (from baseline to 6 months) for patients in SR at 
baseline and in patients in AF at baseline: a mean LVESV decrease of 32.1±43.2 ml (18.1%) vs. 
27.7±36.3 ml (18.6%), was respectively observed; P=0.353 (Figure 2, Table 2). Despite similar 
extent of LV reverse remodeling, improvement in FMR (from baseline to 6 months) was more 
frequently observed among patients in SR at baseline as compared to patients in AF at baseline 
(145 (45.6%) vs. 31 (30.7%), respectively; P=0.011) (Figure 3). Interestingly, after 6 months of 
CRT, patients in SR at baseline demonstrated a smaller LA volume than those in AF at baseline 
(63.0±26.5 ml vs. 103.1±41.0 ml, respectively; P<0.001) (Table 2), as well as a greater de crease 
 
Echocardiographic acquisition and data analysis  
 
Transthoracic echocardiograms were performed in the left lateral decubitus position with a 
commercially available echocardiographic system (E9 or VIVID 7, General Electric Vingmed 
Ultrasound, Milwaukee, USA). ECG-triggered M-mode, 2-dimensional and Doppler data were 
collected and digitally stored in order to facilitate off-line analysis (EchoPac 113, General 
Electric Vingmed Ultrasound, Milwaukee, USA). LV end-systolic (LVESV) and end-diastolic 
(LVEDV) volumes were measured on 2-dimensional apical 2- and 4-chamber views according 
to the Simpson’s method, whereafter LVEF was calculated.13 The LA volume was measured 
during mid-systole in optimized apical 2- and 4-chamber views, while the mitral valve annulus 
diameter was similarly measured during mid-systole in an apical 4-chamber view and a 
parasternal long-axis view (Figure 1). Both qualitative and quantitative parameters were 
employed to grade FMR severity according to contemporary recommendations on an ordinal 
scale, with none=0, mild=1, moderate=2, moderate to severe=3 and severe=4.14 
Improvement in FMR was defined as ≥1 grade decrease from baseline to 6-month follow-up.  
 
 
Figure 1: Measurement of mitral annulus diameter. Mitral valve annulus diameter, measured in mid-systole in 
an apical 4-chamber view (red, dumbbell marker) and left atrial volume, measured in mid-systole in an apical 4-
chamber view (blue grid) (A). Mitral annulus diameter, measured in mid-systole in a parasternal, long-axis view 




 Figure 1: Measurement of mitral annulus diameter. Mitral valve annulus diameter, measured in mid-systole 
in an apical 4-chamber view (red, dumbbell marker) and left atrial volume, measured in mid-systole in an 
apical 4-chamber view (blue grid) (A). Mitral annulus diameter, measured in mid-systole in a parasternal, 
long-axis view (r d, dumbbell marker) (B).
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in LA size (10.2% vs. 2.3%, respectively; P=0.047) (Table 2). Similarly, patients with SR at 
baseline evidenced a smaller mitral annulus diameter (measured in the parasternal, long-axis 
view) (34.5±4.8 mm vs. 39.6±5.2 mm, respectively; P<0.001) and a greater degree of mitral 
annulus remodeling (4.4% vs. 0.0%, respectively; P<0.001) at 6 months post-CRT, compared to 
those with AF at baseline (Table 2). On multivariable, logistic regression analysis, SR at baseline 
remained independently associated with FMR improvement after CRT (adjusted odds ratio (OR) 
1.69; 95% confidence interval (CI) 1.02-2.83; P=0.04). These results suggest that the atriogenic 
component of FMR needs to be corrected in addition to LV reverse remodeling to optimize the 
rate of FMR improvement after CRT implantation.
Table 1: Patient baseline characteristics according to rhythm (atrial fibrillation or sinus rhythm).
AF (n=101) SR (n=318) P-value
Age (years) 70±8 66±10 <0.001
Male gender, n (%) 85 (84.2) 222 (70.0) 0.004
Ischemic etiology, n (%) 53 (52.5) 185 (58.2) 0.357
LBBB, n (%) 41 (40.6) 225 (70.8) <0.001
QRS duration at baseline (ms) 157.0±34.0 156.0±29.3 0.768

















6 MWT (m) 309.4±106.4 317.9±116.9 0.549
QoL score 33.2±19.1 33.4±19.2 0.949
Diabetes mellitus, n (%) 18 (17.8)  63 (19.8) 0.773
eGFR <60 ml/min/1.73 m2, n (%) 47 (46.5) 142 (44.7) 0.819
LVEF (%) 26.2±8.4 25.0±7.6 0.173
LVEDV (ml) 198.7±72.4 233.0±83.9 <0.001
LVEDVi (ml/m2) 101.2±36.0 120.5±41.2 <0.001
LVESV (ml) 149.0±62.9 177.3±74.4 0.001
LVESVi (ml/m2) 76.0±31.5 91.8±37.7 <0.001
LA volume (ml) 105.5±37.7 70.3±25.8 <0.001






















Continuous variables are mean ± standard deviation. AF: atrial fibrillation, ACE: angiotensin-converting enzyme, ARB: an-
giotensin receptor blocker, eGFR: estimated glomerular filtration rate, LA: left atrial, LBBB: left bundle branch block, LVEF: 
left ventricular ejection fraction, LVEDV: left ventricular end-diastolic volume, LVEDVi: indexed left ventricular end-diastolic 
volume, LVESV: left ventricular end-systolic volume, LVESVi: left ventricular end-systolic volume, 6 MWT: 6-minute walk test, 
NYHA: New York Heart Association, QoL: quality of life, SR: sinus rhythm.
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Figure 2: Changes in left ventricular end-systolic volume (LVESV). Change in LVESV from baseline to 6 months 
after cardiac resynchronization therapy in patients with sinus rhythm vs. atrial fibrillation at baseline. Vertical 




Heart failure patients with AF before CRT implantation, experienced less improvement in FMR 
as compared to CRT recipients in SR at baseline. This difference was observed despite a similar 
extent of LV reverse remodeling after 6 months. Importantly, LA volume and mitral annular 
dimension were significantly larger in the baseline AF group as compared to the baseline SR 
group at 6 months after CRT, suggesting an atrial component in the pathophysiology of FMR 
not fully reversed by CRT. 
 
LV remodeling and FMR improvement in CRT: the impact of AF 
 
LV reverse remodeling defined by a reduction in LVESV has been reported in 62-85% of heart 
failure patients treated with CRT and is associated with superior survival at follow-up.15,16 LV 
reverse remodeling is one of the mechanisms by which CRT improves FMR. However, CRT 
reduces the amount of FMR by other mechanisms, including resynchronization of 
atrioventricular, inter- and intraventricular contraction, and an increase in mitral leaflet 




Figure 2: Changes in left ventricular end-systolic volume (LVESV). Change in LVESV from baseline to 6 months 
after cardiac resynchronization therapy in patients with sinus rhythm vs. atrial fibrillation at baseline. Vertical 
bars represent standard error of the mean.
DISCUSSION
Heart failure patients with AF before CRT implantation, experienced less improvement in FMR 
as compared to CRT recipients in SR at baseline. This difference was observed despit  a similar 
extent of LV reverse remodeling after 6 months. Importantly, LA volume and mitral annular 
dimension were significantly larger in the baseline AF group as compared to the baseline SR 
group at 6 months after CRT, suggesting an atrial component in the pathophysiology of FMR 
not fully reversed by CRT.
LV remodeling and FMR improvement in CRT: the impact of AF
LV reverse remodeling defined by a reduction in LVESV has been reported in 62-85% of heart 
failure patients treated with CRT and is associated with superior survival at follow-up.15,16 LV 
reverse remodeling is one of the mechanisms by which CRT improves FMR. However, CRT redu-
ces the amount of FMR by other mechanisms, including resynchronization of atrioventricular, 
inter- and intraventricular contraction, and an increase in mitral leaflet closing forces which 
leads to improved leaflet coaptation.3,17,18
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A4C: apical 4-chamber, AF: atrial fibrillation, LA: left atrial, LVESV: left ventricular end-systolic volume, PSLAX: parasternal 
long-axis, SR: sinus rhythm.
 
Table 2: Changes in LVESV, LA volume and mitral annular diameters, according to baseline 
rhythm. 
 AF SR P-value 
LVESV (ml) 
- Baseline 
- 6 months 
- Change 
















LA volume (ml) 
- Baseline 
- 6 months 
- Change 
















Mitral annular diameter (A4C view) (mm) 
- Baseline 
- 6 months 
- Change 
















Mitral annular diameter (PSLAX view) (mm) 
- Baseline 
- 6 months 
- Change 
















A4C: apical 4-chamber, AF: atrial fibrillation, LA: left atrial, LVESV: left ventricular end-systolic volume, PSLAX: 













Figure 3: Improvement in functional mitral regurgitation. Percentage (%) of patients demonstrating 
improvement of functional mitral regurgitation after cardiac resynchronization therapy, according to baseline 
rhythm. Improvement in FMR (from baseline to 6 months) was more frequently observed among patients in SR 
at baseline (45.6%), compared to patients in AF at baseline (30.7%). AF: atrial fibrillation, FMR: functional mitral 
regurgitation, SR: sinus rhythm. 
 
 
Figure 3: Improvement in functional mitral regurgitation. Percentage (%) of patients demonstrating improve-
ment of functional mitral regurgitation after cardiac resynchronization therapy, according to baseline rhythm. 
Improvement in FMR (from baseline to 6 months) was more frequently observed among patients in SR at 
baseline (45.6%), compared to patients in AF at baseline (30.7%). AF: atrial fibrillation, FMR: functional mitral 
regurgitation, SR: sinus rhythm.
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In a study of 673 CRT recipients (162 with AF), no significant difference in the change in LVESV 
was found between SR and AF groups (P=0.828).19 Our data confirm that there is no appreciable 
difference in the amount of LV reverse remodeling between CRT recipients with AF and SR at 
baseline, while a greater reduction in FMR is noted at 6 months in heart failure patients with 
SR at baseline who are treated with CRT, compared to AF at baseline. The negative impact of 
baseline AF on the extent of FMR reduction, can therefore not be ascribed only to a differential 
effect on LV remodeling, and another mechanism should be considered.
Influence of AF on FMR
It is proposed that AF worsens FMR by means of i) mitral annular dilatation, and ii) atriogenic 
leafl et tethering (Figure 4).20,21 Longstanding AF is firmly linked to LA enlargement.22 Structurally, 
the mitral annulus is closely related to the LA, and due to the absence of a reinforcing fibrous 
skeleton, the posterolateral annulus is susceptible to stretching by longitudinal LA muscle fibers 
when the LA enlarges.5 Mitral annular dilatation leads to a reduced coaptation area of the mi-
tral leaflets, and subsequent worsening of FMR.20 AF may worsen FMR by another mechanism, 
namely atriogenic leaflet tethering, which implies stretching of the posterior mitral leaflet 
across the LV wall by LA enlargement, with subsequent displacement/tethering of the anterior 
mitral valve leaflet away from the papillary muscles.21 Two studies have reported an association 
between AF on the one hand, and an increased mitral annular area and FMR on the other 
hand.23 In the present study we found evidence to support these mechanisms in the context 
of CRT, namely patients with baseline AF having an enlarged LA, less decrease in LA volume, 
a larger mitral annulus diameter, less mitral annular remodeling and worse FMR at 6 months’ 
follow-up, compared to patients in SR at baseline. The decrease in mitral annular diameter is 
much more pronounced when measured in the parasternal long-axis view, compared to the 
apical 4-chamber view. This likely reflects the fact that long-axis measurement transects the 
fixed annulus and the unsupported part, while the apical 4-chamber measurement may still 
transect a second, fixed part of the mitral fibrous skeleton (Figure 5).
Effects of CRT on LA and mitral annular size
LA reverse remodeling has been documented after CRT, especially in responders to CRT.10,24 The 
LA volume decreased from 66.8±25.2 cm3 to 58.4±27.8 cm3 in CRT responders (defined as a 
reduction of ≥10% LVESV) (P=0.014) in a study of 107 CRT recipients.24
The effect of CRT on the mitral annulus per se, has not been extensively investigated. In 
a study of 30 patients with heart failure and FMR, CRT led to an improvement of the mitral 
annulus area deformation (defined as diastolic mitral annulus area minus systolic mitral an-
nulus area divided by diastolic mitral annulus area, percent) in responders (defined as a patient 
having a reduction of ≥15% LVESV) from 19±10% to 25±8%, while there was no change in non-
responders (from 22±9% to 22±9%).18 Conversely, in another study including 26 patients with 




patients with FMR undergoing CRT, there was no immediate change in the mitral annulus 
diameter.25  
 
Figure 4: Mechanism of AF impact on FMR in CRT recipients. The mitral annulus (indicated in red) is closely 
related to the LA, and due to the absence of a reinforcing fibrous skeleton, the posterolateral annulus is 
susceptible to stretching by longitudinal LA muscle fibers when the LA enlarges (blue arrows indicate stretching 
forces of the LA on the posterolateral annulus). Mitral annular dilatation leads to a reduced coaptation area of 
the mitral leaflets (gap between the leaflets in B), and subsequent worsening of FMR. A CRT recipient with SR at 
baseline is shown in A), and a patient with AF at baseline in B). AF: atrial fibrillation, AMVL: anterior mitral valve 
leaflet, CRT: cardiac resynchronization therapy, FMR: functional mitral regurgitation, LA: left atrium, PM: 
papillary muscle, SR: sinus rhythm. 
 
As far as the authors are aware, there are no reports in the literature that describe the 
differential effect of AF vs. SR at baseline on LA and mitral annulus reverse remodeling after 
CRT. Our data demonstrate that LA volume and mitral annular dimension are significantly 
larger after CRT in patients with moderate to severe FMR and AF at baseline, compared to 
those in SR at baseline. 
 
In summary, baseline AF therefore appears to exert an inhibitory effect on LA and mitral 
annular reverse remodeling after CRT in patients with FMR. This resulted in less improvement 
in FMR in CRT recipients with baseline AF as compared to patients in SR at baseline. 
 
Figure 4: Mechanism of AF impact on FMR in CRT recipients. The mitral annulus (indicated in red) is closely 
related to the LA, and due to the absence of a reinforcing fibrous skeleton, the posterolateral annulus is sus-
ceptible to stretching by longitudinal LA muscle fibers when the LA enlarges (blue arrows indicate stretching 
forces of the LA on t e posterolateral annulus). Mitral a lar dilatation leads to a reduced coaptation area of 
the mitral leaflets (gap between the leaflets in B), and subsequent worsening of FMR. A CRT recipient with SR 
at baseline is shown in A), nd a patient with AF at baseli e in B). AF: atrial fibrillation, AMVL: anterior mitral 
valve leaflet, CRT: cardiac resynchronization therapy, FMR: functional mitral regurgitation, LA: left atrium, PM: 
papillary muscle, SR: sinus rhythm.
As far as the authors are aware, there are no reports in the literature that describe the dif-
ferential effect o  AF vs. SR at baseline n LA and mitral an ulus reverse remodeling after CRT. 
Our data demonstrate that LA volume and mitral annular dimension are significantly larger 
after CRT in patients with moderate to severe FMR and AF at baseline, compared to those in 
SR at baseli e.
In summary, baseline AF therefore appears to exert an inhibitory effect on LA and mitral 
annular reverse remodeling after CRT in patients with FMR. This resulted in less improvement 
in FMR in CRT recipients with baseline AF as compared to patients in SR at baseline.
Clinical implications
Since FMR response to CRT is of prognostic importance, and this response is impaired by 
AF, mitigating the negative influence of AF on FMR is an attractive therapeutic strategy. In 
330 patients with permanent AF who received CRT, 34 (10.3%) spontaneously recovered SR 
at 4 months.26 In contrast, in a study of 74 patients (27% with persistent AF and 73% with 
permanent AF), CRT did not induce spontaneous conversion to SR in any patient at 6 months 
of follow-up.27 With the current findings, it is unclear if awaiting a spontaneous return to SR 
after CRT is the optimal strategy. Various additional treatment options could be considered 
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to restore SR in AF patients, including pharmacological and electrical cardioversion, as well 
as catheter ablation. In a study by Gertz et al. 53 patients with moderate to severe FMR who 
underwent AF catheter ablation, the mitral annular dimension was significantly larger in those 
with recurrent AF compared to patients who remained in SR (3.48±0.34 cm vs. 3.24±0.32 cm, 
respectively; P=0.06) at one year.28 In the same study, the LA volume was larger in patients 
with recurrent AF as compared to patients who remained in SR (66.4±18.4 ml vs. 52.4±12.7 ml, 
respectively; P=0.02) at one year follow-up.28 Moreover, significant FMR at one year follow-up 
was observed in 24% of patients in SR as compared to 82% in patients with AF at one year 
follow-up (P=0.005).28 Although this study was not performed in patients undergoing CRT, the 
results suggest that AF ablation has the potential to reduce FMR in CRT recipients by reducing 
LA volume and mitral annular diameter.
Currently, one trial investigated AF recurrence after radiofrequency catheter ablation 
in patients who previously underwent CRT; Di Biase et al. randomized CRT recipients to AF 
ablation or amiodarone use, with a minimum follow-up of 2 years.6 The recurrence of AF was 
significantly lower in the patients undergoing ablation as compared to the patients using amio-
darone (30% vs. 66%, respectively; P<0.001) and a significant mortality difference was observed 
in favour of ablation (8% vs. 18%; P=0.037).6 The concept of an atrial myopathy has gained 
 
 
Figure 5: Differences in mitral annular remodeling, when measured in apical 4-chamber view and parasternal, 
long-axis view. The decrease in mitral annular diameter is much more pronounced when measured in the 
parasternal long-axis view, compared to the apical 4-chamber view. This likely reflects the fact that long-axis 
measurement (red line) transects the fixed annulus (solid grey line) and the unsupported part (dashed, grey 
line), while the apical 4- chamber measurement (green line) may still transect a second, fixed part of the mitral 
fibrous skeleton (solid grey line) in some patients. This will therefore underestimate the effect of cardiac 




Since FMR response to CRT is of prognostic importance, and this response is impaired by AF, 
mitigating the negative influence of AF on FMR is an attractive therapeutic strategy. In 330 
patients with permanent AF who received CRT, 34 (10.3%) spontaneously recovered SR at 4 
months.26 In contrast, in a study of 74 patients (27% with persistent AF and 73% with 
permanent AF), CRT did not induce spontaneous conversion to SR in any patient at 6 months 
of follow-up.27 With the current findings, it is unclear if awaiting a spontaneous return to SR 
after CRT is the optimal strategy. Various additional treatment options could be considered 
to restore SR in AF patients, including pharmacological and electrical cardioversion, as well as 
catheter ablation. In a study by Gertz et al. 53 patients with moderate to severe FMR who 
underwent AF catheter ablation, the mitral annular dimension was significantly larger in those 
with recurrent AF compared to patients wh  remained in SR (3.48±0.34 cm vs. 3.24±0.32 cm, 
Figure 5: Differences in mitral annular remodeling, when measured in apical 4-chamber view and paraster-
nal, long-axis view. The decrease i  mitral annular diam ter is much more pronounced wh n measured in 
the parasternal long-axis view, compared to the apical 4-chamber view. This likely reflects the fact that long-
axis measur ment (red line) trans ts the fixed annulus (solid grey lin ) and the unsupported part (dashed, 
grey line), while the apical 4- chamber measurement (green line) may still transect a second, fixed part of the 
mitral fibrou  skeleton (solid grey line) i  som  patients. This will therefore underestimate the effect of car-
diac resynchronization therapy on mitral annular remodeling. Ao: aorta, MV: mitral valve, TV: tricuspid valve.
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attention in recent years, with those having more advanced electromechanical atrial disease 
(e.g. fibrosis, visualized with cardiac magnetic resonance imaging) responding less well to 
catheter ablation.29 It is not inconceivable that patients with advanced atrial myopathy and/or 
long-standing AF will also respond suboptimally to ablative therapy in terms of FMR reduction. 
Even though the success rate of AF ablation is more variable in persistent and long-standing AF, 
mitral annular reverse remodeling and a decrease in AF recurrence in CRT patients were seen 
in those studies where such patients were included.6, 28
Recently, the Catheter Ablation versus Standard Conventional Therapy in Patients with Left 
Ventricular Dysfunction and Atrial Fibrillation (CASTLE-AF) trial demonstrated lower all-cause 
mortality and heart failure hospitalization in heart failure patients with AF who underwent 
catheter ablation, when compared to medical therapy.30 Of the patients who underwent ab-
lation, 27% had a CRT device in situ.30 Although reduction in FMR was not reported, this trial 
provides further support for the role of catheter ablation in the management of AF in heart 
failure patients, including those with CRT.
Study limitations
This was a single-center, retrospective study. The severity of FMR can be influenced by different 
hemodynamic conditions, although only hemodynamically stable patients were included in the 
current analysis. The differences between the amount of change in chamber dimensions (Table 
2) of CRT recipients with SR and AF at baseline, have to be interpreted cautiously due to fairly 
large standard deviations.
CONCLUSIONS
Improvement of FMR is more often observed in CRT recipients in SR at baseline, as compared 
to patients with AF at baseline, despite a similar degree of LV reverse remodeling at 6 months 
after CRT. LA volume and mitral annular diameter are larger at 6 months in the patients with AF 
at baseline, suggesting that these mechanisms may relate to the adverse effect of AF on FMR 
improvement following CRT. AF rhythm control (especially by means of catheter ablation) is 
therefore a potential therapeutic target to improve FMR after CRT in patients with AF, although 
the response in those with permanent AF may be variable, compared to paroxysmal AF.
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Sudden cardiac death (SCD) is defined as “a non-traumatic, unexpected, fatal event occurring 
within one hour of the onset of symptoms in an apparently healthy subject”, and it causes a 
fifth of all deaths worldwide. It often occurs in individuals not previously known with cardiac 
disease, which makes prevention challenging. The mechanism underlying SCD is thought to be 
a trigger (e.g. ischemia) acting upon a substrate (e.g. scar), causing a lethal arrhythmia. Primary 
prevention refers to patients at high risk of SCD and secondary prevention to those who have 
had an aborted episode of SCD. Insertion of an implantable, cardioverter-defibrillator (ICD) is 
the most effective approach to primary prevention; currently ICD candidate selection is based 
on a left ventricular ejection fraction (LVEF) ≤35%. The LVEF is neither sensitive nor specific in 
identifying individuals who will benefit from ICD therapy, and therefore alternative strategies 
are required. The present review article summarizes the evidence on various non-imaging (e.g. 
microvolt T-wave alternans, signal-averaged ECG, QRS fragmentation and measures of autono-
mic function) and imaging (echocardiography, cardiac magnetic resonance and radionuclide) 
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INTRODUCTION
Sudden cardiac death (SCD) is defined as “a non-traumatic, unexpected, fatal event occurring 
within one hour of the onset of symptoms in an apparently healthy subject” in the guideline 
on management of patients with ventricular arrhythmias (VA) and the prevention of SCD of the 
European Society of Cardiology.1 An unwitnessed death can be still be considered a SCD if the 
individual in question was in good health 24 hours before the event.1 SCD accounts for more 
than 4 million deaths per year globally, which translates into one fifth of all recorded deaths.1 
About half of SCDs occur in individuals who are not known to have underlying heart disease 
before the fatal event, thus presenting a significant challenge to effective prevention.1
SCD: CAUSES, MECHANISMS AND PREVENTION
The most common cause of SCD is coronary artery disease, which accounts for up to 50% of 
SCD in white males. Other causes of SCD are: cardiomyopathies, cardiac hypertrophy, valvulo-
pathies, myocarditis and primary electrical disorders.
The underlying mechanism of SCD is currently understood as a trigger which acts on a 
substrate, thereby causing a lethal arrhythmia (ventricular tachycardia or ventricular fibril-
lation) and subsequent hemodynamic instability. A typical example of such an interaction is 
myocardial ischemia (trigger) interacting with post-infarct myocardial scar (substrate) in the so-
called peri-infarct zone. This zone represents a transition between the infarct core and healthy 
myocardium, and contains scar tissue which is interspersed with normal cardiomyocytes. Slow 
conduction of electrical impulses occurs in the peri-infarct zone, allowing the establishment of 
re-entry circuits and arrhythmias.
Prevention of SCD is twofold: primary, i.e. in patients deemed to be at high risk of SCD, 
or secondary, i.e. who have had an episode of SCD aborted spontaneously or by resuscitation 
efforts. The most effective strategy for both primary and secondary prevention of SCD is the 
implantable, cardioverter-defibrillator (ICD). Evidence for the use of the ICD in primary preven-
tion arose from the Multicenter Automatic Defibrillator Implantation Trial (MADIT II) and the 
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).2,3 The rate of SCD was decreased by 
more than 30% in patients with a myocardial infarction and a left ventricular ejection fraction 
(LVEF) of ≤30% in MADIT II.2 Similarly, all-cause mortality was reduced by more than 20% in 
heart failure patients with LVEF ≤35% in SCD-HeFT.3
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SELECTION OF ICD CANDIDATES: CURRENT PRACTISE
The decision to implant an ICD for primary prevention is currently based primarily on the LVEF. 
An LVEF ≤35% is a class Ia indication for ICD according to current European Society of Cardiology 
guidelines.1 An exception to this recommendation are the patients with LVEF ≤35% within the 
first 6 weeks after myocardial infarction. This is based on the results of the Defibrillator in Acute 
Myocardial Infarction Trial (DINAMIT) showing that prophylactic ICD therapy within 40 days 
post-infarction failed to reduce all-cause mortality.4
However, LVEF ≤35% may not be sensitive enough to select ICD candidates for primary 
prevention. In the Oregon Sudden Unexpected Death Study (2 093 patients with SCD and 448 
with echocardiographic data) only 20.5% of patients had LVEF ≤35%. Furthermore, a number of 
studies have demonstrated that appropriate therapy occurs in less than a third of ICD recipients 
with LVEF ≤35% (while still exposing them to potential complications of the device) (Table 
1).3,5-10 Accordingly, relying on LVEF alone for guiding selection of ICD candidates for primary 
prevention, may not be the ideal strategy.











2015 2 349 <40% in 66% of 
patients
2.5 years 2.6 (shock)
Weeke et al.6 2013 1 609 25 (20-30) Mean 1.9±1.3 
years




2012 3 822 29±11 (women)
31±14 (men)
1 year 15.3 (women)
21 (men) (shock & ATP)
Huikuri et 
al.8
2009 312 30±6 2 years 8 (VT/VF on loop 
recorder)
Chow et al.9 2008 575 24±4.8 Mean 2.1±0.9 
years
11.1 (shock & ATP)
Bardy et al.3 2005 829 24 (19-30) Median 3.8 years 21 (shock)
Moss et al.10 2004 720 23±5 3 years 35 (shock & ATP)
ATP: antitachycardia pacing, LVEF: left ventricular ejection fraction, VF: ventricular tachycardia, VT: ventricular fibrillation. 
*LVEF is presented as mean ± standard deviation or median and interquartile range.
PATIENT SELECTION BASED ON NON-IMAGING TECHNIQUES
Investigation of non-imaging approaches for SCD risk-stratification has been directed mainly at 
electrophysiological parameters, e.g. microvolt T-wave alternans (MTWA), signal-averaged ECG 




Sudden cardiac death and imaging
MWTA is the consequence of abnormal handling of intracellular calcium and has been as-
sociated with increased risk of SCD in a study of 768 patients with ischemic cardiomyopathy 
(hazard ratio 2.29; P=0.049).11 Late potentials, recorded in the terminal QRS complex, are the 
basis for an abnormal SAECG. VA and death occurred in 28% and 17% (P=0.0001) of patients 
with an abnormal and normal SAECG, respectively, after 5 years of follow-up in 1 925 patients 
with coronary artery disease.12 Conversely, no clear link was established with VA or SCD in 
313 patients referred for an electrophysiology study.13 QRS fragmentation can be measured 
non-invasively with magnetocardiography, which records cardiac electromagnetic activity with 
detectors placed close to the thoracic wall. QRS fragmentation was significantly increased in 
patients with VA, compared to those without (67.8±24.3 vs. 55.4±26.3; P=0.006) in a study of 
158 post-infarct patients.14
PATIENT SELECTION BASED ON NOVEL IMAGING TECHNIQUES
Strain echocardiography, late gadolinium contrast-enhanced (LGE) cardiac magnetic resonance 
(CMR) and nuclear imaging techniques have provided measures with incremental value over 
LVEF to identify the patients who may benefit from an ICD. These imaging modalities permit 
visualization of both triggers (e.g. myocardial ischemia) and substrates (e.g. scar) for SCD in 
ischemic and non-ischemic cardiomyopathy.
With speckle tracking echocardiography, the active deformation (strain) of the myocardium 
can be assessed as a measure of LV systolic function and as an indirect reflector of myocardial 
fibrosis/scar. Global longitudinal strain (GLS) has been independently associated with SCD, 
appropriate ICD therapy and VA in ischemic cardiomyopathy patients (Figure 1A-B), cardiac 
systemic sclerosis and in repaired tetralogy of Fallot.15 In patients with myocardial infarction, 
the value of longitudinal strain in the peri-infarct zone predicts appropriate ICD therapy.15 In 
addition, by measuring the time to peak longitudinal strain in 17 LV segments, LV mechanical 
dispersion can be assessed. A large LV mechanical dispersion suggests the presence of slow and 
heterogeneous electrical conduction of the LV myocardium (e.g. due to areas of scar) (Figure 
1C). Each 10 ms increase in LV mechanical dispersion has been associated with increased risk 
of VA in 988 patients after acute ST-segment elevation myocardial infarction (hazard ratio 1.15; 
P=0.032).15
The presence and burden of myocardial scar detected with LGE-CMR relates to SCD, ap-
propriate ICD therapy and VA in patients with ischemic and non-ischemic cardiomyopathies 
(Figure 1D-E).16,17 Most importantly, quantification of the peri-infarct zone area with LGE-CMR 
has shown incremental prognostic value over the extent of myocardial scar, suggesting that 
the peri-infarct zone better reflects the substrate susceptible to develop VA. The size of the 
peri-infarct zone remains independently associated with all-cause mortality when corrected for 




(Figure 1C). Each 10 ms increase in LV mechanical dispersion has been associated with 
increased risk of VA in 988 patients after acute ST-segment elevation myocardial infarction 
(hazard ratio 1.15; P=0.032).15  
 
The presence and burden of myocardial scar detected with LGE-CMR relates to SCD, 
appropriate ICD therapy and VA in patients with ischemic and non-ischemic cardiomyopathies 
(Figure 1D-E).16,17 Most importantly, quantification of the peri-infarct zone area with LGE-CMR 
has shown incremental prognostic value over the extent of myocardial scar, suggesting that 
the peri-infarct zone better reflects the substrate susceptible to develop VA. The size of the 
peri-infarct zone remains independently associated with all-cause mortality when corrected 
for LVEF (hazard ratio 1.42; P=0.002) and for scar burden (hazard ratio 1.25; P<0.001).18 
 
 
Figure 1: Imaging modalities to assess the risk of ventricular arrhythmias and sudden cardiac death. With 
speckle tracking echocardiography (A) left ventricular (LV) global longitudinal strain (B) and mechanical 
dispersion (C) can be assessed. Ischemic heart failure patient with dilated left ventricle (A) and significantly 
impaired LV global longitudinal strain, with LV segments coded in blue (signifying lengthening) and shades of red 
(signifying better shortening) (B) and large mechanical dispersion with the latest activated segments in the 
posterolateral regions (C). Thinned, inferoseptal and inferior, basal segments post-infarct, delineated by late 
gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) imaging (D, arrow). Midwall-fibrosis of the 
interventricular septum in a patient with dilated cardiomyopathy, indicated by LGE-CMR imaging (E, arrow). 
Increased apical uptake of 18F-fluorodeoxyglucose on a fused, positron emission tomography and computed 
tomography scan, indicating the location of cardiac inflammatory activity in a patient with sarcoidosis (F, arrow).  
 
Figure 1: Imaging modalities to assess the risk of ventricular arrhythmias and sudden cardiac death. With 
speckle tracking echocardiography (A) left ventricular (LV) global longitudinal strain (B) and mechanical dis-
persion (C) can be assessed. Ischemic heart failure patient with dilated left ventricle (A) and significantly im-
paired LV global longitudinal strain, with LV segments coded in blue (signifying lengthening) and shades of red 
(signifying better shortening) (B) and large mechanical dispersion with the latest activated segments in the 
posterolateral regions (C). Thinned, inferoseptal and i ferior, basal se ments post-infarct, delineated by late 
gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) imaging (D, arrow). Midwall-fibrosis of the 
interventricular septum in a patient with dilated c rdio yopathy, indic ted by LGE-CMR imaging (E, arrow). In-
creased apical uptake of 18F-fluorodeoxyglucose on a fused, positron emission tomography and computed to-
mography scan, indicating the location of cardiac inflammatory activity in a patient with sarcoidosis (F, arrow).
The use of radionuclide imaging for SCD assessment has focused on cardiac innervation. SCD and 
appropriate ICD therapy is more common in heart failure patients (ischemic and non-ischemic) 
with a high washout rate or a decreased heart/mediastinum uptake ratio (H/M) of Iodine-123 
(123I) metaiodobenzylguanidine (MIBG), an analogue of noradrenaline which indicates areas of 
myocardial denervation.19 An H/M ratio ≥1.6 was independently associated with less SCD and 
VA in heart failure patients when taking LVEF into account (hazard ratio 0.36; P=0.006).19
Similarly, 123I-MIBG imaging has proven useful to identify patients with hypertrophic cardio-
myopathy and arrhythmogenic, right ventricular cardiomyopathy who are at risk of VA.17 Using 
the radiopharmaceutical carbon-11-metahydroxyephedrine, positron emission tomography 
(PET) permits detection of sympathetic denervation in ischemic heart disease, which has been 
associated with increased risk for SCD. The presence of perfusion defects (rubidium-82) and 
inflammation (increased 18F-fluorodeoxyglucose (FDG) uptake) on PET are predictive of VA 
in patients with cardiac sarcoidosis. Integrated PET-computed tomography scans identify the 
location of cardiac inflammation with 18F-FDG uptake, and can diagnose extra-cardiac disease 
and thoracic lymphadenopathy (Figure 1F).
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CONCLUSIONS
Although contemporary selection of ICD candidates for primary prevention is based on an LVEF 
≤35%, novel non-imaging and imaging-based strategies have demonstrated incremental value 
over using LVEF in isolation. Prospective trials are required to validate the benefit of imaging 
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The etiology of dilated cardiomyopathy (DCM) can be grouped as either genetic or non-genetic. 
More than 50 pathogenic genes have been described, with sarcomeric and lamin A/C muta-
tions being the most common. Mutation carriers for genetic DCM are often asymptomatic until 
cardiac disease manifests with heart failure, arrhythmias or sudden cardiac death. Preventive 
strategies are promising, but can only be applied and tested adequately if genetic DCM can 
be diagnosed at an early stage. Early diagnosis of mutation carriers that may develop overt 
DCM requires advanced imaging techniques that can detect subtle structural and functional 
abnormalities. Advanced echocardiographic techniques such as tissue Doppler imaging and 
speckle tracking strain analysis permit early detection of functional abnormalities, whereas 
cardiovascular magnetic resonance (CMR) techniques provide information on tissue cha-
racterization and myocardial energetics that may be altered at an early stage. Furthermore, 
nuclear imaging techniques provide information on cellular function (metabolism, perfusion). 
Once the diagnosis of overt DCM has been established, various imaging parameters such as 
echocardiography-based myocardial mechanics and CMR-based tissue characterization have 
shown incremental benefit to left ventricular ejection fraction in risk-stratification. Further 
research is required to understand how imaging techniques may help to choose management 
strategies which could delay progression when instituted early in the course of the disease. The 
present article reviews the role of imaging in the risk-stratification of genetic DCM in general, 
with specific emphasis on DCM associated with neuromuscular disorders.
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Risk stratification of genetic dilated cardiomyopathies
INTRODUCTION
Dilated cardiomyopathy (DCM) is defined as “left ventricular (LV) or biventricular systolic dys-
function and dilation that are not explained by abnormal loading conditions or coronary artery 
disease”.1 Ischemic heart disease is therefore excluded by definition, and etiologies of DCM are 
divided into two major groups: genetic and non-genetic.1 The distinction between genetic and 
non-genetic DCM is sometimes less clear, since the likelihood of certain non-genetic etiologies (e.g. 
chemotherapy) of causing DCM can be superimposed on the genetic susceptibility of an individual.1
More than 50 pathogenic genes have been described, with sarcomeric and lamin A/C 
mutations being the most common, but defects of the desmosome, nucleus, mitochondrion, 
lysosome and ion channels are also associated with the development of DCM.2,3 More than one 
pathogenic mutation may be present in a single individual, and this may be (at least in part) 
responsible for the large variation in penetrance of many of the genetic defects causing DCM.4
The clinical manifestations of a genetic defect can vary from being “preclinical” (mutation 
carrier without clinical manifestations, LV dilation without hypokinesia or arrhythmias) to 
“clinical” (hypokinetic but non-dilated cardiomyopathy or DCM).1 The entity of hypokinetic 
but non-dilated cardiomyopathy has recently been formally defined as “hypokinesia without 
significant LV dilation”.1
Early diagnosis of mutation carriers who may develop overt DCM requires advanced imaging 
techniques that detect subtle structural and/or functional abnormalities. Advanced echocardio-
graphic techniques such as tissue Doppler imaging and speckle tracking strain analysis permit 
early detection of functional abnormalities, whereas cardiovascular magnetic resonance (CMR) 
techniques provide information on tissue characterization and myocardial energetics that may 
be altered at an early stage. Furthermore, nuclear imaging techniques provide information on 
cellular function (metabolism, perfusion). The evidence supporting these imaging techniques 
in the diagnosis and risk-stratification of patients with DCM is accumulating, specifically in 
DCM associated with neuromuscular disorders (genetics and extracardiac features: Table 1).5-7 
The present article reviews the role of imaging in the early diagnosis and risk-stratification in 
established disease of patients with DCM associated with neuromuscular disorders.
EARLY DIAGNOSIS OF VENTRICULAR DYSFUNCTION IN DCM 
ASSOCIATED wITH NEUROMUSCULAR DISORDERS
Early diagnosis is integral to the process of risk-stratification in DCM, since patients often remain 
asymptomatic until cardiac disease manifests with heart failure, life-threatening arrhythmias 
or sudden cardiac death.8,9 The onset or progression of ventricular systolic dysfunction and 
the development of myocardial fibrosis may be slowed by early initiation of therapy resulting 
eventually in improved prognosis.
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Examples include: the early use of systemic steroids, angiotensin-converting enzyme (ACE)-
inhibitors or beta-blockers in patients with Duchenne muscular dystrophy (DMD).10-16 Barber et 
al.16 demonstrated in 462 patients with DMD that every year of steroid treatment decreased 
the probability of developing cardiomyopathy (defined by abnormal LV fractional shortening or 
ejection fraction (EF)) by 4%. Additionally, in a randomized, double-blind study of 56 DMD pa-
tients with normal LVEF, ACE-inhibitors delayed the onset of LV systolic dysfunction (P=0.02).11 
In a similar fashion, either an ACE-inhibitor or a beta-blocker improved LV fractional shortening 
in patients with DMD and Becker muscular dystrophy and cardiac involvement (P<0.05).15 Expe-
rimental therapies hold promise of influencing disease processes when initiated early, e.g. the 
membrane sealant poloxamer (which repairs damaged biologic membranes), growth hormone 
treatment or gene therapy in DMD.17-19 Approaches to early diagnosis have focused on advan-
ced imaging techniques to demonstrate abnormalities of cardiac structure, and mechanical as 
well as cellular function.
Table 1: Neuromuscular diseases which are associated with genetic, dilated cardiomyopathies (DCM).5-7
Disorder Abnormal gene/
protein; chromosome















•  Emerin; Xq28, 
Xq26
• Lamin A/C; 1q21
• X-linked recessive
•  Autosomal 
dominant
• Autosomal recessive
•  Contractures, e.g. Achilles tendons and 
elbows






• Lamin A/C; 1q22
• Autosomal recessive
•  Autosomal 
dominant
Weakness of shoulder and pelvic girdles
Myotonic 
dystrophy
•  DMPK; 19q13 
(type I)
•  ZNF9; 3q21 (type 
II)
Autosomal dominant •  Skeletal muscle weakness, e.g. facial, 
sternocleidomastoid and intrinsic muscles 
of hand
•  Myotonia (slow relaxation after 
contraction)




FXN; 9q13 Autosomal recessive • Ataxia of gait and limbs
•  Abnormal reflexes: absence of deep tendon 
reflexes and extensor plantar responses
•  Loss of position and vibration sense in 
lower limbs
DMPK: myotonic dystrophy protein kinase, FKRP: fukutin-related protein, FXN: frataxin, ZNF9: zinc finger protein 9.
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Cardiac structure
Increased extracellular matrix and fibrosis of the myocardium are the hallmark of changes 
in the cardiac structure in DCM. Myocardial late gadolinium enhancement (LGE) allows the 
non-invasive detection of replacement myocardial fibrosis with CMR imaging.20 Segmental LGE 
has been demonstrated in individuals with DMD and Becker muscular dystrophy before the 
onset of LV or right ventricular systolic dysfunction, and may therefore indicate early disease 
(Figure 1).20-24 Similarly, segmental LGE has been visualised in carriers of lamin A/C mutations 
and in patients with myotonic dystrophy and preserved LVEF.25-28 Segmental LGE has also been 
detected in mitochondrial diseases with cardiac involvement (chronic progressive external 
ophthalmoplegia and Kearns-Sayre syndrome) but normal LV systolic function.29
However, in early phases of DCM, reactive fibrosis (increase of interstitial space by deposi-
tion of collagen) rather than replacement fibrosis is present. This reactive fibrosis is detected 
with T1 mapping CMR imaging techniques. For example, longitudinal relaxation is described by 
a T1 recovery curve, and the time constant (when 63% of recovery has occurred) of such a curve 
can be represented by a pixelwise, colour-coded map (a T1 map).30 Increased reactive fibrosis 
will result in long T1 times in native T1 maps (acquired without the use of a gadolinium-based 
contrast agent). In contrast, when T1 maps are registered after gadolinium-based contrast 
media administration, the T1 times are shorter in segments with increased fibrosis as compared 
to normal myocardium.31
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Figure 1: Cardiac magnetic resonance with late gadolinium enhancement (LGE) in a patient with Becker 
muscular dystrophy. Transmural fibrosis in the lateral free wall of the left ventricle in a short-axis view (indicated 
by arrows) (A) and a horizontal long-axis view (B). Adapted with permission from Yilmaz et al.21 
 
Different CMR sequences are employed in T1 mapping, e.g. modified Look-Locker Inversion 
(MOLLI) recovery and shortened MOLLI (ShMOLLI).30 The extracellular volume fraction (ECV) 
of the myocardium, which is a measure of the size of the extracellular space, can be calculated 
from the native myocardial and precontrast blood T1 values, the post-contrast myocardial 
and blood T1 values, as well as the haematocrit.32 Interstitial, reactive myocardial fibrosis, 
representing an early form of myocardial damage, can be both diagnosed and quantified by 
T1 mapping and ECV calculation.33 An elevated ECV was found in lamin A/C mutation carriers 
with normal LV systolic function, and even in some individuals without LGE. ECV may 
therefore be an even more sensitive marker of early disease than LGE.34 An elevated ECV and 
native T1 values have also been documented in patients with DMD and normal LV systolic 
function (including some without LGE) (Figure 2).35-37 T1 mapping may be particularly suited 
to the investigation of cardiac involvement in myotonic dystrophy, since fibrosis is most 
frequently diffuse, rather than localised, in this condition.38 Postcontrast T1 values were 
significantly lower in a group of individuals diagnosed with type 1 and type 2 myotonic 
dystrophy and normal LV systolic function, compared to controls.38 Segmentally-increased 
ECV and focal lipid deposits have been described in patients affected with type 2 myotonic 
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cated by arrows) (A) and a horizontal long-axis view (B). Adapted with permission from Yilmaz et al.21
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presenting an early form of myocardial damage, can be both diagnosed and quantified by T1 
mapping and ECV calculation.33 An elevated ECV was found in lamin A/C mutation carriers with 
normal LV systolic function, and even in some individuals without LGE. ECV may therefore be an 
even more sensitive marker of early disease than LGE.34 An elevated ECV and native T1 values 
have also been documented in patients with DMD and normal LV systolic function (including 
some without LGE) (Figure 2).35-37 T1 mapping may be particularly suited to the investigation 
of cardiac involvement in myotonic dystrophy, since fibrosis is most frequently diffuse, rather 
than localised, in this condition.38 Postcontrast T1 values were significantly lower in a group 
of individuals diagnosed with type 1 and type 2 myotonic dystrophy and normal LV systolic 
function, compared to controls.38 Segmentally-increased ECV and focal lipid deposits have 
been described in patients affected with type 2 myotonic dystrophy and preserved LV systolic 
function – including regions without LGE – supporting the concept that reactive, diffuse fibrosis 
is a very sensitive marker of cardiac involvement.28
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concept that reactive, diffuse fibrosis is a very sensitive marker of cardiac involvement.28  
 
Myocardial tissue characterization can also be performed with echocardiography by analysis 
of the reflected ultrasound signal, which is known as integrated backscatter (IBS). Two 
parameters are generally measured in the anteroseptal and posterior walls of the left 
ventricle which include the magnitude of cyclical variation and the IBS intensity (both 
expressed in dB).39,40 A decrease in the magnitude of cyclical variation denotes an increase 
 
Figure 2: Cardiac magnetic resonance T1 mapping in a patient with Duchenne muscular dystrophy, 
demonstrating fibrosis of the lateral wall in short-axis views. The images show a native T1 map of the left 
ventricle (a) a post-contrast T1 map, (b) an extracellular volume (ECV) map, and (c) late gadolinium enhancement 
(LGE), with arrows indicating LGE of the lateral wall and stars denoting normal, septal myocardium (d). 
Reproduced with permission from Olivieri et al.35 
 
in myocardial collagen content, even though it can be influenced by myocardial water 
content, myofibril architecture and contractility, while the degree of IBS intensity shows a 
correlation with myocardial fibrosis.39,40 In a study of 25 patients with DMD, the IBS intensity 
was higher, and the magnitude of cyclical variation lower, in the outer half of the LV 
myocardium compared to controls, suggesting epicardial fibrosis.39 Similarly, a lower 
magnitude of cyclical variation and a higher IBS intensity were noted in 20 children with DMD, 
compared to age-matched controls (Figure 3).41  
 
Figure 2: Cardiac magnetic resonance T1 mapping in a patient with Duchenne muscular dystrophy, demon-
strating fibrosis of the lateral wall in short-axis views. The images show a native T1 map of the left ventricle 
(a) a post-contrast T1 map, (b) n extracellular volume (ECV) map, and (c) late ga linium enhancement (LGE), 
with arrows indicating LGE of the lateral wall and stars denoting normal, septal myocardium (d). Reproduced 
with permission from Olivieri et al.35
Myocardial tissue characterization can also be performed with echocardiography by analysis of 
the reflected ultrasound signal, which is known as integrated backscatter (IBS). Two parameters 
are generally measured in the anteroseptal and posterior walls of the left ventricle which 
include the magnitude of cyclical variation and the IBS intensity (both expressed in dB).39,40 A 
decrease in the magnitude of cyclical variation denotes an increase in myocardial collagen con-
tent, even though it can be influenced by myocardial water content, myofibril architecture and 
contractility, while the degree of IBS intensity shows a correlation with myocardial fibrosis.39,40 
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In a study of 25 patients with DMD, the IBS intensity was higher, and the magnitude of cycli-
cal variation lower, in the outer half of the LV myocardium compared to controls, suggesting 
epicardial fibrosis.39 Similarly, a lower magnitude of cyclical variation and a higher IBS intensity 
were noted in 20 children with DMD, compared to age-matched controls (Figure 3).41
Mechanical function
Although LVEF is the measure of choice to characterize LV systolic function, subtle changes in 
myocardial function can be detected with more sensitive measures based on deformation and 
tissue velocity imaging. Myocardial deformation can be quantified by strain, which reflects a 
unitless measure of change in dimension.42 Echocardiographic strain imaging is most commonly 
performed with speckle tracking echocardiography. Myocardial “speckles”, which arise from 
the interaction of ultrasound and myocardium, are identified by imaging software and their 
displacement followed from frame to frame.42 Strain is most commonly reported in the longitu-
dinal, radial or circumferential directions of LV deformation and can be reported at segmental 
level (pertaining only to one segment of the ventricle) or global level (reflecting all segments 
of the ventricle).43 Global LV longitudinal strain is the deformation parameter which has been 
most extensively studied, and demonstrates the best reproducibility. Myocardial strain imaging 
has demonstrated value in both the early diagnosis and risk-stratification of various cardiac 
diseases, including genetic and non-genetic cardiomyopathies.43 Different CMR techniques can 
also be employed to measure strain, e.g. myocardial tagging and feature tracking.44,45
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Figure 3: Integrated backscatter (IBS) in a patient with Duchenne muscular dystrophy. Assessment of the basal 
anterior septum (AS), basal posterior wall (PW) and pericardium (PC) by placement of regions of interest on a 
parasternal, long-axis view (A). Tracking of IBS during three cardiac cycles with color coding: anterior septum 
(yellow curve), posterior wall (blue curve) and pericardium (red curve) in a normal individual (B). The cyclic 
variations of IBS are clearly visible. IBS values of the posterior wall (blue curve) are similar to the pericardium 
(red curve) in a patient with Duchenne muscular dystrophy, suggesting myocardial fibrosis (C). 
 
Impaired LV longitudinal, circumferential and radial strain, as well as reduced longitudinal and 
radial strain rates (using speckle tracking echocardiography) have been reported in individuals 
with DMD and normal LVEF on echocardiography or CMR.46-51 Impaired segmental LV systolic 
and diastolic radial strain rates were noted in patients with Becker muscular dystrophy and a 
normal LVEF.52 Reduced LV segmental, circumferential strain (despite normal LVEF) was 
observed in patients with Emery-Dreifuss muscular dystrophy due to lamin A/C mutations.53 
An abnormal transmural LV strain pattern (comparing endo-, mid- and epicardial strain 
values) was identified in patients with DMD and preserved LVEF.54  
Figure 3: Integrated backscatter (IBS) in a patient with Duchenne muscular dystrophy. Assessment of the 
basal ant rior septum (AS), basal posterior wall (PW) and pericardium (PC) by placem nt of regions of inte-
rest on a parasternal, long-axis view (A). Tracking of IBS during three cardiac cycles with color coding: anterior 
septum (yellow curve), posterior wall (blue curve) and pericardium (red curve) in a normal individual (B). 
The cyclic variations of IBS are clearly visible. IBS values of the posterior wall (blue curve) are similar to the 
pericardium (red curve) in a patient with Duchenne muscular dystrophy, suggesting myocardial fibrosis (C).
Impaired LV longitudinal, circumferential and radial strain, as well as reduced longitudinal and 
radial strain rates (using speckle tracking echocardiography) have been reported in individuals 
with DMD and normal LVEF on echocardiography or CMR.46-51 Impaired segmental LV systolic 
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and diastolic radial strain rates were noted in patients with Becker muscular dystrophy and 
a normal LVEF.52 Reduced LV segmental, circumferential strain (despite normal LVEF) was ob-
served in patients with Emery-Dreifuss muscular dystrophy due to lamin A/C mutations.53 An 
abnormal transmural LV strain pattern (comparing endo-, mid- and epicardial strain values) was 
identified in patients with DMD and preserved LVEF.54
The myocardial tissue velocity can be determined by tissue Doppler echocardiography 
during both systole and diastole.55,56 Systolic myocardial tissue velocity is a reflection of longi-
tudinal LV function, which is caused by endocardial fibre shortening, while diastolic myocardial 
tissue velocity is a surrogate of early diastolic, LV relaxation.57 Impaired LV systolic and diastolic 
myocardial tissue velocities are markers of early cardiac disease and have been associated with 
outcome in various cardiac disorders.57-60 Systolic and diastolic LV tissue velocities are reduced 
in patients with DMD and Friedreich ataxia who display a normal LVEF.47,48,61-63 Similarly, systolic 
and diastolic LV tissue velocities are impaired in patients with myotonic dystrophy with a nor-
mal LVEF.64,65
In a normal heart, LV endocardial velocity (measured with tissue Doppler imaging) is greater 
than epicardial velocity, which reflects the rate of increase in wall thickening with contraction. 
The myocardial velocity gradient is the difference in myocardial velocity between the endo- and 
epicardium, divided by the myocardial wall thickening, and is an index of regional myocar-
dial function.66 Abnormal myocardial velocity gradients were identified in the interventricular 
septum, as well as the posterior wall of the left ventricle, in patients with Friedreich ataxia, 
DMD and Emery-Dreifuss muscular dystrophy (in the presence of a lamin A/C mutation) and 
preserved LV systolic function.53,67,68
Cellular function
Phosporus-31 magnetic resonance spectroscopy (31P-MRS) allows non-invasive examination of 
cardiac energetics by quantification of high-energy phosphate metabolites.69 Altered cardiac 
energetics are early markers of cardiomyopathy, often preceding morphological and overt 
functional abnormalities. Evaluation of LV myocardial metabolism can be obtained on a cellular 
level with 31P-MRS.70 Current 1.5T and 3T scanners do not allow voxel sizes with a spatial reso-
lution which is high enough to produce spectra of individual myocardial segments (according 
to the American Heart Association 17-segment model) and subsequently, a volume of interest 
is placed in either the anterior LV wall or the interventricular septum.71,72 Peaks in the 31P-MR 
spectra reflect the concentrations of the three phosphorous atoms of adenosine triphosphate 
(ATP), i.e. γ-ATP, α-ATP and β-ATP, as well as phosphocreatine (PCr) (Figure 4).69 From the ATP 
and PCr concentrations, the ratio of PCr to ATP can be calculated, which is influenced by ab-
normal cardiac metabolism in disease states. The reaction equilibrium of the creatine kinase 
reaction favours the synthesis of ATP rather than PCr, leading to a reduction in PCr when ATP 








Figure 4: 31P-magnetic resonance spectroscopy. The spectrum of a healthy individual, demonstrating peaks for 
2,3-diphosphoglycerate (2,3-DPG), phosphodiesters (PDE), phosphocreatine (PCr), γ-adenosine triphosphate 
(ATP), α-ATP and β-ATP (A). Reduced PCr:ATP ratio in a patient with dilated cardiomyopathy (B). Region of 
interventricular septum in a short-axis view (red box, indicated by yellow arrow) for which quantification of 
myocardial metabolites is performed with 31P-magnetic resonance spectroscopy (C). PPM: parts per million. 
Adapted with permission from Holloway et al.71 
 
Some carriers of Xp21 mutations (the gene encoding dystrophin, causing DMD and Becker 
muscular dystrophy) with normal LV wall thickness, systolic and diastolic function, 
nevertheless manifest a reduced PCr/ATP.73 Abnormal cardiac energetics, diagnosed with 31P-
MRS, may therefore also be a signal of early cardiac involvement in such patients. Similarly, a 
reduced myocardial PCr/ATP has been detected in patients with myotonic dystrophy, 
Friedreich ataxia and mitochondrial encephalomyopathy with lactic acidosis and stroke-like 
episodes (MELAS) syndrome – all without evident structural or functional heart disease.7,70,74 
Additionally, 31P-MRS can be used to interrogate skeletal muscle energetics, thereby allowing 
a comprehensive assessment of cardio-neuromuscular disorders.70  
 
Nuclear imaging can also evaluate the cellular integrity and function. Global and regional 
myocardial perfusion can be visualised with gated imaging with single-photon emission 
computed tomography (SPECT).75 Dystrophin-deficient myocardium is more vulnerable to 
pressure overload than normal myocardium, particularly in the LV inferior wall which is 
exposed to greater wall stress than other segments of the left ventricle.8 Patients with DMD 
and Becker muscular dystrophy may show myocardial perfusion defects in the LV inferior wall 
on 99mtechnetium SPECT imaging.8 In addition, the myocardial cells of the LV apical segments 
are rich in dystrophin protein and may also show myocardial perfusion defects (Figure 5). This 
technique has not only shown potential for the early identification of cardiac involvement, 
but also for monitoring treatment response to systemic steroid therapy in DMD.8 After a 
follow-up period of two years in patients with DMD who received systemic steroids, a 
significant improvement in myocardial perfusion was detected while no change was evident 
in LV dimensions or LVEF.8 Positron emission tomography (PET) imaging, using 13N-ammonia 
as tracer, can image myocardial perfusion, as well as 99mtechnetium SPECT; the advantage of 
PET over SPECT is that PET permits absolute quantification of processes, whereas SPECT 
provides semiquantitative measurements.75 Furthermore, myocardial metabolism can be 
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for 2,3-diphosphoglycerate (2,3-DPG), phosphodiesters (PDE), phosphocreatine (PCr), γ-adenosine triphos-
phate (ATP), α-ATP and β-ATP (A). Reduced PCr:ATP ratio in a patient with dilated cardiomyopathy (B). Region 
of interventricular septum in a short-axis view (red box, indicated by yellow arrow) for which quantification of 
myocardial metabolites is perform  with 31 -magnetic resonance spectroscopy (C). PPM: parts per million. 
Adapted with permissio  from Holloway et al.71
Some carriers of Xp21 mutations (the gene encoding dystrophin, causing DMD and Becker 
muscular dystrophy) with normal LV wall thickness, systolic and diastolic function, nevertheless 
manifest a reduced PCr/ATP.73 Abnormal cardiac energetics, diagnosed with 31P-MRS, may 
therefore also be a signal of early cardiac involvement in such patients. Similarly, a reduced 
myocardial PCr/ATP has been detected in patients with myotonic dystrophy, Friedreich ataxia 
and mitochondrial encephalomyopathy with la tic acidosis a d stroke-like episodes (MELAS) 
syndrome – all without evident structural or functional heart disease.7,70,74 Additionally, 31P-MRS 
can be used to interrogate skeletal muscle energetics, thereby allowing a comprehensive as-
sessment of cardio-neuromuscular disorders.70
Nuclear imaging can also evaluate the cellular integrity and function. Global and regional 
myocardial perfusion can be visualised with gated imaging with single-photon emission com-
puted tomography (SPECT).75 Dystrophin-deficient myocardium is more vulnerable to pressure 
overload than normal myocardium, particularly in the LV inferior wall which is exposed to 
greater wall stress other segments of the left ventricle.8 Patients with DMD and Becker 
muscular dystrophy may show myocardial perfusion defects in the LV inferior wall on 99mtech-
netium SPECT imaging.8 In addition, the myocardial cells of the LV apical segments are rich in 
dystrophin protein and may also show myocardial perfusion defects (Figure 5). This technique 
has not only sh wn potential for the e rly identification of cardiac involvement, but also for 
monitoring treatment response to systemic steroid therapy in DMD.8 After a follow-up period 
of two years in patients with DMD who received systemic steroids, a significant improvement in 
myocardial perfusion was detected while no change was evident in LV dimensions or LVEF.8 Po-
sitron emission tomography (PET) imaging, using 13N-am onia as tracer, can image myocardial 
perfusion, as well as 99mtechnetiu  SPECT; the advantage of PET ver SPECT is that PET permits 
absolute quantification of processes, whereas SPECT provides semiquantitative measure-
ments.75 Furthermore, myocardial metabolism can be investigated with 18F-fluorodeoxyglucose 
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(FDG) PET.75 Patients with DMD and normal LVEF have shown reduced myocardial perfusion in 
the LV posterobasal and posterolateral segments on 13N-ammonia PET, whereas the uptake of 
18F-FDG was increased, suggesting the presence of regional metabolic alteration in uptake and 
trapping, a reduction in regional blood flow or both.76
RISK-STRATIFICATION IN ESTABLISHED DISEASE
Once a diagnosis of genetic DCM has been established, risk-stratification is of paramount 
importance. Risk may entail ventricular arrhythmias, incident heart failure or sudden cardiac 
death. Various imaging parameters of myocardial structure and function have been identified 
which may be useful in risk-stratification.
Cardiac structure
LGE of the interventricular septum (denoting myocardial fibrosis), was associated with ven-
tricular arrhythmias in a cohort of lamin A/C mutation carriers with a normal LVEF (LGE was 
present only in patients experiencing ventricular arrhythmias, P=0.007), and may therefore 
help to risk-stratify these individuals, who are at high risk of ventricular arrhythmias and sud-
den cardiac death.27 Patients with Friedreich ataxia and cardiac involvement experienced more 
frequent cardiac symptoms in the presence of LGE: after 12 months of follow-up, 3 of 14 (20%) 
patients with LGE experienced cardiac events, while no events were recorded in LGE-negative 
patients (P=0.1).77 Not only the presence of LGE, but also the extent thereof may be important 
in the quantification of risk: transmural LGE in patients with DMD or Becker muscular dys-
trophy was an independent predictor of ventricular tachycardia and hospitalization for heart 
failure (hazard ratio (HR) 2.89; 95% confidence interval (CI) 1.09-7.68; P=0.033) regardless of 
preserved or reduced LVEF.78
The presence of LGE in patients with DMD has been associated with the development of 
heart failure symptoms and impaired LVEF (64±6% in LGE-negative patients vs. 57±7% in LGE-
positive patients; P=0.014), while the extent of LGE has been correlated with the degree of 
decline in LVEF over time (2.2±0.31% decline per year in LGE-positive patients vs. 0.21±0.22% 
decline per year in LGE-negative patients; P=0.34).79,80 LGE is therefore a potential marker of not 
only the presence of heart failure, but also of its progression.79,80
An increased ECV has been associated with arrhythmias (odds ratio (OR) 1.97; 95% CI 1.21-
32.22; P=0.032) in patients with Becker muscular dystrophy, while the presence of LGE per se 
(considered in a binary fashion) was not.81 While the presence of LGE is useful in the diagnosis 




Risk stratification of genetic dilated cardiomyopathies
Mechanical function
In 88 patients with DMD or Becker muscular dystrophy and cardiac involvement, an LVEF <45% 
independently predicted ventricular tachycardia and hospitalization for heart failure (HR 0.94; 
95% CI 0.89-0.97; P=0.001).78 Similarly, an LVEF <45% was associated with appropriate implan-
table cardioverter-defibrillator therapy and sudden cardiac death (HR 4.4; 95% CI 1.7-11.0; 
P=0.021) in lamin A/C mutation carriers.82
However, in patients with preserved LVEF, strain imaging may refine the risk-stratification 
of these patients. Longitudinal, septal (averaged from four septal segments) strain, measured 
with speckle tracking echocardiography, was reduced when compared to longitudinal strain in 
non-septal segments of the LV in 41 lamin A/C mutation carriers (Figure 6).27 In the same study, 
reduced septal strain correlated with the PR-interval on electrocardiography (R=0.41, P=0.03), 
while a prolonged PR-interval was associated with ventricular arrhythmias (P<0.001).27
 
 
Figure 5: Myocardial perfusion defects at rest assessed with 99mtechnetium single-photon emission computed 
tomography in three patients with Duchenne muscular dystrophy. Cross-sectional myocardial perfusion images 
are displayed in A-C panels (short-axis, horizontal long-axis and the vertical long axis from top to bottom) and 
the polar maps are presented in panels D-F. The patient presented in panels A and D shows normal myocardial 
perfusion whereas the patients in panels B/E and C/F show perfusion defects in the inferior and apical segments. 
REST_FBP: filtered back projection images acquired at rest, (G): gated. Reproduced with permission from Zhang 
et al.8  
 
The presence of LGE in patients with DMD has been associated with the development of heart 
failure symptoms and impaired LVEF (64±6% in LGE-negative patients vs. 57±7% in LGE-
positive patients; P=0.014), while the extent of LGE has been correlated with the degree of 
decline in LVEF over time (2.2±0.31% decline per year in LGE-positive patients vs. 0.21±0.22% 
declin  per year in LGE-negative patients; P=0.34).79,80 LGE is therefore a potenti l marker of 
not only the presence of heart failure, but also of its progression.79,80 
 
An increased ECV has been associated with arrhythmias (odds ratio (OR) 1.97; 95% CI 1.21-
32.22; P=0.032) in patients with Becker muscular dystrophy, while the presence of LGE per se 
(considered in a binary fashion) was not.81 While the presence of LGE is useful in the diagnosis 
of cardiac involvement in Becker muscular dystrophy, quantification of ECV may have more 




Figure 5: Myocardial perfusion defects at rest assessed with 99mtechnetium single-photon emission com-
puted tom graphy in three patients with Duchenne muscular dystrophy. Cross-sectio al yocardial perfu-
sion images are displayed in A-C panels (short-axis, horizontal long-axis and the vertical long axis from top 
to bottom) and the polar maps are presented in panels D-F. The patient presented in panels A and D shows 
normal myocardial perfusion whereas the patients in panels B/E and C/F show perfus on defects in the infe-
rior and apical segments. REST_FBP: filtered back projection images acquired at rest, (G): gated. Reproduced 






In 88 patients with DMD or Becker muscular dystrophy and cardiac involvement, an LVEF 
<45% independently predicted ventricular tachycardia and hospitalization for heart failure 
(HR 0.94; 95% CI 0.89-0.97; P=0.001).78 Similarly, an LVEF <45% was associated with 
appropriate implantable cardioverter-defibrillator therapy and sudden cardiac death (HR 4.4; 
95% CI 1.7-11.0; P=0.021) in lamin A/C mutation carriers.82  
 
However, in patients with preserved LVEF, strain imaging may refine the risk-stratification of 
these patients. Longitudinal, septal (averaged from four septal segments) strain, measured 
with speckle tracking echocardiography, was reduced when compared to longitudinal strain 
in non-septal segments of the LV in 41 lamin A/C mutation carriers (Figure 6).27 In the same 
study, reduced septal strain correlated with the PR-interval on electrocardiography (R=0.41, 




Figure 6: Impaired septal strain in a patient with lamin A/C mutation. Longitudinal strain is assessed with 2-
dimensional speckle tracking echocardiography in the apical 4-chamber view. Different myocardial segments 
are indicated by different colours. White arrows identify impaired strain curves from the inferoseptal basal and 
midventricular myocardial segments. AVC: aortic valve closure. 
 
In addition, LV mechanical dispersion measures the standard deviation of the time to peak 
systolic deformation of 16-17 segments of the left ventricle, and is an application of strain 
imaging performed with speckle tracking echocardiography.83,84 LV mechanical dispersion is 
an indicator of the degree of mechanical heterogeneity, and has been associated with 
ventricular arrhythmias in a number of different cardiac pathologies.83,85,86 Increased 
mechanical dispersion has been reported in lamin A/C mutation carriers with ventricular 
arrhythmias as compared with mutation carriers without ventricular arrhythmias (49±14 ms 
vs. 38±10 ms; P=0.02), while LVEF alone could not distinguish between individuals with and 
without ventricular arrhythmias (Figure 7).87  
Figure 6: I paired septal strain in a patient with lamin A/C mutation. Longitudinal strain is assessed with 
2-dimensional speckle tracking e hocardiography in the pical 4-chamb r view. Different myocardial seg-
m nts are indicated by different colours. White arrows identify impaired strain curves from the inferoseptal 
basal and midventricular myocardial segments. AVC: aortic valve closure.
In addition, LV mechanical dispersion measures the standard deviation of the time to peak 
systolic deformation of 16-17 segments of the left ventricle, and is an application of strain 
imaging performed with speckle tracking echocardiography.83,84 LV mechanical dispersion is an 
indicator of the degree of mechanical heterogen ity, and has been associated with ve t icular 
arrhythmias in a number of different cardiac pathologies.83,85,86 Increased mechanical dispersion 
has been reported in lamin A/C mutation carriers with ventricular arrhythmias as compared 
with mutation carriers without ventricular arrhythmias (49±14 ms vs. 38±10 ms; P=0.02), while 
LVEF alone could not distinguish between individuals with and without ventricular arrhythmias 
(Figure 7).87
CLINICAL INTEGRATION OF CARDIAC IMAGING IN RISK-
STRATIFICATION OF GENETIC DCM ASSOCIATED wITH 
NEUROMUSCULAR DISORDERS
Position statements on the diagnosis, risk-stratification and treatment of DCM (including 
the role of genetic testing) have been published by the American Heart Association and the 
European Society of Cardiology.1,9,88 Based on the abovementioned position statements, an al-
gorithm can be proposed which integrates cardiac imaging modalities into the risk-stratification 
of genetic DCM (Figure 8).
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European Society of Cardiology.1,9,88 Based on the abovementioned position statements, an 
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Figure 7: Segmental mechanical dispersion (MD) displayed in a parametric map of the left ventricle. In a lamin 
A/C mutation carrier without ventricular arrhythmias, all segments are activated simultaneously (panel A). A 
patient with a lamin A/C mutation and ventricular arrhythmias, in whom late activation of the inferior and 
posterior and segments (orange-red areas) is present, resulting in increased mechanical dispersion (MD) (panel 
B). 
 
Although there are no specific position statements for genetic DCM associated with 
neuromuscular disorders, the principles are similar, and therefore, it can be applied to these 
genetic conditions. This algorithm (Figure 8) includes both early diagnosis and risk-
stratification of established disease. In general, it is not recommended to screen children 
before the age of 10-12 years.88 There are two approaches to screening family members of 
an index patient (the proband) with genetic DCM: genetic and clinical cascade screening. 
Genetic cascade screening involves testing family members for the specific mutation present 
in the proband. If the result is negative, no risk exists for development of the specific, genetic 
DCM, and further screening is not required.88 If: i) genetic screening is not available, ii) the 
mutation is present, or iii) no disease-causing mutation can be found in the proband, clinical 
cascade screening is indicated. This involves history-taking, physical examination, a 12-lead 
ECG and transthoracic echocardiography.  
 
If the LVEF is reduced (≤50%) or the LV end-diastolic diameter or volume is increased, the 
presence of disease is established.1 Genetic testing to risk-stratify patients with established 
disease is of limited utility, except in lamin A/C mutations, which portend a high risk.88 
Advanced cardiac imaging can be used to further risk-stratify these individuals by means of 
Figure 7: Segmental mechanical dispersion (MD) displayed in a parametric map of the left ventricle. In a 
lamin A/C mutation carrier without ventricular arrhythmias, all segments are activat d simultaneously (p nel 
A). A patient with a lamin A/C mutation and ventricular arrhythmias, in whom late activation of the inferior 
and posterior and segments (orange-red areas) is present, resulting in increased mechanical dispersion (MD) 
(panel B).
Although there are no specific position statements for genetic DCM associated with neuro-
m scular disorders, th  principles are similar, and therefore, it can be applied to th se genetic 
conditions. This algorithm (Figure 8) includes both early diagnosis and risk-stratification of 
established disease. In general, it is not recommended to screen children before the age of 
10-12 years.88 There are two approaches to screening family members of an index patient (the 
proband) with genetic DCM: genetic and clinical cascade screening. Genetic cascade screening 
i volves testing family members for the specific mutati n present in the proband. If the result 
is negative, no risk exists for development of the specific, genetic DCM, and further screening 
is not required.88 If: i) genetic screening is not available, ii) the mutation is present, or iii) no 
disease-causing mutation can be found in the proband, clinical cascade screening is indicated. 
This involves history-taking, physical examination, a 12-lead ECG and transthoracic echocardio-
graphy.
If the LVEF is reduced (≤50%) or the LV end-diastolic diameter or volume is increased, the 
presence of disease is established.1 Genetic testing to risk-stratify patien s with established 
disease is of limited utility, except in lamin A/C mutations, which portend a high risk.88 Advanced 
cardiac imaging can be used to further risk-stratify these individuals by means of early diagno-
sis: LV longitudinal strain and mechanical dispersion can be derived from routinely-acquired, 
2-dimensional echocardiographic data without additional cost. When echocardiography does 
not provide a definitive answer regarding the presence/absence of disease, or when the echo-




early diagnosis: LV longitudinal strain and mechanical dispersion can be derived from 
routinely-acquired, 2-dimensional echocardiographic data without additional cost. When 
echocardiography does not provide a definitive answer regarding the presence/absence of 
disease, or when the echocardiographic window is suboptimal, CMR can be considered.  
 
 
Figure 8: Proposed algorithm for integration of cardiac imaging in risk-stratification of genetic, dilated 
cardiomyopathy (DCM). Color coding denotes the following: blue = guideline-directed approach for risk-
stratification, orange = guideline-based role for imaging, red = suggested role of imaging in risk-stratification for 
established disease, green = suggested role of imaging for early diagnosis.  
 
If the LVEF is preserved (>50%) and/or the left ventricle is not dilated, clinical cascade 
screening has to be repeated at 1-2 yearly intervals until the age of 20 years, and every 2-5 
years until the age of 50-60 years.88 Transthoracic echocardiography is included in each 
screening event. For the risk-stratification of established disease, assessment of IBS, strain 
and myocardial velocities on clinically acquired echocardiographic data could help identify 
patients with increased risk of progression of the disease or ventricular arrhythmias. 
However, the impact of these measures on the clinical management of the patients is still 
being evaluated. Similar to risk-stratification for established disease, CMR can be performed 
when uncertainty remains. If contrast is administered for LGE, post-contrast T1 maps and ECV 
Figure 8: Proposed algorithm for integration of cardiac imaging in risk-stratification of genetic, dilated car-
diomyopathy (DCM). Color coding denotes the following: blue = guideline-directed pproach for risk-strati-
fication, orange = guideline-based role for imaging, red = su gested role of imaging in risk-stratification for 
established diseas , green = sugge ted role f i i  for early diagnosis.
If the LVEF is preserved (>50%) and/or the left ventricle is not dilated, clinical cascade screening 
has to be repeated at 1-2 yearly intervals until the age of 20 y ar , and every 2-5 years until the 
age of 50-60 years.88 Transthoracic echocardiography is included in each screening event. For 
the risk-stratification of established disease, assessment of IBS, strain and myocardial velocities 
on clinically acquired echocardiographic data could help identify patients with increased risk of 
progression of the disease or ventricular arrhythmias. However, the impact of these measures 
n th  clinical anagement of th  patients is still bei g evaluated. Similar to risk-stratification 
for established disease, CMR can be performed when uncertainty remains. If contrast is admi-
nistered for LGE, post-contrast T1 maps and ECV calculation can be performed. Strain imaging 
and 31P-MRS are promising but still considered investigational techniques. Nuclear imaging 
techniques can be considered if requested for additional indications, e.g. exclusion of coronary 
artery disease as potential cause of cardiomyopathy.
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The clinical applicability of various imaging techniques is summarized in Table 2. In general, 
the reproducibility of imaging parameters is good in genetic DCM (Table 3). In the absence 
of studies comparing different imaging modalities and parameters for risk-stratification of 
genetic DCM, a specific order of testing cannot be recommended currently, and the sequence 
of imaging modalities will depend more on the availability, cost and concomitant indications, 
as discussed above.
Table 2: Summary of imaging techniques and their clinical applicability.




Native T1 mapping Investigational






LV global longitudinal strain Investigational
LV global circumferential strain Investigational
LV systolic myocardial tissue 
velocity
Investigational
LV diastolic myocardial tissue 
velocity
Investigational
LV myocardial velocity gradient Investigational
Mechanical dispersion Investigational
CMR CMR circumferential strain Investigational
Cellular function (metabolism, 
perfusion)
CMR 31P-MRS (metabolism) Investigational
Nuclear imaging
99mtechnetium SPECT (perfusion) Routine
PET (perfusion, metabolism) Routine
CMR: cardiac magnetic resonance imaging, ECV: extracellular volume fraction, IBS: integrated backscatter, LGE: late gado-
linium enhancement, LV: left ventricular, LVEF: left ventricular ejection fraction, PET: positron emission tomography, 31P-MRS: 
phosphorous-31 magnetic resonance spectroscopy, SPECT: single-photon emission computed tomography.
CURRENT STATE OF KNOwLEDGE AND FUTURE PERSPECTIVES
Even though the diagnostic role of cardiac imaging is well defined for genetic DCM, there are 
two evident research opportunities, where imaging will play a pivotal role: the prediction 
of outcome with imaging parameters and the benefit of early therapy in the prevention (or 
inhibition of progression) of genetic DCM. Lack of data regarding early therapy may be partly 
ascribed to the absence of effective, directed therapies. Prospective trials will be required to 
obtain evidence that any directed therapy or standard heart failure therapy (e.g. ACE-inhibitors) 
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improves patient outcomes when started early in the course of the disease. Treatment effects 
have generally been evaluated with only conventional functional imaging parameters (e.g. 
LV fractional shortening or LVEF), although LV global longitudinal strain has been employed 
to measure the effect of enalapril and carvedilol in patients with DMD and Becker muscular 
dystrophy.15
Despite various imaging parameters providing data on risk-stratification in established 
disease, prospective studies are also necessary to determine if these data will translate into im-
proved outcomes, e.g. when used for guidance of primary prevention implantable cardioverter 
defibrillator (ICD) placement.
Few studies have systematically studied multimodality imaging in a single mutation or 
disease entity in order to compare their relative usefulness in early diagnosis or risk-stratificati-
on, or to compare a single technique between different etiologies of genetic DCM.
In summary, the following steps are required before cardiac imaging parameters can guide 
therapy for genetic DCM. Both conventional (LVEF) and novel (LV strain) parameters have to be 
evaluated for their ability to predict long-term outcome (development of symptoms, decrease 
in LV systolic function, ventricular arrhythmias and mortality), especially in asymptomatic 
mutation carriers. Furthermore, a variety of therapies (ACE-inhibitors and ICD) have to be 
evaluated for their abilities to influence the course of disease, either when instituted early 
in asymptomatic mutation carriers or in established disease that has been risk-stratified with 
imaging techniques. Moreover, the impact of such therapies can be measured by imaging (for 
example change in ECV) or mortality endpoints and, finally, multicentre studies will be required.
Employing imaging markers as therapeutic targets may prove especially useful, since 
obtaining long-term follow-up of uncommon cardiomyopathies in multicentre studies, will be 
challenging. Two lines of evidence suggest that imaging parameters could be useful as thera-
peutic targets. First, pharmacotherapy (beta-blockers and systemic steroids) has been shown 
to reverse LV remodeling in genetic DCM (DMD and Becker muscular dystrophy).13,14 This likely 
reflects an inhibitory effect on myocardial fibrosis, and T1 mapping CMR techniques (including 
calculation of myocardial ECV) have the potential to reflect a treatment effect. In addition, early 
therapy has been proven to delay the onset or slow the progression of systolic dysfunction in 
some types of genetic DCM, e.g. systemic steroids and ACE-inhibitors in patients with DMD.10,11 
Parameters from imaging techniques could therefore be used to guide therapy.
9
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Table 3: Reproducibility of various imaging techniques.





Native T1 mapping -
Post-contrast T1 
mapping
ICC for inter-observer agreement=0.997; 95% CI 
0.994-0.999
ECV •  ICC for intra-observer agreement=0.957; 
P<0.001






LVEF •  ICC for intra-observer agreement=0.80; 95% CI 
0.47-0.94
•  ICC for inter-observer agreement=0.77; 95% CI 
0.48-0.93
LV global longitudinal 
strain
• ICC for intra-observer agreement=0.72
• ICC for inter-observer agreement=0.78
LV global 
circumferential strain
• ICC for intra-observer agreement=0.91
• ICC for inter-observer agreement=0.88
LV systolic myocardial 
tissue velocity
•  Intra-observer mean percentage 
variation=6.7-9.2% for systolic indices
•  Inter-observer mean percentage 
variation=3.8-6.8% for systolic indices
LV diastolic myocardial 
tissue velocity
•  Intra-observer mean percentage 
variation=5.6-11.8% for diastolic indices
•  Inter-observer mean percentage 
variation=6.6-9.9% for diastolic indices
LV myocardial velocity 
gradient
•  Mean intra-observer difference=8.2±5.3% 
(interventricular septum) and 8.0±6.9% 
(posterior wall)
•  Mean inter-observer difference=9.3±44% 















CI: confidence interval, CMR: cardiac magnetic resonance, ECV: extracellular volume fraction, IBS: integrated backscatter, 
ICC: intraclass correlation coefficient, LGE: late gadolinium enhancement, LV: left ventricular, LVEF: left ventricular ejection 
fraction, PET: positron emission tomography, 31P-MRS: phosphorous-31 magnetic resonance spectroscopy, 99mTc-MIBI/SPECT: 




Genetic DCM represents a substantial proportion of DCM. Affected individuals are at high risk of 
complications, and strategies to identify disease early and effectively risk-stratify these patients 
are needed. A variety of cardiac imaging modalities have proven their ability to identify disease 
early and they have shown promise in risk-stratification. Further research is required to apply 
imaging techniques to the evaluation of management strategies which could delay progression 
when instituted early in the course of disease.
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Background: Genetic, dilated cardiomyopathy (DCM) can be caused by a large variety of muta-
tions. Mutation carriers are often asymptomatic until DCM is well established, presenting with 
heart failure, arrhythmias or sudden cardiac death. Preventive strategies can only be applied if 
DCM is detected early. Echocardiographic, left ventricular (LV) global longitudinal strain (GLS) 
is a promising tool for early diagnosis, i.e. before a decrease in LV ejection fraction (EF) has oc-
curred. We therefore investigated the role of LV GLS as an early disease marker in genetic DCM.
Methods: Genetic DCM patients and genotyped family members were evaluated. The study 
population was grouped as: i) genotype-positive, phenotype-positive patients (GPFP) with 
a pathogenic mutation and LVEF<55%, ii) genotype-positive, phenotype-negative (GPFN) 
individuals with a pathogenic mutation and LVEF≥55%, and iii) genotype-negative, phenotype-
negative (GNFN) individuals without a pathogenic mutation and LVEF≥55%.
Results: A total of 115 individuals (mean age 53±15 years, 51% male) were analyzed: 28 (24%) 
were classified as GNFN, 50 (44%) as GPFN and 37 (32%) as GPFP. Various mutations were re-
presented: 39 (34%) titin, 14 (12%) lamin A/C, 13 (11%) sarcomeric and 21 (18%) less frequent 
mutations (grouped together). The mean LVEF was 58±14% for all subjects. The mean LV GLS 
in the GNFN group was -21.7±1.5% vs. -19.7±3.5% for the GPFN group (P=0.036). The mean LV 
GLS was -12.9±4.3% for the GPFP category (P<0.001 vs. GPFN and GNFN).
Conclusions: Decreased LV GLS discriminates GPFN individuals from normal controls, which 
may permit early institution of therapy for genetic DCM.
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INTRODUCTION
Dilated cardiomyopathy (DCM) is defined as “left ventricular (LV) or biventricular systolic 
dysfunction and dilation that are not explained by abnormal loading conditions”.1 There 
are two main etiological groups, i.e. genetic and non-genetic.1 A broad variety of mutations 
underlie genetic DCM, with sarcomeric, lamin A/C (LMNA) and titin (TTN) mutations being 
most frequent.2,3 Mutation carriers often remain asymptomatic until cardiac disease is well 
established, and then present clinically with advanced heart failure and depressed LV ejection 
fraction (LVEF), life-threatening arrhythmias or sudden cardiac death.4 In order to institute ef-
fective preventive therapies for these serious complications, clinicians will require the ability to 
diagnose genetic DCM early.
Echocardiographic strain imaging is most commonly performed with 2-dimensional (2D) 
speckle tracking strain echocardiography and LV global longitudinal strain (GLS) is the most 
frequently used measure of LV systolic (dys)function. LV GLS has proven useful for diagnosing 
early phases of both genetic and non-genetic cardiomyopathies, as well as in risk-stratification.5 
The utility of LV GLS in the early diagnosis of genetic DCM has not been thoroughly investigated. 
The purpose of the present study is therefore to investigate LV GLS as a potential marker of 
early LV systolic dysfunction in individuals who are mutation carriers for genetic DCM.
METHODS
Study population and data collection
Clinical and echocardiographic data from genotyped patients with DCM, as well as genotyped 
family members of probands, were analyzed from an ongoing clinical registry of genetic DCM. 
For retrospective analysis of data collected for clinical purposes and handled anonymously, 
the institutional review board waived the requirement for patient written informed consent. 
Mutation screening was clinically performed in family members with a cardiomyopathy-related 
gene panel. Patients gave consent for mutation screening. LV dysfunction (phenotype positive) 
was defined as an LVEF<55%.6 Mutations were considered pathogenic or likely pathogenic (ge-
notype positive) if associated with DCM in the literature or in the local population, as described 
previously.2,7 Individuals were excluded if a mutation was considered of uncertain significance, 
likely benign or benign.7 In addition, significant valvular and coronary artery disease were 
exclusion criteria.
The study population was divided into three categories: i) genotype-positive, phenotype-
positive (GPFP) ii) genotype-positive, phenotype-negative (GPFN) and iii) genotype-negative, 
phenotype-negative (GNFN). Patient groups were compared in terms of LV systolic function 
as assessed with conventional (LVEF) and 2D speckle tracking echocardiography (LV GLS) to 
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investigate whether LV GLS is more sensitive than LVEF to identify the patients with subclinical 
DCM.
Echocardiographic data acquisition
Transthoracic echocardiography was performed in the left lateral decubitus position, using a 
commercially available system (E9 or VIVID 7, General Electric Vingmed Ultrasound, Milwaukee, 
USA) equipped with either a 3.5 MHz or a M5S transducer and with adjustment of the depth 
and gain settings as appropriate. M-mode, 2D and Doppler data were stored digitally after 
acquisition to allow for off-line analysis (EchoPac 113, General Electric Vingmed Ultrasound, 
Milwaukee, USA).
Chamber quantification, i.e. LV end-systolic volume (LVESV), LV end-diastolic volume 
(LVEDV), left atrial volume and calculation of the LVEF, was performed on 2- and 4-chamber 
apical views, according to contemporary guidelines.6 LV GLS was measured with 2D speckle 
tracking echocardiography and averaged from standard apical views (2-, 4- chamber, and long-
axis).6,8
Statistical analysis
Continuous variables are presented as means and standard deviations, and categorical data as 
numbers and percentages. Independent samples t-tests, as well as one-way analysis of variance 
(ANOVA), were employed for the comparison of continuous variables. The χ2 and Fisher’s exact 
tests (as appropriate) were used to compare categorical variables. Post-hoc analyses were uti-
lized for inter-group comparisons, where appropriate. All analyses were conducted with SPSS 
for Windows, version 23.0 (SPSS, Armonk, NY, USA). All statistical tests were two-sided, and a 
P-value of <0.05 was considered statistically significant.
RESULTS
Clinical, genetic and electrocardiographic characteristics
A total of 115 persons (mean age 53±15 years, 51% male) were analyzed. Thirty-seven (32%) 
patients were GPFP, 50 (44%) individuals were GPFN and 28 (24%) individuals were classified 
as GNFN. The distribution of specific, pathogenic mutations is presented in Table 1. Mutations 
of TTN and LMNA were the most common: 39 (34%) and 14 (12%), respectively. Baseline 
characteristics of individuals, according to their genotype-phenotype classification, are sum-
marized in Table 2. Use of heart failure medication (diuretics, mineralocorticoid antagonists, 
angiotensin-converting enzyme (ACE)-inhibitors and beta-blockers) was significantly higher in 
patients who were classified as GPFP, compared to GPFN and GNFN individuals (P<0.05 for both 
interactions). Patients in the GPFP group were less frequently in sinus rhythm, and more often 
paced, compared to GPFN and GNFN groups (P<0.05 for both comparisons).
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Conventional and 2D speckle tracking echocardiographic parameters in 
genotype-phenotype groups
GPFP patients had larger LV volumes and lower LVEF as compared with the other groups, but 
there were no differences between GNFN and GPFN groups (Table 2). The mean LV GLS for 
all study subjects was -18.0±4.9%. Measurement of LV GLS was feasible in all 115 (100%) of 
patients. Interestingly, LV GLS was significantly more impaired in GPFN patients than in GNFN 
individuals, whereas the GPFP group showed the most impaired LV GLS (Figures 1 and 2). 
Therefore, in contrast to conventional echocardiographic parameters, GPFN individuals could 
be distinguished from GNFN controls using LV GLS.
Table 1: Distribution of mutations in genotype-positive, phenotype-negative (GPFN) and genotype-positive, 
phenotype-positive (GPFP) categories.



















TTN: titin, LMNA: lamin A/C, ANKRD1: cardiac ankyrin repeat protein, MYH7: β-myosin heavy chain, MYH6: α-myosin heavy 
chain, VCL: metavinculin, TPM1: α-tropomyosin, TNNT2: cardiac troponin T, MYBPC3: myosin-binding protein C, DSP: desmo-
plakin, PLN: phospholamban, LAMA4: laminin-α-4, SCN5A: sodium channel type V, PKP2: plakophilin 2, PSEN1: presenillin 1, 
MYPN: myopalladin, DES: desmin, ANO5: anoctamin-5.
DISCUSSION
The principal result of this study, is that LV GLS is substantially more impaired in GPFN individu-
als as compared to controls. Therefore, LV GLS may identify mutation carriers for genetic DCM 
with a normal LVEF (GPFN) at an early (subclinical) stage.
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Clinical and genetic characteristics of DCM
Even though more than 50 pathogenic genes have been identified in genetic DCM, sarcomeric, 
LMNA and TTN mutations are the most frequent.2,3 In the study by Van Spaendonck et al. 
(which did not include TTN mutations), LMNA mutations represented 23% of the mutation-
positive patients, while sarcomeric mutations accounted for another 16%.2 The corresponding 
percentages in our study are 16% and 14%, respectively, and are comparable. Despite the fact 
that TTN mutations are commonly found in genetic DCM, it is still not completely clear what 
percentage of these mutations is truly pathogenic.1 In a Finnish study of 145 patients with DCM, 
TTN mutations were identified in 20.6% of these patients.9 In our study, TTN mutations were 
present in 45% of mutation-positive (i.e. GPFN and GPFP) individuals.
Table 2: Clinical characteristics.
GNFN (n=28) GPFN (n=50) GPFP (n=37)
Age (years) 52.1±13.8 50.0±14.5 56.2±16.7
Male gender, n (%) 12 (42.9) 22 (44.0) 25 (67.6)
















































































LA volume (ml) 34.7±13.4 36.8±12.5 51.0±26.2*†
LVEF (%) 66.8±5.7 64.3±6.7 42.2±11.0*†
LVEDV (ml) 77.9±23.2 80.2±25.0 106.3±51.3*†
LVESV (ml) 26.2±9.3 29.3±12.4 65.7±48.8*†
Values are mean ± standard deviation. AII: angiotensin II receptor antagonist, ACE: angiotensin converting enzyme inhibi-
tor, AV: atrioventricular, GNFN: genotype-negative phenotype-negative, GPFN: genotype-positive phenotype-negative, GPFP: 
genotype-positive phenotype-positive, LA: left atrial, LVEF: left ventricular ejection fraction, LVEDV: left ventricular end-di-
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The identification of a pathogenic mutation does not necessarily imply the presence of 
clinically-relevant cardiac disease, nor does it aid in risk-stratification. Alternative strategies are 
therefore required for identifying cardiac involvement and predicting the risk of complications.
Conventional echocardiographic parameters in genetic DCM
Lakdawala et al. compared 21 patients with overt, genetic DCM, 12 asymptomatic genotyped 
family members with disease-causing mutations (subclinical DCM) and 29 normal controls.10
“Overt” genetic DCM was defined as an LVEF <55% and/or LV enlargement (according to 
published reference values).10 The LV end-diastolic diameter (LVEDD) was not found to be 
significantly different between the subclinical group (4.3±0.7 cm) and the controls (4.3±0.6 
cm) (P=0.65).10 Neither the LV end-systolic diameter (LVESD) in individuals with “subclinical 
 
“Overt” genetic DCM was defined as an LVEF <55% and/or LV enlargement (according to 
published reference values).10 The LV end-diastolic diameter (LVEDD) was not found to be 
significantly different between the subclinical group (4.3±0.7 cm) and the contr ls (4.3±0.6 
cm) (P=0.65).10 Neither the LV end-systolic diameter (LVESD) in individuals with “subclinical 
DCM” (3.1±0.6 cm) and controls (2.8±0.5 cm) (P=0.09) nor the LVEF (59±3% and 62±5%, 
respectively; P=0.07) could discriminate individuals with “subclinical DCM” from controls.10 In 
a study of 674 first-degree relatives of patients with familial DCM, only 50 (7%) demonstrated 
evidence for cardiac involveme t by either LV dilatation or reduced LVEF on 
echocardiographic screening.11 Baig et al. interrogated a cohort of 225 family members of 
patients with familial DCM on echocardiography, and also found only a small percentage (3%) 
with reduced LVEF.12 Therefore, conventional echocardiographic parameters (LVEDD, LVESD, 
LVEF) are unable to reliably distinguish GPFN patients from GNFN controls. Our data are in 
agreement with these findings, and argue in favor of explor g no el echocardiograph  
parameters with which to diagnose genetic DCM early.  
Figure 1: Characterization of groups: GNFN, GPFN, GPFP. The genotype status, global longitudinal, left 
ventricular strain (GLS) and left ventricular ejection fraction (LVEF) of three different individuals are shown to 
illustrate the following groups: genotype-negative, phenotype-negative (GNFN), genotype-positive, 
phenotype-negative (GPFN) and genotype-positive, phenotype-positive (GPFP). On the left-sided panel, a 
GNFN individual is shown, without a genetic mutation, with a normal GLS of -20.9% and a normal LVEF of 59%. 
The patient in the middle panel has a titin mutation, an impaired GLS of -14.6% and a normal LVEF of 56%, and 
is therefore GPFN. In the right-hand panel, a GPFP patient is shown, with a lamin A/C mutation, an impaired 
GLS of -8.3% and a depressed LVEF of 34%. Despite a normal LVEF of ≥55%, reduced GLS distinguishes the 
individual in the middle panel from a normal control (left-sided panel). 
Figure 1: Characterization of groups: GNFN, GPFN, GPFP. The genotype status, global longitudinal, left ven-
tricular strain (GLS) and left ventricular ej ction fraction (LVEF) of iff r t individuals are shown to 
illustrate the following groups: genotype-negative, phenotype-negative (GNFN), genotype-positive, pheno-
type-negative (GPFN) and genotype-positive, phenotype-positive (GPFP). On the left-sided panel, a GNFN 
individual is shown, without a genetic mutation, with a normal GLS of -20.9% and a normal LVEF of 59%. The 
patient in the middle panel has a titin mutation, an impaired GLS of -14.6% and a normal LVEF of 56%, and 
is therefore GPFN. In the right-hand panel, a GPFP p tient is shown, with a lamin A/C mutatio , an impaired 
GLS of -8.3% and a epress d LVEF of 34%. Despite a normal LVEF of ≥55%, reduced GLS distinguishes the 
individual in the middle panel from a normal control (left-sided panel).
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DCM” (3.1±0.6 cm) and controls (2.8±0.5 cm) (P=0.09) nor the LVEF (59±3% and 62±5%, re-
spectively; P=0.07) could discriminate individuals with “subclinical DCM” from controls.10 In a 
study of 674 first-degree relatives of patients with familial DCM, only 50 (7%) demonstrated 
evidence for cardiac involvement by either LV dilatation or reduced LVEF on echocardiographic 
screening.11 Baig et al. interrogated a cohort of 225 family members of patients with familial 
DCM on echocardiography, and also found only a small percentage (3%) with reduced LVEF.12 
Therefore, conventional echocardiographic parameters (LVEDD, LVESD, LVEF) are unable to 
reliably distinguish GPFN patients from GNFN controls. Our data are in agreement with these 
findings, and argue in favor of exploring novel echocardiographic parameters with which to 
diagnose genetic DCM early.
 
 
Figure 2: Left ventricular strain, according to genotype-phenotype group. Mean left ventricular global 
longitudinal strain (LV GLS), stratified according to the following groups: genotype-negative, phenotype-negative 
(GNFN), genotype-positive, phenotype-negative (GPFN) and genotype-positive, phenotype-positive (GPFP). 
Color-coded squares indicate mean values of GLS, while horizontal bars represent 95% confidence intervals.  
 
The role of 2D speckle tracking strain echocardiography to assess LV longitudinal strain in 
genetic DCM 
 
Early diagnosis is integral to the process of risk-stratification in genetic DCM, since affected 
individuals are often asymptomatic until established heart failure, life-threatening 
arrhythmias or sudden cardiac death occurs.4 Effective, preventive strategies can only be 
implemented if genetic DCM can be reliably diagnosed at an early stage of the disease 
process.  
 
Structural signs of early genetic DCM have been described with cardiac magnetic resonance 
(CMR) imaging. In a cohort of 41 LMNA mutation carriers, late gadolinium enhancement (LGE) 
on CMR was visualized in the basal septum only in individuals who experienced ventricular 
Figure 2: Left ventricular strain, according to genotype-phenotype group. Mean left ventricular global longi-
tudinal strain (LV GLS), stratified according to the following groups: genotype-negative, phenotype-negative 
(GNFN), genotype-positive, phenotype-negative (GPFN) and genotype-positive, phenotype-positive (GPFP). 
Color-coded squares indicate mean values of GLS, while horizontal bars represent 95% confidence intervals.
The role of 2D speckle tracking strain echocardiography to assess LV 
longitudinal strain in genetic DCM
Early diagnosis is integral to the process of risk-stratification in genetic DCM, since affected 
individuals are often asymptomatic until established heart failure, life-threatening arrhythmias 
or sudden c rdiac death occurs.4 Effective, preventive strategies can only be implemented if 
genetic DCM can be reliably diagnosed at an early stage of the disease process.
Structural signs of arly geneti  DCM have been described with cardiac magnetic resonance 
(CMR) imaging. In a cohort of 41 LMNA mutation carriers, late gadolinium enhancement (LGE) 
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on CMR was visualized in the basal septum only in individuals who experienced ventricular 
arrhythmias, while LVEF was similar in those with and without ventricular arrhythmias (56±13% 
vs. 53±14%; P=0.55).13 In the same study, there were also no significant differences in LVEDD 
(51±9 mm vs. 54±9 mm; P=0.34) or LVESD (36±10 mm vs. 39±9 mm; P=0.29) between subjects 
with and without ventricular arrhythmias.13 Basal, septal LGE therefore appears to be a sign of 
early disease, which could not be diagnosed with conventional echocardiographic parameters.13 
The myocardial extracellular volume fraction, determined by CMR imaging, was increased in 
19 LMNA mutation carriers (28.0±3.2%) compared to controls (22.7±3.0%) (P<0.001).14 Even 
though the indexed LVEDV was slightly higher in mutation carriers than in controls (87±20 ml/m2 
vs. 76±12 ml/m2, respectively; P<0.05), LVEF was normal in both groups.14 Although arrhythmia 
risk was not specifically addressed, 3 LMNA mutation carriers (16%) had sustained ventricular 
tachycardia on ECG monitoring, while another 3 (16%) manifested non-sustained ventricular 
tachycardias.14 Reverse LV remodeling has been documented with early therapy in selected 
subgroups of genetic DCM, e.g. beta-blockers and systemic steroids in patients with Duchenne 
and Becker muscular dystrophy, probably reflecting an effect on myocardial fibrosis.15,16
Impaired LV GLS (partially) reflects myocardial fibrosis in patients with heart failure, and 
is more accurate in this regard than LVEF or other deformation parameters (e.g. LV global cir-
cumferential strain).17 The functional impairment seen in early genetic DCM (impaired LV GLS) 
therefore most likely follows structural abnormalities, such as myocardial fibrosis, although 
the contribution of a purely functional (e.g. sarcomeric dysfunction) component cannot be 
excluded. In the study by Lakdawala et al., LV GLS was significantly decreased in individuals 
with “subclinical” genetic DCM, compared to normal controls, and LV GLS was lower in patients 
with “overt” genetic DCM, compared to the “subclinical” group (P<0.001 for all interactions).10 
Of note, all mutations were sarcomeric, and >90% of individuals were female.10 In contrast, 
TTN, LMNA, sarcomeric and other mutations were represented in our study, with about half 
of the individuals being male. This is in agreement with published mutation and gender distri-
butions for genetic DCM.2,9 The key finding of our study is that LV GLS is substantially lower in 
GPFN individuals than in normal controls (GNFN) in a representative cohort. Therapy which is 
instituted early, has already been proven to delay the onset or slow the progression of systolic 
dysfunction in some types of genetic DCM, e.g. systemic steroids and ACE-inhibitors in patients 
with Duchenne muscular dystrophy.18,19
It is therefore clear that GPFN individuals who cannot be reliably identified by conventional 
echocardiographic parameters, demonstrate structural and functional cardiac abnormalities 
on different imaging modalities (CMR and 2D speckle tracking strain echocardiography). The 
results of the present study support the validity of identifying GPFN persons with 2D speckle 
tracking strain echocardiography, using LV GLS.
The true value of early diagnosis in patients with genetic DCM can only be addressed by 
prospective studies, investigating both the predictive value of imaging markers (e.g. LV GLS) 
for the development of a positive phenotype (decreased LVEF, dilated LV, arrhythmias, heart 
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failure, sudden cardiac death), as well as the efficacy of early initiation of preventive measures, 
e.g. standard heart failure therapy with ACE-inhibitors or primary prevention and implantable 
cardioverter defibrillator implantation.
Study limitations
This was a retrospective, single-center study. Nonetheless, all the major groups of mutations 
associated with genetic DCM are well represented. Subgroup analyses were not conducted on 
different mutation groups, due to the limited study population. In addition, the association 
between LV GLS and hard endpoints, such as arrhythmic events, was not evaluated since this 
was beyond the scope of the present study and the follow-up was relatively short (median 
follow-up was 4 months (interquartile range (IQR) 1-25)) to observe a significant number of 
events that can lead to clinically meaningful conclusions. Likewise, LV diastolic function was 
not evaluated. Measurements of LV GLS are not vendor-independent, and the threshold for 
reduced LV GLS may vary among different echocardiographic vendors, although the amount of 
variation is acceptable for clinical use.8 Finally, CMR data were not systematically available in 
this population to perform tissue characterization analysis.
CONCLUSIONS
Mutation carriers in genetic DCM (GPFN) often remain asymptomatic until presenting with 
advanced cardiac disease. Decreased LV GLS can help to discriminate GPFN individuals from 
normal controls (GNFN). This may allow early disease detection in genetic DCM. Larger, pros-
pective studies are required to confirm these findings.
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SUMMARY, CONCLUSIONS AND FUTURE PERSPECTIVES
SUMMARY Part I: The role of echocardiography in predicting outcome after 
CRT
Cardiac resynchronization therapy (CRT) is an established treatment for heart failure patients 
who remain symptomatic despite optimal medical therapy (New York Heart Association func-
tional class II-III and ambulatory class IV) with a wide QRS complex (≥130 ms) and reduced left 
ventricular ejection fraction (LVEF) ≤35%. The benefits of CRT, however, may differ according to 
the QRS complex duration and morphology. In chapter 2, the effect of baseline QRS duration 
and morphology on LV reverse remodeling and LVEF improvement after CRT was investigated. 
Patients with a baseline QRS ≥150 ms demonstrated more LV reverse remodeling (mean re-
duction in LV end-systolic volume (LVESV) of 34.3 ml vs. 14.8 ml; P<0.001) and a greater LVEF 
improvement (mean increase 6.8% vs. 5.2%; P<0.001), compared to those with QRS <150 ms. 
Similarly, CRT recipients with left bundle branch block (LBBB) at baseline, evidenced more LV 
reverse remodeling (P<0.001) and LVEF improvement (P<0.001) than those with non-LBBB QRS 
morphology. LBBB QRS morphology and increasing QRS duration therefore translated into a 
greater degree of LV reverse remodeling and systolic function improvement than non-LBBB 
morphology and a lesser QRS duration, which is supportive of contemporary guidelines for CRT 
placement.
In chapter 3, different CRT response definitions were compared. An LV volumetric response 
to CRT is conventionally defined as a ≥15% reduction in LVESV at 6 months post-CRT. An im-
provement in global longitudinal strain (GLS) on speckle tracking echocardiography may also 
be seen in response to CRT. A CRT volumetric response and an improvement in LV GLS are not 
always seen in the same patient, and the prognostic impact of seeing: i) an improvement in GLS 
or a reduction in LVESV or ii) an improvement in GLS and a reduction in LVESV, was subsequently 
investigated. CRT recipients with an improvement in LV GLS and a reduction in LVESV, had sig-
nificantly lower all-cause mortality compared to those who had either: i) an improvement in LV 
GLS or a reduction in LVESV, but not both and ii) no improvement in either LV GLS and no re-
duction in LVESV (P<0.001). This reflects the fact that these two parameters (LV GLS and LVESV) 
represent different mechanisms, and supports the use of LV GLS as a meaningful parameter in 
defining CRT response, in addition to the more commonly used definition which is based on a 
reduction in LVESV.
Chapter 4 examines the role of LV mechanical dispersion (LVMD) in the long-term outcome 
of CRT recipients. LVMD is a novel, echocardiographic parameter which quantifies mechanical 
heterogeneity of the LV, and is defined as the standard deviation of the time from the onset of 
the QRS complex on the triggered ECG to the peak longitudinal myocardial strain (measured 
with speckle tracking echocardiography) in a 17-segment model of the LV. LVMD has been as-
sociated with ventricular arrhythmias in a number of cardiac diseases. Risk stratification of 
patients after CRT implantation remains a clinical challenge, and LVMD was calculated in a 
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cohort of heart failure CRT recipients post-implant. They were divided into groups according 
to the median LVMD at 6 months after CRT implantation. Those with less LVMD (≤84 ms) ex-
perienced fewer ventricular arrhythmias and lower all-cause mortality than those with LVMD 
>84 ms, and a greater LVMD was independently associated with a higher mortality risk (hazard 
ratio (HR) 1.002; confidence interval (CI) 1.000-1.005; P=0.037) and more frequent ventricular 
arrhythmias (HR 1.003; CI 1.000-1.005; P=0.026).
CRT restores mechanical efficiency to the failing LV by resynchronization of contraction. 
In chapter 5, global, LV myocardial work efficiency was measured with a recently introduced, 
non-invasive technique, synthesizing data from speckle tracking strain echocardiography and 
sphygmomanometric blood pressure recordings. Patients with class I indications for CRT were 
dichotomized according to the baseline, mean global LV myocardial work efficiency before CRT 
implantation. Those recipients with less efficient myocardial energetics at baseline (global, LV 
myocardial work efficiency <75%), experienced lower mortality rates than those with more 
efficient left ventricles (log-rank test, P=0.029). On multivariable analysis, global LV myocardial 
work efficiency <75% was associated with a decreased risk of all-cause mortality (HR 0.48; 
95% CI 0.25-0.92; P=0.027). Global, LV myocardial work efficiency at baseline therefore holds 
promise to risk-stratify heart failure patients before CRT implantation, and may help to refine 
selection criteria in those who already have class I indications for CRT implantation.
Functional mitral regurgitation (FMR) is a common complication of heart failure, which 
worsens prognosis, but is also amenable to improvement with CRT. In chapter 6, the prognostic 
impact of FMR evolution in CRT patients was evaluated. Moderate or severe FMR at baseline, 
which remained unchanged at 6 months after the institution of CRT, was independently associ-
ated with long-term mortality (HR 1.77; 95% CI 1.41-2.22; P<0.001). The prognostic implication 
of moderate or severe FMR, which did not improve with CRT at 6 months, was independent of 
LV volumetric response to CRT, indicating that FMR evolution is not merely a reflection of the 
LV volumetric change, but contributes uniquely to long-term survival. Chapter 7 focuses on the 
impact of atrial fibrillation (AF) on FMR improvement after CRT. FMR improved in 45.6% of CRT 
recipients with sinus rhythm (SR) before implantation, compared to 30.7% with AF (P=0.011). 
Despite a similar degree of LV reverse remodeling at 6 months post-CRT, patients with SR at 
baseline had smaller left atrial volumes (63.0±26.5 ml vs. 103.1±41.0 ml; P<0.001) and mitral 
annular diameters (42.3±5.6 mm vs. 46.1±5.8 mm; P<0.001) in comparison to those with AF. 
This suggests an inhibitory effect of AF on left atrial and mitral annular reverse remodeling, 
leading to less FMR improvement after CRT.
SUMMARY Part II: Imaging approaches to risk-stratification of cardiac disease
Chapter 8 provides a brief review of the role of multimodality imaging in the risk-stratification 
of sudden cardiac death (SCD). Since SCD is the cause of up to one-fifth of global deaths, and 
often occurs in individuals who have not previously been diagnosed with cardiac disease, 
primary prevention remains a challenge. The most effective strategy for primary and secondary 
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prevention of SCD is insertion of an implantable, cardioverter-defibrillator (ICD). Currently, the 
decision to implant an ICD is predicated mainly on an LVEF ≤35%; however, this approach is 
known to lack sensitivity and specificity. Multimodality imaging has shown incremental value 
over LVEF to identify patients who stand to benefit from ICD implantation, e.g. speckle tracking 
strain echocardiography, late gadolinium contrast enhanced (LGE) cardiac magnetic resonance 
(CMR) imaging and radionuclide imaging (e.g. iodine-123 metaiodobenzylguanidine uptake).
The role of cardiac imaging techniques in the risk-stratification of genetic, dilated cardio-
myopathy (DCM) is extensively reviewed in chapter 9. Mutation carriers for genetic DCM are 
often asymptomatic until cardiac disease manifests with heart failure, arrhythmias or SCD. 
Risk-stratification of such individuals encompasses both early diagnosis and the phenotyping of 
established disease. Various imaging modalities are able to demonstrate early functional and 
structural abnormalities in genetic DCM mutation carriers, e.g. tissue Doppler imaging, speckle 
tracking strain echocardiography, integrated backscatter echocardiography, CMR LGE and 
phosphorous-31 magnetic resonance spectroscopy. Functional, cellular abnormalities can be 
probed with nuclear techniques, e.g. myocardial perfusion by means of single-photon emission 
computed tomography. In the case of established disease, echocardiography-based methods 
and CMR have demonstrated incremental benefit to LVEF for effective risk-stratification.
Chapter 10 investigates the use of GLS speckle tracking echocardiography in the early diag-
nosis of genetic DCM patients. Three groups were compared: i) genotype-positive, phenotype-
positive (GPFP) patients, with a pathogenic mutation and an LVEF <55%, ii) genotype-positive, 
phenotype-negative (GPFN) individuals, with a pathogenic mutation and an LVEF ≥55% and iii) 
genotype-negative, phenotype-negative (GNFN) controls. Decreased LV GLS distinguished GPFN 
individuals from normal controls (P<0.001), in contradistinction to LVEF. Such early diagnosis 
of cardiac involvement in genetic DCM mutation carriers may permit the timely institution of 
therapy to delay or prevent disease progression.
CONCLUSIONS AND FUTURE PERSPECTIVES
Characterization and risk-stratification of CRT candidates remain a clinical challenge. Reducing 
the percentage of CRT non-responders, as well as optimizing management of recipients of CRT, 
continue to be priorities in cardiology practice. Novel cardiac imaging parameters are expected 
to play a pivotal role in refining the characterization of heart failure patients who are conside-
red for CRT, as well as in the risk-stratification of those who have already received such therapy. 
The EuroCRT study will prospectively evaluate various cardiac imaging markers (including LVMD 
and global, LV myocardial work efficiency) for their prognostic value.1
The effect of FMR treatment on outcome, is currently under scrutiny. The recently pub-
lished Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral 
Regurgitation (MITRA-FR)2 and Cardiovascular Outcomes Assessment of the MitraClip Percuta-
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neous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT)3 studies 
investigated the impact of transcatheter mitral valve repair on outcome in heart failure patients 
with FMR. Both these trials, however, included patients with and without CRT. The COAPT trial 
demonstrated a lower rate of hospitalization for heart failure and lower all-cause mortality in 
the device treatment group (HR 0.53; 95% CI 0.40-0.70; P<0.001), while the MITRA-FR trial 
failed to show a decrease in the composite primary outcome of all-cause mortality and heart 
failure hospitalization (odds ratio 1.16; 95% CI 0.73-1.84; P=0.53). Clearly, more data are re-
quired to resolve the question of prognostic benefit in the treatment of FMR. AF rhythm control 
(especially by means of catheter ablation) is a potential therapeutic target to improve FMR in 
CRT recipients with AF at baseline, and warrants further study.
Although the diagnostic role of multimodality cardiac imaging is well defined for genetic 
DCM, further research will inform on its ability to predict long-term outcome (e.g. the develop-
ment of symptoms, decrease in LVEF, ventricular arrhythmias and mortality) in asymptomatic 
mutation carriers. Additionally, the utility of imaging in effectively guiding the early institution 
of therapy (e.g. angiotensin converting enzyme (ACE)-inhibitors or ICDs) which may delay or 
prevent disease progression in genetic DCM mutation carriers, remains to be explored. Ade-
quately defining the role of multimodality cardiac imaging in both the prediction of long-term 
outcome and the guidance of early therapy, will require prospective studies. Since long-term 
follow-up in uncommon cardiomyopathies in prospective, multicenter studies will no doubt be 
challenging, employing imaging biomarkers as therapeutic targets in themselves, may prove 
especially useful.
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SAMENVATTING, CONCLUSIES EN TOEKOMSTPERSPECTIEVEN
SAMENVATTING DEEL I: DE ROL VAN ECHOCARDIOGRAFIE IN HET 
VOORSPELLEN VAN DE UITKOMSTEN NA CRT IMPLANTATIE
Cardiale resynchronisatietherapie (CRT) is een bekende behandeling voor patiënten met hart-
falen die symptomatisch blijven ondanks optimale medicamenteuze therapie (New York Heart 
Association functionele klasse II-III en ambulante klasse IV) met een breed QRS-complex (≥130 
ms) en een verminderde linkerventrikel ejectiefractie (LVEF) van ≤35%. De voordelen van CRT 
kunnen echter verschillen afhankelijk van de duur en morfologie van het QRS-complex.
In hoofdstuk 2 wordt het effect van baseline QRS-duur en QRS-morfologie op LV reverse 
remodeling en verbetering van LVEF na CRT onderzocht. Patiënten met een baseline QRS van 
≥150 ms vertoonden meer LV reverse remodeling (gemiddelde vermindering van het LV eind-
systolisch volume (LVESV) van 34.3 ml vs. 14.8 ml; P<0.001) en een grotere LVEF verbetering 
(gemiddelde toename 6.8% vs. 5.2%; P<0.001), vergeleken met diegenen met een QRS duur 
van <150 ms. Evenzo vertoonden ontvangers van CRT, met bij baseline een aanwezig linkerbun-
deltakblok (LBBB), meer LV reverse remodeling (P<0.001) en meer LVEF verbetering (P<0.001) 
dan patiënten met een niet-LBBB QRS-morfologie. LBBB QRS-morfologie en toenemende QRS-
duur leidde tot meer LV reverse remodeling en verbetering van LV systolische functie dan niet-
LBBB morfologie en een lagere QRS-duur, hetgeen de huidige richtlijnen voor CRT-plaatsing 
ondersteunt.
In hoofdstuk 3 worden verschillende definities voor CRT-respons in kaart gebracht. Een LV 
volumetrische respons op CRT wordt conventioneel gedefinieerd als een ≥15% vermindering in 
LVESV 6 maanden na CRT. Een verbeterde globale longitudinale strain (GLS) op speckle tracking 
echocardiografie, kan ook worden waargenomen met CRT. Een CRT volumetrische respons en 
een verbetering in LV GLS wordt niet altijd bij dezelfde patiënt gezien. Het prognostisch impact 
van: i) een verbetering van GLS óf een verlaging van LVESV, óf ii) een verbetering van GLS en 
een verlaging van LVESV werd onderzocht. CRT-patiënten met een verbetering in LV GLS en een 
verlaging van LVESV, hadden een lagere algemene sterftekans in vergelijking met diegenen met: 
i) een verbetering in LV GLS óf een verlaging van LVESV, maar niet beiden, en ii) geen verbete-
ring in LV GLS én geen vermindering van LVESV (P<0.001). Voorgenoemde weerspiegelt het feit 
dat deze twee parameters (LV GLS en LVESV) verschillende mechanismen vertegenwoordigen. 
Dit ondersteunt het eventuele gebruik van LV GLS als een waardevolle parameter bij het defi-
niëren van CRT-respons – naast de meer algemeen gebruikte definitie, die is gebaseerd op een 
verlaging van het LVESV.
Hoofdstuk 4 beschrijft de rol van LV mechanical dispersion (LVMD) in de lange termijn 
uitkomsten van CRT-patiënten. LVMD is een nieuwe echocardiografische parameter die 
de mechanische heterogeniteit van de LV kwantificeert en wordt gedefinieerd als de stan-
daardafwijking van de tijd vanaf het begin van het QRS-complex op het getriggerde ECG tot 
de piek longitudinale myocardiale strain (gemeten met speckle tracking echocardiografie) in 
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een 17-segmentmodel van de LV. LVMD wordt geassocieerd met ventriculaire aritmieën bij 
verschillende hartaandoeningen. Risicostratificatie van patiënten na CRT-implantatie blijft een 
klinische uitdaging. Wij berekenden daarom LVMD na implantatie van CRT in een cohort van 
patiënten met hartfalen. Ze werden verdeeld in groepen volgens de LVMD mediaan 6 maanden 
na de CRT-implantatie. Diegenen met een lagere LVMD (≤84 ms) hadden minder ventriculaire 
aritmieën en een lagere algemene sterftekans dan die met LVMD >84 ms. Een hogere LVMD 
had een onafhankelijk voorspellende waarde voor sterfterisico (hazard ratio (HR) 1.002; be-
trouwbaarheidsinterval (confidence interval (CI)) 1.000-1.005; P=0.037) en voor ventriculaire 
aritmieën (HR 1.003; CI 1.000-1.005; P=0.026).
CRT herstelt de mechanische efficiëntie van een falende LV door resynchronisatie. In hoofd-
stuk 5 werd global LV myocardial work efficiency gemeten met een recent geïntroduceerde 
niet-invasieve techniek, waarbij gegevens werden gesynthetiseerd van speckle tracking strain 
echocardiografie en sphygmomanometrische bloeddrukmetingen. Patiënten met klasse I 
indicaties voor CRT werden gedichotomiseerd volgens de baseline gemiddelde global LV myo-
cardial work efficiency (vóór CRT-implantatie). De CRT-ontvangers met een minder efficiënte 
myocard-energetica bij baseline (global LV myocardial work efficiency <75%) hadden een lagere 
mortaliteit dan diegenen met efficiëntere linkerventrikels (log-rank test, P=0.029). Via multiva-
riabele analyse was global LV myocardial work efficiency <75% voorspellend voor een verlaagd 
risico op mortaliteit (HR 0.48; 95% CI 0.25-0.92; P=0.027). Baseline global LV myocardial work 
efficiency geeft de mogelijkheid om patiënten met hartfalen vóór CRT-implantatie te risico 
stratificeren, en kan mogelijk een rol spelen bij het bepalen van fijnere selectiecriteria van 
diegenen die reeds klasse I-indicaties hebben voor CRT-implantatie.
Functionele mitralisklepinsufficiëntie (functional mitral regurgitation (FMR)) is een veel 
voorkomende complicatie van hartfalen, die de prognose verergert, maar ook te verbeteren 
valt met CRT. In hoofdstuk 6 wordt de prognostische impact van de evolutie van FMR bij CRT-
patiënten geëvalueerd. Matige of ernstige FMR bij baseline, die 6 maanden na CRT implantatie 
onveranderd bleef, had een onafhankelijk voorspellende waarde voor mortaliteit (HR 1.77; 95% 
CI 1.41-2.22; P<0.001). De prognostische implicatie van matige of ernstige FMR die niet verbe-
terde na 6 maanden CRT, was onafhankelijk van de LV volumetrische respons op CRT. Dit geeft 
aan dat de evolutie van FMR niet alleen een weerspiegeling is van de verandering in LV-volume, 
maar ook op unieke wijze bijdraagt  tot de overleving op langere termijn. Hoofdstuk 7 richt zich 
op de invloed van atriumfibrilleren (AF) op de verbetering van FMR na CRT. FMR verbeterde na 
de implantatie in 45.6% van CRT-patiënten met sinusritme (SR), vergeleken met 30.7% met AF 
(P=0.011). Ondanks een vergelijkbare mate van LV reverse remodeling 6 maanden na CRT, had-
den patiënten in SR bij baseline kleinere linker atrium volumes (63.0±26.5 ml vs. 103.1±41.0 ml; 
P<0.001) en kleinere mitralisklepannulus diameters (42.3±5.6 mm vs. 46.1±5.8 mm; P<0.001) in 
vergelijking met de patiënten met AF. Dit suggereert dat de aanwezigheid van AF een negatief 
effect heeft op de linker atrium en mitralisklepannulus reverse remodeling, wat weer op hun 
beurt leidt tot minder FMR-verbetering na CRT.
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SAMENVATTING DEEL II: BEELDVORMING IN DE RISICO STRATIFICEREN VAN 
CARDIALE AANDOENINGEN
Hoofdstuk 8 geeft een kort overzicht van de rol van multimodale beeldvorming in de risicostra-
tificatie van plotselinge hartdood (sudden cardiac death (SCD)). Aangezien SCD de oorzaak is 
van tot wel één vijfde van de sterfgevallen wereldwijd en vaak voorkomt bij personen die niet 
eerder zijn gediagnosticeerd met een hartaandoening, blijft primaire preventie een uitdaging. 
De meest effectieve strategie voor primaire en secundaire preventie van SCD is het inbrengen 
van een implanteerbare cardioverter defibrillator (ICD). Momenteel wordt de beslissing om een 
ICD te implanteren voornamelijk gebaseerd op een LVEF ≤35%. Het is echter bekend dat deze 
benadering weinig sensitief en specifiek is. Multimodale beeldvorming levert een toegevoegde 
waarde aan LVEF om patiënten te identificeren die baat zullen hebben bij een ICD-implantatie. 
Voorbeelden hiervan zijn: speckle tracking strain echocardiografie, aankleuring (late gadoli-
nium contrast-enhanced (LGE)) cardiale magnetische resonantie (CMR) imaging en nucleaire 
beeldvorming (bijvoorbeeld 123-jood metaiodobenzylguanidine opname).
De rol van cardiale beeldvormingstechnieken in de risicostratificatie van genetische, dila-
terende cardiomyopathie (DCM) wordt uitgebreid besproken in hoofdstuk 9. Mutatiedragers 
voor genetische DCM zijn vaak asymptomatisch totdat ze zich presenteren met hartfalen, arit-
mieën of SCD. Risicostratificatie van dergelijke individuen omvat zowel vroege diagnostiek als 
de fenotypering van aangetoonde ziekte. Verschillende beeldvormende technieken zijn in staat 
om vroeg functionele en structurele abnormaliteiten in genetische DCM-mutatiedragers aan 
te tonen, bijv. tissue Doppler, speckle tracking strain echocardiografie, integrated backscatter 
echocardiografie, CMR LGE en fosfor-31 magnetische resonantie spectroscopie. Functionele, 
cellulaire abnormaliteiten kunnen worden onderzocht met nucleaire technieken, bijv. myocard 
perfusie d.m.v. single-photon emission computed tomography. In het geval van aangetoonde 
hartziekte, hebben echocardiografie en CMR een toegevoegde waarde tot LVEF in het kader 
van risicostratificatie.
Hoofdstuk 10 beschrijft het gebruik van GLS speckle tracking echocardiografie bij de vroege 
diagnostiek van genetische DCM-patiënten. Drie groepen werden vergeleken met elkaar: i) 
genotype-positieve, fenotype-positieve (GPFP) patiënten, met een pathogene mutatie en een 
LVEF <55%, ii) genotype-positieve, fenotype-negatieve (GPFN) individuen, met een pathogene 
mutatie en een LVEF ≥55%, en iii) controles die genotype-negatief, fenotype-negatief (GNFN) 
waren. Een verlaagde LV GLS onderscheidde GPFN-individuen van normale controles (P<0.001) 
– in tegenstelling tot LVEF. Een dergelijk vroege diagnose van cardiale betrokkenheid bij gene-
tische DCM-mutatiedragers kan mogelijk resulteren in de tijdige instelling van therapie die de 




Karakterisering en risicostratificatie van CRT-kandidaten blijven klinische uitdagingen. Het ver-
minderen van het aantal non-responders op CRT en het optimaliseren van CRT, zijn prioriteiten 
in de dagelijkse praktijk. Nieuwe cardiale beeldvormingstechnieken zullen naar verwachting 
een cruciale rol spelen bij zowel het karakteriseren van patiënten met hartfalen bij wie CRT 
wordt overwogen, alsook bij de risicostratificatie van diegenen die reeds dergelijke behande-
ling hebben ontvangen. Het doel van het EuroCRT-onderzoek is om de verschillende cardiale 
beeldvormingsmarkers prospectief te evalueren (inclusief LVMD en global LV myocardial work 
efficiency) met betrekking tot hun prognostische waarde.1
Het effect van de behandeling van FMR op prognose wordt momenteel onderzocht. De 
recentelijk gepubliceerde Percutaneous Repair with the MitraClip Device for Severe Functional/
Secondary Mitral Regurgitation (MITRA-FR)2 en Cardiovascular Outcomes Assessment of the 
MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation 
(COAPT)3 trials onderzochten de invloed van percutane mitralisklepreparatie op de uitkomst 
van patiënten met hartfalen en FMR. In beide onderzoeken waren echter patiënten met én 
zonder CRT geïncludeerd. De COAPT-studie liet een lager aantal ziekenhuisopnamen voor hart-
falen zien en een lager sterftecijfer in de MitraClip groep (HR 0.53; 95% CI 0.40-0.70; P<0.001), 
terwijl de MITRA-FR-studie geen afname toonde in het samengestelde, primaire eindpunt van 
mortaliteit en hospitalisatie voor hartfalen (odds ratio 1.16; 95% CI 0.73-1.84; P=0.53). Het 
is duidelijk dat verder onderzoek nodig is om het prognostisch voordeel van de behandeling 
van FMR, te helpen verklaren. AF ritmecontrole (vooral d.m.v. katheterablatie) is mogelijk een 
therapeutisch doelwit voor het verminderen van FMR bij CRT-patiënten die bij baseline al AF 
hebben.
Hoewel de diagnostische rol van multimodale cardiale beeldvorming goed gedefinieerd is 
voor genetisch DCM, zal verder onderzoek opheldering moeten leveren over het vermogen 
ervan om ongunstige lange termijn uitkomsten (bijv. de ontwikkeling van symptomen, ver-
mindering van LVEF, ventriculaire aritmieën en sterfte) bij asymptomatische mutatiedragers 
te voorspellen. Bovendien moet de specifieke waarde van beeldvorming bij therapie (bijv. 
angiotensin converting enzyme (ACE)-remmers of ICDs, die de progressie van de ziekte in 
genetische DCM-mutatiedragers vertragen of zelfs voorkomen) nog worden onderzocht. Voor 
het definiëren van de rol van multimodale cardiale beeldvorming bij zowel de voorspelling 
van uitkomsten op lange termijn, alsook de begeleiding van therapie, zullen prospectieve 
studies noodzakelijk zijn. Aangezien langetermijn follow-up bij zeldzame cardiomyopathieën 
in prospectieve, multicentrum studies ongetwijfeld uitdagend zullen zijn, zou het gebruik van 
beeldvormende-biomarkers als therapeutisch doelwit op zichzelf, bijzonder nuttig kunnen zijn.
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